



**Biofit** FOSTERING  
INNOVATION  
& TRANSFER



**MedFIT**  
Fostering Innovation in MedTech

**medigIT**  
Inspiring Digital Health Innovation

# PROGRAMME

The leading European partnering events for  
early-stage deals and investment rounds in  
**LIFE SCIENCES, MEDTECH & DIGITAL HEALTH**

**December  
3<sup>rd</sup> & 4<sup>th</sup> 2024**

**IN-PERSON | Lille, FR**

**December  
11<sup>th</sup> & 12<sup>th</sup> 2024**

**ONLINE MEETINGS**





# Welcome

Dear participants,

We are delighted to welcome you to this unique edition, which for the first time brings together three major events - BioFIT, MedFIT and MEDigIT - into one outstanding experience. This triple edition has been carefully designed to foster innovation, collaboration, and business opportunities across the Life Sciences, MedTech, Diagnostic and Digital Health sectors.

Over the next two days, you will have access to a wide range of activities designed to support your growth and connections within these industries. From inspiring keynote sessions and panel discussions with leading experts to pitch presentations, a vibrant exhibition area and invaluable one-on-one partnering meetings, this edition promises a unique opportunity to discover cutting-edge technologies, meet key players and build impactful collaborations.

In addition to the in-person experience here in Lille, we are pleased to extend the event with two additional days of digital partnering next week, allowing you to continue your discussions and explore even more partnership opportunities. This hybrid format ensures that you can maximise the value of your participation, no matter where you are.

We hope you find inspiration, new ideas and lasting partnerships during these exciting days. On behalf of the entire organising team, we thank you for joining us and we wish you a productive and memorable BioFIT, MedFIT, and MEDigIT experience.

Welcome to Lille, and let's shape the future of Life Sciences, MedTech and Digital Health together!



**Étienne Vervaecke**  
General Manager  
Eurasanté & Clubster NHL



**Émilie Royère**  
General Manager  
Eurobiomed



**Caroline Dreyer**  
General Manager  
BioValley France



**Sébastien Weisbuch**  
Executive Director  
MEDICALPS

Institutional partners:



With the support of:



Organisers:





# DISCOVER LILLE AND THE HAUTS-DE-FRANCE REGION: A HEALTHTECH INNOVATION HUB

Lille and the Hauts-de-France region are at the forefront of European innovation in Life Sciences and MedTech, providing a fertile environment for growth, research and collaboration in biotech, pharma, diagnostic and MedTech. With its strategic position as a gateway to major European cities such as Paris, London and Brussels, Lille offers exceptional connectivity and accessibility, making it a prime destination for companies, researchers and investors looking to thrive in the healthcare landscape.

## A leading region for Life Sciences innovation

The Hauts-de-France region is home to a **dynamic Life Sciences ecosystem** supported by leading institutions such as Eurasanté, the Lille University Hospital and the Pasteur Institute of Lille. This ecosystem brings together academia, industry and clinical practice to **foster collaboration and drive advances in healthcare**. With world-class research facilities and highly regarded universities, the region supports ground-breaking discoveries and cutting-edge medical technologies that push the boundaries of healthcare innovation.

Lille is also home to successful Life Sciences companies such as GENFIT and Bayer, which have established themselves as key players both locally and internationally. These companies, along with a growing number of innovative start-ups, contribute to the region's reputation as a centre of scientific excellence and medical research. For those seeking collaboration, R&D opportunities or expansion in the Life Sciences sector, Lille and the Hauts-de-France region offer a fertile ground for growth.

## A thriving hub for MedTech, Diagnostic and Digital Health

In addition to its Life Sciences strengths, the Hauts-de-France region is recognised as a major hub for the MedTech industry in Europe. With over 1,100 companies active in the healthcare sector, and more than 32,000 professionals working in MedTech and related industries, the region supports a robust network of research institutes, start-ups, and established players. Renowned companies such as Bio-Rad, Medtronic, Macopharma and Japet have selected this location for its strategic advantages and the opportunities it offers within a collaborative ecosystem.

The region's commitment to innovation is demonstrated by its many research clusters, innovation centres and incubators, including Eurasanté, which plays a key role in facilitating partnerships between academia, industry and healthcare providers. This interconnected ecosystem offers the development of novel diagnostic solutions, advanced medical devices and transformative technologies, reinforcing Hauts-de-France as a top destination for MedTech innovation and investment.

*Whether you are in Life Sciences or MedTech, Lille and the Hauts-de-France region offer a vibrant and innovative environment which empowers professionals, companies and researchers to connect, collaborate and shape the future of healthcare. Join us in exploring the unique opportunities this region has to offer in advancing science and technology.*






# TABLE OF CONTENTS



9	Organisers
11	Steering Committee
12	Sponsors
<b>22</b>	<b>PROGRAMME AT A GLANCE</b>
<b>24</b>	<b>NETWORKING</b>
24	One-on-one meetings
28	Project - CEO matchmaking
<b>30</b>	<b>PITCH SESSIONS</b>
30	Jury members
31	Start-up Slams
34	Collaborative and Licensing Opportunity Presentations
36	Animal Health Presentations
<b>38</b>	<b>CONFERENCE PROGRAMME</b>
39	Keynote sessions
41	Plenary session
42	Track 1: Best practices in academia-industry R&D collaborations
44	Track 2: Nurturing and licensing early-stage assets
48	Track 3: From pre-seed to Series A: Accessing early-stage investment
50	Track 4: Animal Health Highlights
<b>52</b>	<b>HOSTED EVENTS</b>
52	R&D dating for Animal Health and Innovation
53	Awards Ceremony - PUI Lille Innovation Contest
54	Advancing Data Incorporation and Interoperability for Cancer Image Europe
<b>56</b>	<b>EXHIBITORS</b>
78	They support us


85	Organisers
87	Steering Committee
88	Sponsors
<b>90</b>	<b>PROGRAMME AT A GLANCE</b>
<b>92</b>	<b>NETWORKING</b>
92	One-on-one meetings
94	Project - CEO matchmaking
<b>96</b>	<b>PITCH SESSIONS</b>
96	Jury members
97	Start-up Slams
100	Collaborative and Licensing Opportunity Presentations
<b>102</b>	<b>CONFERENCE PROGRAMME</b>
103	Keynote sessions
105	Plenary session
106	Track 1: Growing early-stage innovation
108	Track 2: Bringing innovation to market
110	Track 3: Digital Health & medicine innovation 
<b>112</b>	<b>HOSTED EVENTS</b>
112	Periodontitis treatments of the future, discover the Healthy Teeth project
113	Advancing Data Incorporation and Interoperability for Cancer Image Europe
114	The augmented human: Technological advances and research partnerships
115	Microplait: A microfluidic platform to accelerate the development of medical devices for tissue reconstruction
116	Getting smarter in the dressing industry: Towards a connected dressing with the DIAMOND project
117	Awards Ceremony – PUI Lille Innovation Contest
<b>118</b>	<b>EXHIBITORS</b>
135	They support us



# BIOFIT AT A GLANCE

BioFIT is the leading partnering event in Europe for **technology transfer, academia-industry collaborations, early-stage innovation deals and pre-seed, seed and Series A investment rounds** in the field of Life Sciences.

BioFIT provides the ideal environment to build partnerships, source innovative and competitive early-stage R&D projects, foster the emergence of collaborative projects, increase licensing opportunity, obtain funding and facilitate market access.



# ORGANISERS



[lille.eurasante.com](http://lille.eurasante.com)

Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within an European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic), MEDiGIT (Digital Health) and NutrEvent (Food, Nutrition).



[www.clubster-nhl.com](http://www.clubster-nhl.com)

Clubster NHL is a competitiveness cluster and a network gathering 360 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals, and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.



[www.biovalley-france.com](http://www.biovalley-france.com)

Based in Eastern France, the BioValley France cluster brings to the health sector its unique expertise and personalized support around 4 fields of expertise: Drugs and Innovative Therapies, E-health, Medical Technologies and Diagnosis. For more than eighteen years, BioValley France has built a powerful community in order to deploy a strong network mixing academics and industrials in the health sector: more than 203 members et 55 partners have decided to join the Cluster in order to share, exchange and develop tomorrow's innovation in the best conditions. BioValley France offers services in: Business Competitiveness, Innovative Project, International Relations, Visibility and Influence.



[www.eurobiomed.com](http://www.eurobiomed.com)

Founded in 2009 by regional stakeholders, Eurobiomed is the Life Science cluster from Southern France. We gather more than 420 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centers, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.



Zoetis is  
proud to  
support  
BioFIT  
2024

zoetis.com

zoetis

## STEERING COMMITTEE

### PHARMA, BIOTECH



**Damien Chopy**  
Senior Director, Business Development  
Roche Pharma Partnering



**Chloé Leprêtre**  
Head of Global R&D Search and Evaluation  
Servier



**Niharika Sharma**  
Principal, Corporate Development  
Roivant Sciences



**Florence Dal Degan**  
Senior Director, External Innovation,  
Rare Diseases and Neuroscience  
Ipsen



**Alain Martelli**  
Emerging Science Lead, France  
Pfizer



**Philippe Verwaerde**  
CEO & Chief Scientific Officer  
Alzproctel



**Julie Edwards**  
Director, Alliance Management  
Boehringer Ingelheim



**Marie-Ange N'Zoutani**  
Head of Acceleration Office  
Sanofi



**Joachim Vogt**  
Director, Search and Evaluation,  
International  
AbbVie



**Guy Hélin**  
Co-founder & CEO  
Syngulon



**Steve Nanchen**  
Senior Director, Head External Innovation  
Elanco Animal Health



**Sebastian Karrer**  
Head of Business Development and  
Licensing Region Europe & EMEA  
Bayer



**Hervé Poulet**  
Director, Strategic Partnering  
Boehringer Ingelheim Animal Health

### ACADEMIA, TTOs



**Hervé Ansanay**  
BIOTECH Sector Manager – Industrial  
Partnerships Department  
Réseau SATT



**Garold Breit**  
CEO  
Breit Ideas LLP



**Esther Lange**  
Industry Liaison Manager  
Ascension



**Jürgen Bauer**  
Deputy Managing Director  
EMBLEM Technology Transfer



**Jean-Luc Chagnaud**  
Head of Business Development in  
Health Innovations  
Aquitaine Science Transfert

### INVESTORS



**Clément Bertholet**  
Partner  
AdBio Partners



**Jérôme Majoie**  
General Manager  
Fournier-Majoie Foundation



**Daniel Parera**  
Senior Advisor  
Kurma Partners



**Frank Hensel**  
Principal  
High-Tech Gründerfonds



**Juliette Lee**  
Associate  
EQT Life Sciences Dementia Fund

### ASSOCIATIONS, CLUSTERS



**Caroline Dreyer**  
General Manager  
BioValley France



**Jean-Louis Hunault**  
President  
SIMV - The French association of  
the animal health industry



**Corinne Szilagyi**  
Senior Partner  
Biotech Développement Conseils  
& Member of the Business  
Development Committee  
France Biotech



**Yohan Grosjean**  
COO  
AFSSI - The French association  
of outsourcing and innovative  
companies



**Émilie Royère**  
General Manager  
Eurobiomed



**Etienne Vervaecke**  
General Manager  
Eurasanté & Clubster NHL



## OUR SPONSORS

### Platinum sponsor



Zoetis is the world's leading animal health company. Our purpose is to nurture our world and humankind by advancing care for animals. After more than 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of \$8.5 billion in 2023 with ~14,100 employees. For more, visit [www.zoetis.com](http://www.zoetis.com).

#### Partnering with Zoetis

We strive to be the partner of choice in the vibrant and growing animal health industry. We collaborate with partners across the life sciences industries and academia, at any stage of development, from early research to commercial products – all with a shared interest in developing innovative solutions to improve the health and wellbeing of animals and the people who care for them.

#### Our areas of partnering interest

- Livestock health
- Companion animal therapeutics, including osteoarthritis, chronic pain, renal health, allergy and dermatitis
- Preventatives
- Diagnostics and Genetics
- Platform technologies in biopharma, formulation, biomarkers and target discovery
- Digital and Data Solutions

[www.zoetis.com](http://www.zoetis.com)

**STAND D35**

Zoetis conference: **The Ageing of Man and Animal: crafting longer, happier and healthier lives for an ageing population of Pets and People through collaborative translational approaches**  
Tuesday, December 3<sup>rd</sup> | 3.00 - 3.30 pm | Marseille room

## OUR SPONSORS

### Silver sponsors



As an independent company active in both human and animal health, Boehringer Ingelheim has learned over generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action. Decades of cutting-edge science and innovation has enabled us to deliver many pioneering breakthroughs in some of the most devastating diseases and challenging areas we face globally. Continuing this journey hinges on collaboration.

We believe that working together with our global community of partners brings critical diversity to innovation and accelerates the next breakthroughs in human and animal health that will transform lives now and in generations to come. This collective power, in the tireless pursuit of science and solutions, enables us to build together a healthier, more sustainable, and equitable tomorrow.

[www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)

**PARTNERING BOOTH 10**



Ceva Animal Health (Ceva) is the 5<sup>th</sup> global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals and equipment and services to provide the best experience for our customers. At Ceva, innovation is at the heart of what we do. Our ambition is to pioneer the most valued animal healthcare solutions through cutting-edge science and a deep commitment to improving animals' livelihood and well-being under the umbrella of One Health.

[www.ceva.com](http://www.ceva.com)

**PARTNERING BOOTH 46**

# The **ACLF** Company

Developing a pipeline of therapies to **reshape** the current treatment landscape for patients with **Acute-on-Chronic Liver Failure (ACLF)** and other rare life-threatening liver diseases with **high unmet medical needs**

We're in relentless pursuit of **breakthroughs** that **change patients' lives.**

We innovate every day to make the world a healthier place. It was Charles Pfizer's vision at the beginning and it holds true today.

Learn more at [Pfizer.com](http://Pfizer.com)



## OUR SPONSORS

### Silver sponsors



GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).

[www.genfit.com](http://www.genfit.com)

**PARTNERING BOOTH 28**

GENFIT conference: The synergy of partnership: the journey of Ipsen and GENFIT  
Tuesday, December 3<sup>rd</sup> | 1.30 - 2.00 pm | Lille room



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us.

[www.pfizer.com](http://www.pfizer.com)

**PARTNERING BOOTH 1**





## Our Services



2 000 sqm of premium life science facility

- Coworking lab
- Private Lab & private Office
- Coworking offices
- Meeting room
- Gathering space



€3M State-of-the-art laboratory equipment with a dedicated technical team



Benefits from the advantages of BioLabs network



Benefiting from Servier's medical and scientific expertise

# Spartners

by Servier & BioLabs

a unique Bio innovation hub

Spartners by Servier & BioLabs was designed alongside our founding partner Servier, to be the best coworking space in Paris-Saclay for life sciences startups – a unique place to test, develop and grow revolutionary ideas.

Our mission is to support startups in their research and development phase, accelerating their "time to market."



## OUR SPONSORS

### Silver sponsors


# Spartners

by Servier & BioLabs

Spartners by Servier & BioLabs is on a mission to empower life science innovation in Paris-Saclay by creating a unique place for life science startups to test, develop and grow game changing ideas. Spartners offers state-of-the-art facilities with fully equipped laboratory and office spaces that are supported by an experienced, dedicated, technical team. Designed to build community, Spartners enables high-potential life science companies to work, collaborate and innovate in a setting perfectly suited to meet their needs. Our exclusive approach combines BioLabs' expertise with Servier's know-how, making it stand out in France.

[servier.com/en/newsroom/spartners-biotech-start-up-welcome-to-apply/](http://servier.com/en/newsroom/spartners-biotech-start-up-welcome-to-apply/)  
**STAND B14-C13/3**

## PURE & SAFE THERAPEUTIC PROTEINS !



«Protein on demand» Service



Chemical synthesis of proteins



Endotoxin-free (very high purity)



Maximized bioactivity

# X'PROCHEM

PURE & SAFE

Founded in 2012, X'PROCHEM is a CRO (Contract Research Organization) specialized in chemical protein synthesis.

We design and produce therapeutic proteins for our pharmaceutical and biotech partners. We manufacture complex and highly customized proteins up to 400 amino acids (40 kDa) by using an automated process.

[xprochem.com](http://xprochem.com)  
**STAND D19**



Using the power of leading-edge science to save and improve lives around the world

For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for some of the world's most challenging diseases.

With scores of "firsts" in our legacy, we know what it takes to nurture emerging ideas and we will be an enthusiastic and experienced partner on your journey. Meet our team and learn about our interests at [msdlicensing.com](https://msdlicensing.com).



Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. HQ-NON-01065 09/22

## OUR SPONSORS

### Bronze sponsors



We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depository Receipt program (ADR: IPSEY). For more information, visit [www.ipsen.com](https://www.ipsen.com).

Our partnering team look forward to seeing you.

[www.ipsen.com](https://www.ipsen.com)

**IPSEN conference: The synergy of partnership: the journey of Ipsen and GENFIT**  
Tuesday, December 3<sup>rd</sup> | 1.30 - 2.00 pm | Lille room



MSD's success stems from translating research into life-saving medical breakthroughs. From our development of the first measles and mumps vaccines to treatments for cancer and diabetes, we've become an industry leader in bringing innovative new medicines to patients. Approximately half of our pipeline is attributable to acquisitions, alliance partnerships and patents with our team executing 76 significant business development transactions in 2023. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at [www.merck.com/licensing](https://www.merck.com/licensing).

[www.msd.com](https://www.msd.com)



Roche is a leading healthcare company and is heavily investing into R&D, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the CNS. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. Our Pharma Partnering team provides comprehensive BD and alliance management support for Roche and Genentech's R&D units and the broader pharmaceutical division. Alongside the broad internal pipeline, external innovation has always been a critical component of our R&D strategy.

[www.roche.com](https://www.roche.com)



## Collaboration is in our DNA.

Partnering is a cornerstone of our strategy. We join forces with forward-thinking companies to pursue groundbreaking healthcare innovations that can transform lives. By combining our world-class scientists with our partners' expertise, we collectively drive breakthrough ideas, ultimately creating innovative medicines and diagnostics.



Find out more on [roche.com/partnering](https://roche.com/partnering)



# OUR SPONSORS

## Bronze sponsors



Roquette is a family-owned global leader in plant-based ingredients, and a leading provider of pharmaceutical excipients.

Founded in 1933, the company currently operates in more than 100 countries, has a turnover of 5 billion euros, and employs more than 10,000 people worldwide. Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them we develop a diverse portfolio of versatile and reliable excipients for the pharmaceutical, nutraceutical and biopharmaceutical markets.

[www.roquette.com](http://www.roquette.com)



Transpharmation is an accredited preclinical contract research organization specializing in translational pharmacology across various therapeutic areas. We offer neuroscience and animal health expertise, using behavioral, electrophysiological and protein-based biomarker assays to help clients benchmark compounds. Committed to on-time data delivery and flexible, customized solutions we support clients in optimizing preclinical assets for the development of life-changing medicines.

[www.transpharmation.com](http://www.transpharmation.com)

**STAND C38**



WuXi AppTec is a full-service provider of open-access capabilities and technology that enables customers worldwide to advance discoveries in the health sciences and deliver treatment to those in need.

[www.wuxiapptec.com](http://www.wuxiapptec.com)

**STAND E43**

# OUR SPONSORS

## Contributing sponsors



Launched in 2021, Captech Santé, is an early-stage fund, investing in projects in Biotech, Medtech, Digital Health and Nutrition. With a capital of €35 to €40 million, the fund invests in Seed or Series A. Thanks to its expertise and integration in the healthcare ecosystem, Captech supports its investments over the long term, and co-invests with international funds.

[www.finorpa.fr/gestion/fonds-captech-sante](http://www.finorpa.fr/gestion/fonds-captech-sante)



Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we're driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.

[www.elanco.com](http://www.elanco.com)



Because improved diagnostic solutions contribute to a more precise and personalised medicine and improve the quality of life for patients worldwide, Innobiochips provides disruptive technologies to improve the accuracy, quality and sustainability of in vitro diagnostic approaches.

[www.innobiochips.fr](http://www.innobiochips.fr) - **STAND D20-F21 / 1**






The smart manufacturing industry (High Tech Systems and Materials) is characteristic for the Twente region in East-Netherlands. The World Trade Center Twente is building a MedTech cluster together with the Techmed Center at the University and companies in the medical technology sector.


[medtechtwente.nl](http://medtechtwente.nl) - **STAND D32-E31**

# PROGRAMME AT A GLANCE

Tuesday, December 3<sup>rd</sup>

	Conference sessions	Pitch sessions	Partnering	
8.00 am 9.00 am	☕ Welcome coffee		One-on-one meetings	
9.00 am 9.30 am	<small>Strasbourg room</small> <b>Keynote session</b> Global investment trends in health industries: 2025 outlook			
9.45 am 10.45 am	<small>Strasbourg room</small> <b>Academia-biotech collaborations:</b> An alternative itinerary to foster innovation	<small>BioFIT Innov/Area</small> <b>Start-up Slams</b> <small>Diagnostic Metabolic diseases</small>		
10.45 am 11.15 am	Networking break			
11.15 am 12.30 pm	<small>Strasbourg room</small> <b>Plenary session</b> Recent trends within dealmaking and investment industry: An increasing Pharma M&A appetite?	<small>BioFIT Innov/Area</small> <b>Collaborative and Licensing Opportunity Presentations</b> <small>Diagnostic   Immunology   Oncology</small>		
12.30 pm 1.30 pm	🍴 Lunch			
1.30 pm 2.00 pm	<small>Lille room</small> The synergy of partnership: the journey of Ipsen and GENFIT  			
2.00 pm 2.45 pm	<small>Strasbourg room</small> <b>Navigating a deal structure:</b> Overview, market practices and how to approach	<small>Marseille room</small> <b>Investors and Animal Health:</b> Expectations and perspectives for 2025		<small>BioFIT Innov/Area</small> <b>Start-up Slams</b>
3.00 pm 3.45 pm	<small>Strasbourg room</small> <b>Information is the key:</b> What should you have ready to present your academic asset to potential industry partners?	<small>Marseille room</small> <b>The Ageing of Man and Animal</b> 		<small>Oncology</small>
3.45 pm 4.15 pm	Networking break			
4.15 pm 5.00 pm	<small>Strasbourg room</small> <b>TTO to TTO collaborations:</b> Examples and success stories of spinning off academic assets from different institutions into a single company	<small>BioFIT Innov/Area</small> <b>Animal Health Presentations</b>		
5.15 pm 6.00 pm	<small>Strasbourg room</small> <b>Gear up for years to come:</b> How to get a 'seedable' company?	<small>BioFIT Innov/Area</small> <b>Animal Health Presentations</b>		
From 6.45 pm	🍷 BioMed Party			

Wednesday, December 4<sup>th</sup>

	Conference sessions	Pitch sessions	Partnering	
8.00 am 9.00 am	☕ Welcome coffee		One-on-one meetings	
9.00 am 9.30 am	<small>Strasbourg room</small> <b>Keynote session</b> The Future of Medicine: Unlocking the potential of data			
9.45 am 10.45 am	<small>Strasbourg room</small> <b>Diving into the venture builder model:</b> Unpacking the value proposition in nurturing biotech assets	<small>2.3 room</small> <b>Advancing Data Incorporation and Interoperability for Cancer Image Europe</b>		<small>BioFIT Innov/Area</small> <b>Start-up Slams</b> <small>CNS Cell &amp; Gene Therapy</small>
10.45 am 11.15 am	Networking break			
11.15 am 12.30 pm	<small>Strasbourg room</small> <b>Biotech investors' forecast:</b> Where will early-stage investment go in 2025?	<small>2.3 room</small> <b>Advancing Data Incorporation and Interoperability for Cancer Image Europe</b>		<small>BioFIT Innov/Area</small> <b>Collaborative and Licensing Opportunity Presentations</b> <small>Cell &amp; Gene   CNS   Drug Discovery</small>
12.30 pm 2.00 pm	🍴 Lunch			
2.00 pm 3.00 pm	<small>Strasbourg room</small> <b>A tale of academia-pharma collaborations:</b> What does the story teach us?	<small>Marseille room</small> <b>The path to becoming a successful CEO:</b> Tips to wannabe founders		<small>BioFIT Innov/Area</small> <b>Start-up Slams</b> <small>Enabling Technologies</small>
3.15 pm 4.15 pm	<small>Strasbourg room</small> <b>Asset-based vs. technology platform-based start-ups:</b> Analysing investors' preferences and mechanisms in funding	<small>Lille room</small> <b>Awards Ceremony</b> PUI Lille Innovation Contest		
4.30 pm 5.00 pm	<small>BioFIT Innov/Area</small>  Pitch sessions - Award ceremony			
5.00 pm 6.00 pm				

- ◆ TRACK 1: BEST PRACTICES IN ACADEMIA-INDUSTRY R&D COLLABORATIONS
- ◆ TRACK 2: NURTURING AND LICENSING EARLY-STAGE ASSETS
- ◆ TRACK 3: FROM PRE-SEED TO SERIES A: ACCESSING EARLY-STAGE INVESTMENT
- ◆ TRACK 4: ANIMAL HEALTH HIGHLIGHTS
- ◆ PROJECT - CEO MATCHMAKING
- ◆ HOSTED EVENTS

December 11<sup>th</sup> & 12<sup>th</sup>  
Online meetings



# ONE-ON-ONE MEETINGS

**4  
DAYS**

**TO MEET YOUR FUTURE PROJECT PARTNERS, OBTAIN FUNDING AND ACCELERATE INNOVATION**

BioFIT's partnering platform is your chance to **make meaningful connections** that could take your projects forward. The partnering activity allows participants to meet each other during **30-minute pre-qualified one-on-one meetings** scheduled prior to the event.

#### **It's time to meet your future partners!**

- Print out your meeting schedule at the partnering desk or consult it via your partnering account on [biofit-medfit-medigit.vimeet.events](https://biofit-medfit-medigit.vimeet.events).
- Attend your one-on-one meetings at the time and place indicated.
- Remember to check your schedule regularly throughout the event.



*Access the partnering platform* 

**You did not get the chance to schedule all your meetings?**

**BioFIT continues online on December 11<sup>th</sup> & 12<sup>th</sup>**





# Discovering together



Let's connect to drive innovation and begin new journeys of discovery together in:

Cardio-Renal-Metabolic | Immunology & Respiratory | Mental Health & Neuroscience  
Oncology | Retinal Health | Research Beyond Borders | Technologies

Life forward

Discover more



## Open Access Enabling Platform for Your Drug Discovery


### WuXi Chemistry

- Small Molecule
- Oligonucleotide
- Peptide
- Conjugate



### WuXi Biology

- Target Discovery
- Hit Finding
- Lead Optimization
- Preclinical Pharmacology
- Non-clinical & Clinical Biomarkers



[www.wuxiapptec.com](http://www.wuxiapptec.com) ✉ E-mail: [wuxiconcierge@wuxiapptec.com](mailto:wuxiconcierge@wuxiapptec.com)

## WHO WILL YOU MEET?



**25%**  
TTOs, Research institutions, Incubators, Academics



**20%**  
Pharma & Diagnostic companies



**20%**  
Biotech companies



**10%**  
Investors (pre-seed, seed and Series A)



**15%**  
R&D services - Preclinical CROs & CDMOs



**5%**  
Consulting companies, law firms



**5%**  
Associations, clusters, media

## INVESTOR LUNCH

BioFIT has the pleasure to organise an Investor Lunch on:

**Wednesday, December 4<sup>th</sup> at 12.30 pm (VIP lunch room)**

This dedicated lunch will provide an opportunity for investors to discuss **early-stage investment trends** and exchange views on the **2024 highlights**. Most importantly, this networking time will be the perfect moment to **strengthen co-investment networks**.

Investors can sign-up on-site at the partnering desk until December 4<sup>th</sup>.



# PROJECT – CEO MATCHMAKING

## YOU ARE A BIOENTREPRENEUR SEEKING NEW PROJECTS TO LEAD OR YOU ARE LOOKING FOR A PASSIONATE CEO TO LEAD YOUR PROJECT?

As talented CEOs are often sought after by many players in the biotech industry, the Project – CEO matchmaking activity aims to connect representatives of emerging start-ups, technology transfer offices, incubators, and investment networks with CEOs and aspiring CEOs.

### Find the perfect match:

◇ Any incubator, technology transfer entity or scientific founder looking for an entrepreneur to lead their innovative projects is welcome to participate in the matchmaking activity to meet with qualified candidates! You will be visible on the partnering platform, to be contacted by potential CEOs.

◇ If you are a bioentrepreneur looking for a new project to undertake: Projects looking for a CEO will be visible on the platform and easily identifiable.

### Get inspired:

Having the right team is essential for the development of a biotech project. The Project – CEO matchmaking activity also offers a **conference session** to get inspired and explore the best ways to find the right talents for a successful project:

## The path to becoming a successful CEO: Tips to wannabe founders

Day 2 - Wednesday, December 4<sup>th</sup> | 2.00 - 3.00 pm

Marseille room

For emerging start-ups in the healthcare industry, the journey to success begins with effective leadership. This session will feature MedTech and Biotech CEOs, sharing their journey and insights for aspiring founders seeking to navigate the challenges of start-up leadership.

What are the essential qualities and skills for effective start-up leadership? How to ensure founders are "business ready", especially when coming from academia? How to build the right team that will convince investors? How to work with your board and engage them as proper advisors? What are the strategies for attracting and retaining top talents?

### Moderator



**Lynn Coorevits**  
Digital Health  
Innovation Manager  
imec




**Alain Barbal**  
Director, Board Advisor  
Novostia



**Georges Rawadi**  
CEO  
StromaCare



**Véronique Foutel**  
CEO  
InBrain Pharma



**Neel Patel**  
CEO  
Zio Health

# PITCH SESSIONS

The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development in the Life Sciences and Animal Health fields.

The most innovative start-up, most promising technology and most innovative animal health project will be announced during the **Award Ceremony** on:

**December 4<sup>th</sup> at 4.30 pm within the BioFIT Innov'Area**



## ◆ Jury members ◆

- Farzad Abdi-Dezfuli**, Partner, **Sarsia** 🇫🇷
- Jürgen Bauer**, Deputy Managing Director, **EMBLEM Technology Transfer** 🇩🇪
- Gary Breit**, CEO, **Breit Ideas** 🇩🇪
- Jean-Luc Chagnaud**, Head of Business Development in Health Innovations, **Aquitaine Science Transfert** 🇫🇷
- Florence Dal Degan**, Senior Director External Innovation, Rare Diseases and Neuroscience, **Ipsen** 🇫🇷
- Shobhit Dhawan**, Fund Manager, **Oncode Bridge Fund** 🇮🇳
- Marie Duranteau**, Associate, Program Manager, **Sofinnova Partners** 🇫🇷
- Guy Hélin**, CEO, **Syngulon** 🇫🇷
- Frank Hensel**, Principal, **High-Tech Gründerfonds** 🇩🇪
- Esther Lange**, Industry Liaison Manager, **Ascenion** 🇩🇪
- Chloé Leprêtre**, Head of Global R&D Search and Evaluation, **Servier** 🇫🇷
- Jérôme Majoie**, General Manager, **Fournier-Majoie Foundation** 🇫🇷
- Eduardo Salas**, Head of Technology Transfer and Business Development, **IBEC** 🇪🇸
- Corinne Szilagyi**, Senior Partner, Member of the Business Development Committee, Biotech Développement Conseils, **France Biotech** 🇫🇷
- Joachim Vogt**, Director, Search and Evaluation, International, **Abbvie** 🇩🇪
- Anela Vukoja**, COO, **Apollo Health Ventures** 🇩🇪
- Jean-Pascal Marc**, General Manager, **Ceanothus Consulting** 🇫🇷
- Steve Nanchen**, Senior Director - Head External Innovation, **Elanco Animal Health** 🇨🇭
- Edouardo De Oliveira Pontes**, Associate Director Research Alliances - External Innovation, **Zoetis** 🇺🇸
- Hervé Poulet**, Director, Strategic Partnering, **Boehringer Ingelheim Animal Health** 🇫🇷
- Edouard Timsit**, Director of Global Innovation Livestock Health and Sustainability, **Ceva Animal Health** 🇫🇷

## Start-up Slams

The Start-up Slams showcase young promising companies seeking to raise a seed or a Series A financing round.

**Tuesday, December 3<sup>rd</sup> | 9.45 - 10.45 am | BioFIT Innov'Area**

### DIAGNOSTIC

**FLUONIR** 🇫🇷 Stand IA5

NIR-II Fluorescence - Fluorescence-Guided Surgery - Cancer Diagnosis and Treatment

**BELIVER** 🇫🇷 Stand IA2

Liver Cancer - Treatment Prediction - Medtech

**DAMOCLES DIAGNOSTICS** 🇫🇷 Stand B11

Rapid Diagnostics - Antibiotic Resistance - Point of Care

### METABOLIC DISEASES

**V4CURE** 🇫🇷 Stand IA14

Drug - Aquaretic - Cardio-Renal Pathologies





# PITCH SESSIONS

## Start-up Slams

Tuesday, December 3<sup>rd</sup> | 2.00 - 3.45 pm | BioFIT Innov'Area

### ONCOLOGY

#### HEMERION THERAPEUTICS Stand IA7

Oncology - Neurology - Drug-Device Combo

#### CASINVENT PHARMA

Resistance in Cancer - New Mechanism to Fight Resist - AML-Venetovclax, PDAC Chemo

#### PEPKON Stand IA11

Peptides - Oncology - First in Class

#### STARKAGE THERAPEUTICS Stand IA13

Senescence - Oncology - ADC

#### ACTIPULSE NEUROSCIENCE Stand IA18

Blood-Brain Barrier - Non-Invasive Neuromodulation - CNS Drug Delivery

#### SIMMUNEXT BIOTHERAPEUTICS Stand IA12

Immunofilaments - Immunotherapy for Cancer - Bioconjugate

#### GLYCOTHERAPEUTICS Stand IA6

Oncology - Glycobiology - Small Molecule

## Start-up Slams

Wednesday, December 4<sup>th</sup> | 9.45 - 10.45 am | BioFIT Innov'Area

### CNS

#### INBRAIN PHARMA Stand IA8

Dopamine Based DAT - Device Aided Therapy - Advanced Parkinson Disease

#### IPCURE Stand IA9

Dementia - Drug Development - Small Peptidomimetics

### CELL & GENE THERAPY

#### ABLEVIA Stand IA1

Anti-Drug Antibody Removal - Orphan Diseases - Gene Therapy Vectors

Wednesday, December 4<sup>th</sup> | 2.00 - 3.00 pm | BioFIT Innov'Area

### ENABLING TECHNOLOGIES

#### IRUBIS Stand IA10

Bioprocessing - Spectroscopy - Process Analytical Technology

#### BIOMIMIX Stand IA3

Mechanical Stimulation - 3D Human Tissues - Drug Safety/Efficacy

#### BIOTACTICAL Stand IA4

Sterility Testing - Bioluminescence - ATMP

#### GOODBOT Stand A16

Lab Automation - Liquid Handling - Pipetting Robot

# PITCH SESSIONS

## Collaborative and Licensing Opportunity Presentations

The Collaborative and Licensing Opportunity Presentations showcase early-stage technologies from TTOs, universities, research institutes and companies.

Tuesday, December 3<sup>rd</sup> | 11.15 am - 12.30 pm | BioFIT Innov'Area

### DIAGNOSTIC

**PANADEA DIAGNOSTICS**  Stand B13  
Antibody test - Highly specific - Multi-species

**BIOGEM**   
Biosensor - Oncology - Diagnosis

### IMMUNOLOGY

**INSTITUT PASTEUR**   
Human Immune Response - 1,000-person cohort - Personalised Medicine

**SATT LUTECH (ALLERGIMMUNE)**    
Adjuvant - Allergy - Immunotherapy

### ONCOLOGY

**EUROPEAN INSTITUTE OF ONCOLOGY (IEO) - EPIKIN**   
Clinical Kinase Inhibitors - Unbiased Functional Profiling - High-throughput platform

**BRENUS PHARMA**   
Precision immuno-oncology - Anti-cancer vaccine - Deep-tech biotechnology

## Collaborative and Licensing Opportunity Presentations

Wednesday, December 4<sup>th</sup> | 11.15 am - 12.30 pm | BioFIT Innov'Area

### CELL & GENE THERAPY

**FONDAZIONE TELETHON - THE FUTURE OF GENE THERAPY**   
Gene editing - Mobilisation conditioning - HSPC

**IRCCS OSPEDALE GALEAZZI SANT'AMBROGIO - PCART-PROGENITOR CARTILAGE CELLS**   
Osteoarthritis - Regenerative Medicine - Cartilage Stand E26-F25

**BESPARKBIO**   
Gene therapy - Enabling Technology - Viral Vector

### CNS

**OKINAWA INSTITUTE**   
Alzheimer - Peptide drug - Tau

**SATT LINKSIUM - ASTROPROTECT**    
Alzheimer Disease - Neuroprotection - TRPA1

**SATT AXLR - WOLTHER**    
Wolfram Syndrome - Alzheimer Disease - Sigma-1 agonists

### DRUG DISCOVERY

**NEBULA**   
Generative AI - Drug targets discovery - Protein dynamics



# PITCH SESSIONS

## Animal Health Presentations

The Animal Health Presentations focus on innovations in relation to animal well-being and health.

Co-organised by:  **SIMV**  
SYNDICAT DE L'INDUSTRIE DU  
MÉDICAMENT ET DIAGNOSTIC VÉTÉRINAIRES

Supported by:  **Boehringer Ingelheim**  **Ceva**  **Elanco**  **zoetis**

Tuesday, December 3<sup>rd</sup> | 4.15 - 5.00 pm | BioFIT Innov'Area

### BENNO THERAPEUTICS

Vaccine - Canine cancer - Tumor vasculature

### DAMOCLES DIAGNOSTICS - DAMAST Stand B11

Point of Care - Diagnostic test - Fast AST

### FINDIMMUNE - WOOF

Oral melanoma - Squamous cell carcinoma - Immunotherapy

### INRAE TRANSFERT Stand E37

SVCV - Vaccine platform - Host-pathogen model

Tuesday, December 3<sup>rd</sup> | 5.15 - 6.00 pm | BioFIT Innov'Area

### INRAE TRANSFERT Stand E37

Influenza A virus - Vaccine - H5N1

### GHENT UNIVERSITY

Bacterial infections - Antibiotic resistance - Pyoderma

### VAXINANO

Nasal vaccines - Delivery system - Platform

### AIHERD

Dairy - Monitoring - Detection

# Transforming lives



Together with our global family of innovation partners, we're working hard to accelerate the discovery and development of the next generation of breakthroughs in animal health.

Learn more:



CardioMetabolic Diseases | Central Nervous System Diseases  
Immunology & Inflammation | Infectious Diseases | Oncology | Oral Health  
Pain & Osteoarthritis | Parasitology Technologies | Digital Science

## Life forward

# Transpharmation

Science that translates into results 

## The Future Of Drug Discovery Is At

# BOOTH C38

Advanced Animal Health Models  
Cutting-Edge Neuroscience Research

Your Partner in Translational and Collaborative Neuroscience

[TRANSPHARMATION.COM](https://www.transpharmation.com)

# CONFERENCE PROGRAMME

## Keynote sessions

Steered by its **prestigious committee**, the BioFIT conference programme is shaped to match the interests of every player in the sector and to meet the expectations of its stakeholders, whose sharp minds operate in the fast-paced Life Sciences sector.

The 2024 programme is rooted in four custom-made tracks, addressing the right funding sources for **early-stage innovation**, **best practices in academia-industry R&D collaborations**, winning ways to **nurture early-stage assets** and **animal health highlights**.

### ◆ Sessions' format ◆

**Keynote:** A keynote is designed to convey a central message, set the tone, and captivate the audience by featuring notable and high-level speakers.

**Plenary session:** Panel of high-level speakers discussing a main topic/trend for the industry.

**Toolbox session:** A toolbox session is designed to provide practical skills, easy-to-follow guidelines and take-home tools which delegates can put into practice to deal with their current issues.

**Panel discussion:** Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.

**Case studies:** Session that comprise a series of illustrative presentations followed by Q&As from the moderator and the audience.

**Fireside chat:** Personal and interactive discussion involving a moderator and a guest, in which the audience can gain insights through the guest's personal stories and thoughts on various topics.

### Global investment trends in health industries: 2025 outlook

Day 1 - Tuesday, December 3<sup>rd</sup> | 9.00 - 9.30 am - Keynote session

Strasbourg room

Let's explore the landscape of global investments in health industries, emerging opportunities and challenges for 2025. What are the key drivers in the sectors of biotech and MedTech? What can we anticipate for the increasingly popular digital health sector, as well as for the One Health approach? How are regulatory changes, technological advancements, and market dynamics impacting these fields? Gain insight into the evolving priorities of investors and the strategic approaches shaping the future of growth and innovation in the health sector.



**Antoine de Lachaux**


Head of Unit –  
Life Sciences and Biotech  
European Investment Bank

### The Future of Medicine: Unlocking the potential of data

Day 2 - Wednesday, December 4<sup>th</sup> | 9.00 - 9.30 am - Keynote session

Strasbourg room

Data is the new gold. And what better way to invest it than in health? From precision diagnostics to predictive care models, how is data already transforming medicine and what future breakthroughs lie ahead? How are advancements in data analytics, AI, and secure data sharing impacting patient outcomes and healthcare efficiency, and what challenges need to be addressed? Gain a forward-looking perspective on how data-driven insights are paving the way for more personalised healthcare —making better outcomes and accessibility a reality for all.



**Hema Purohit**

Strategic Advisor &  
CTO Healthcare  
Microsoft





## Plenary session

### Recent trends within dealmaking and investment industry: An increasing Pharma M&A appetite?

Day 1 - Tuesday, December 3<sup>rd</sup> | 11.15 am - 12.30 pm - Plenary session

Strasbourg room

While deal volumes have slowed down in recent years, in line with the overall M&A activity, deals in the life sciences sector started to pick up again at the end of 2023 and continued in 2024.

Experts will discuss this M&A resurgence and its implications for early-stage deals, funding availability, business development prospects and deal pattern observations. What trends are observed in recent M&A deals? What is the current state of M&As and what patterns can be observed in deal structures? Are deals differing for mid-size companies? What are BD heads observing and how are they responding? What has been the impact of IRA on R&D and M&A strategies? What is the balance between acquisitions and partnerships in global strategies? Is the resurgence of M&A activity creating more opportunities or challenges for early-stage dealmaking? What therapeutic areas have been targeted by M&As and how does it affect biotech in a pre-deal environment? Are investors more likely to take risks earlier on as a result? What will large pharmas and investors be looking for in 2025?

#### Moderator



**Claudia Andretta**  
Founder, Strategic Science  
and Business Advisor  
Sichem Bio 



**Joachim Vogt**  
Director, Search and  
Evaluation, International  
Abbvie 



**Jessica Garestier**  
Counsel - Life Sciences  
Dentons 



**Michel de Baar**  
Executive Director  
BD&L Europe  
MSD 

# Track 1

## Best practices in academia-industry R&D collaborations

Fostering academia-industry partnerships is key to fuel innovation in the sector. Which sectors are prone to fuel collaborations? What are the elements to forgather to merge the scientific, academic, advocacy and industry spheres? How are the advances in specific fields influencing academia-pharma partnerships? How can these collective efforts question the way the industry is covering the pre-competitive status?

### Academia-biotech collaborations: An alternative itinerary to foster innovation

Day 1 - Tuesday, December 3<sup>rd</sup> | 9.45 - 10.45 am - Panel discussion

Strasbourg room

Academia and industry have been joining their strengths through collaboration deals to bring cutting-edge research to life as practical innovations. While pharma companies are often considered as the go-to partner for collaborations, biotech can also serve as strategic partner in bringing academic projects to light. What are the differences between collaborating with biotech vs big pharmas? What advantages does partnering with a biotech offer? How can academic assets spark the interest of biotech? From an academic perspective, what defines the right biotech partner? What are the current challenges for academia and biotech when working side by side?


Moderator



**Gerald Law**  
Chief Executive  
Innovation DB



**Fadwa Benkessou**  
Academia-Industry  
Alliance Manager  
Karolinska Institutet



**Kevin Carvalho**  
Head of Strategic Partnerships  
Deeplife



**Eduardo Salas**  
Head of Technology Transfer  
and Business Development  
IBEC



**Segolene Martin**  
CEO  
Kantify

### A tale of academia-pharma collaborations: What does the story teach us? Day 2 - Wednesday, December 4<sup>th</sup> | 2.00 - 3.00 pm - Case studies

Strasbourg room

Throughout the years, academia-pharma collaborations have enabled the translation of insights into therapeutics that impact patients' lives for the better. In this session, the experts will analyse success stories of collaboration deals to try and draw some guidance. Which success stories have made their mark in the recent history of academia and pharma partnerships and what can we learn from them? Is there a common pattern between these collaborations? What challenges did these partnerships come across and how did they overcome them? What best practices can TTOs draw from these academia-pharma collaborations?


Moderator



**Matthieu Flourakis**  
Team Lead «Strategic Partnerships  
& Stakeholder Management» &  
Senior Project Manager  
Akkodis




**Patrick di Stefano**  
Industrial Relations Manager  
and Technology Transfer Expert  
Université libre de Bruxelles



**Julie Edwards**  
Director Alliance Management  
Boehringer Ingelheim



**Stefanie Possek**  
Director Technology  
Management  
Ascenion



**Alain Martelli**  
Director External Science  
and Innovation  
Pfizer



# Track 2

## Nurturing and licensing early-stage assets

Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. Understanding the mechanisms and difficulties of nurturing and licensing assets is key to properly influence the valuation of assets at an early stage. How can we fully understand the proposition behind the value? How can we transform science into business more frequently and efficiently?

### Navigating a deal structure: Overview, market practices and how to approach

Day 1 - Tuesday, December 3<sup>rd</sup> | 2.00 - 2.45 am - Toolbox session

Strasbourg room

Discussing the landscape of deal structures in the biotech industry, experts will provide their experience in deal-making and asset-licensing. What are the different deal structures? Has there been any innovative and less conventional deal structure types in the past few years for licensing early-stage assets to big pharma? How do deal structures vary based on the area of technology or therapeutic indication, and what factors influence their adoption? What considerations should biotech or TTOs take into account when exploring deal structures with pharma? How will Pharma select potential assets in the future? What are the key points of a successful deal? What best practices can we learn from the recent years and what advice can the experts offer to the newcomers in the sector?

#### Moderator



**Chris Shelley**

Partner – IP, IT & Commercial

Penningtons Manches  
Cooper LLP



**Tamar Raz**

CEO

Hadasit



**Lubor Gaal**

Chief Financial Officer

Circio Holding ASA



**Lilian Alcaraz**

VP, Early Innovation

Partnering EMEA

Johnson & Johnson  
Innovation

## Information is the key: What should you have ready to present your academic asset to potential industry partners?

Day 1 - Tuesday, December 3<sup>rd</sup> | 3.00 - 3.45 pm - Panel discussion

Strasbourg room

Effective communication and presentation of academic assets are essential for engaging potential partners. At what point is a university research asset considered ready to seek potential partners? What information is essential for effectively presenting to industry? How do research and development teams evaluate opportunities and assess the potential value of academic assets? What are the respective roles of the researcher and the university in the preparation process?

#### Moderator



**Markus Lang**

Managing Director

Dr Lang Consulting



**Katya Ascher**

Counsel

McDermott Will & Emery



**Geoff Davison**

CEO

Bionow



**Benjamin August**

Senior Director, Research  
& Technology Search  
& Evaluation

Daiichi Sankyo

## TTO to TTO collaborations: Examples and success stories of spinning off academic assets from different institutions into a single company

Day 1 - Tuesday, December 3<sup>rd</sup> | 4.15 - 5.00 pm - Case studies

Strasbourg room

This session intends to explore technology pooling between TTOs and how they are working together on innovative assets. What motivates TTOs to collaborate on spinning off academic assets? Which feedback can we get from experience: what works, what doesn't, for which kind of assets? How to overcome the challenge of different organisations working under a license?

#### Moderator



**Jürgen Walkenhorst**

Manager Patents  
and Licenses

PROvendis GmbH



**Eric Wyart**

Operational Director

Réseau LiEU



**Mikaël Le Clech**

Business Development

Manager

ChemBioFrance



**Jürgen Bauer**

Deputy Managing

Director

EMBLEM Technology  
Transfer



# Track 2

## Diving into the venture builder model: Unpacking the value proposition in nurturing biotech assets

Day 2 - Wednesday, December 4<sup>th</sup> | 9.45 - 10.45 am - Panel discussion

Strasbourg room

The venture builder or start-up studio model has gained prominence in nurturing early-stage biotech assets, offering a unique approach to supporting innovation. What distinguishes them from more traditional incubators and accelerators? Is there really a single start-up studio model? How do they collaborate with academic institutions, research organisations, and industry partners? How do venture builders effectively add value to early-stage biotech companies and has this proven effective? What are the challenges and limitations of the model?

### Moderator



**Gerald Law**  
Chief Executive  
Innovation DB



**Clément Bertholet**  
Partner  
AdBio Partners



**William Hariri**  
Co-founder & CBO  
Exert Therapeutics



**Kåre Engkilde**  
Entrepreneur in Residence  
BioInnovation Institute

## The synergy of partnership: The journey of Ipsen and GENFIT

Day 1 - Tuesday, December 3<sup>rd</sup> | 1.30 - 2.00 pm - Fireside chat

Lille room

An inside look into the successful partnership between Ipsen and GENFIT, where leaders from both companies will share the story of their journey from collaboration to impactful innovation. This fireside chat will explore how each partner leveraged their strengths to accelerate drug development, while overcoming challenges, nurturing a collaboration that has become a model for success in the life sciences industry.



**Jean-Patrick Hennebelle**  
SVP, Late Stage Partnering  
Ipsen



**Pascal Prigent**  
Chief Executive Officer  
GENFIT



# Track 3

## From pre-seed to Series A: Accessing early-stage investment

This track aims to understand the mechanisms enforcing investors' presence in early stages of development. Are we witnessing surges of investment in specific therapeutic areas? Who are the new players involved in investing on the biotech sector and what are their pre-requisites? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?

### Gear up for years to come: How to get a 'seedable' company?


Day 1 - Tuesday, December 3<sup>rd</sup> | 5.15 - 6.00 pm - Toolbox session

Strasbourg room


Pre-seed funding is the very first stage for founders to test their hypothesis and prepare for the next round of funding. Yet, at these early-stage times, there is more needed than just good data for companies to attract investors. This panel will try to provide the necessary ingredients to the funding recipe for early-stage companies.

What are investors looking for in a successful pre-seed company? What role TTOs and incubators play in supporting biotech at the pre-seed financing stage? How to prepare for your first round of financing? What are the investors' expectations in terms of governance? How to build an early-stage biotech dream team and set a healthy ground ready to handle the future ups and downs?


#### Moderator



**Shobhit Dhawan**  
Fund Manager  
Oncode Bridge Fund 🇮🇳



**Ulrich Mahr**  
Member General Manager  
Max Planck Innovation 🇩🇪



**Jeroen Blokhuis**  
Head of Academic Innovation Sourcing and VC Partnership Europe  
General Inception 🇳🇱



**Marie Duranteau**  
Associate, Program Manager  
Sofinnova Partners 🇫🇷

## Biotech investors' forecast: Where will early-stage investment go in 2025?

Day 2 - Wednesday, December 4<sup>th</sup> | 11.15 am - 12.30 pm - Panel discussion

Strasbourg room

It's time for an end-of-year review of biotech investing; expert investors share the trends they saw for 2024 and the deals that made a difference. Was 2024 a good year for early-stage investing? Where did larger funds' money go? What was the geographical diversity of early-stage deals? What's under and on the radar? What can we expect in 2025? Which therapeutic areas will attract or increase VC interest?

#### Moderator



**Philippe Monteyne**  
Partner  
Aliath Bioventures 🇧🇪




**Frank Hensel**  
Principal  
High-Tech Gründerfonds 🇩🇪



**Anela Vukoja**  
COO  
Apollo Health Ventures 🇭🇷



**Oliver Boucher**  
Vice President, Business Development & Strategic Alliances  
Zoetis 🇧🇪



**Florian Denis**  
Investment director  
Elaia Partners 🇫🇷

## Asset-based vs. technology platform-based start-ups: Analysing investors' preferences and mechanisms in funding

Day 2 - Wednesday, December 4<sup>th</sup> | 3.15 - 4.15 pm - Panel discussion


Strasbourg room

Biotech start-ups may adopt different business models, either focusing on developing specific assets or leveraging technology platforms to address multiple indications. What are the key differences between asset-based and technology platform-based start-ups, and how do they impact investors' perceptions and preferences? What are the advantages and challenges of each business model from an investment perspective, and how can entrepreneurs effectively communicate their value proposition to investors? How do funding mechanisms vary and what implications do they have for entrepreneurs?


#### Moderator




**Ester Caffarel-Salvador**  
Director, Strategic Innovation, Rare Diseases  
Chiesi USA 🇺🇸



**Farzad Abdi-Dezfuli**  
Partner  
Sarsia 🇩🇪



**Paul Bravetti**  
CEO  
Brenus Pharma 🇮🇹



**Audrey Cacaly**  
Life Science Venture Capital Principal  
Forbion 🇧🇪



**Andreas Kastenbauer**  
Partner  
MIG Capital 🇩🇪

# Track 4

## Animal Health Highlights

This track features the latest innovation challenges in animal health R&D and intends to provide a clear understanding of the bridges that can be built between human and animal health. International experts from veterinary research and industry will discuss the latest initiatives to improve and accelerate the development of new diagnostics, vaccines and pharmaceuticals for animal diseases and beyond.

### Investors and Animal Health: Expectations and perspectives for 2025

Day 1 - Tuesday, December 3<sup>rd</sup> | 2.00 - 2.45 pm - Panel discussion

Marseille room

Co-organised by:



Supported by:



The animal health market is influenced by the demand of sustainable products, the ongoing search for more efficiency, safety and quality, as well as the evolving behaviour of a younger generation towards animal health services. In this session, key players of the sector will discuss the current challenges in animal health investments. What is the state of market dynamics in animal health investments and what trends can we anticipate for 2025? How can the sector become more appealing to investors and stimulate growing interest? In what ways the One Health approach positively impact the sector and what roles can companies and investors play in drawing the bigger picture?


#### Moderator



**Pascal Breton**  
Manager Business Development & Global Alliances, Europe  
Vetoquinol



**Oliver Boucher**  
Vice President, Business Development & Strategic Alliances  
Zoetis



**Gueric Radière**  
Independent vet and consultant, Investor  
Animal Health  
Angels



**Steve Nanchen**  
Senior Director, Head External Innovation  
Elanco Animal Health

## The Ageing of Man and Animal: Crafting longer, happier and healthier lives for an ageing population of Pets and People through collaborative translational approaches

Day 1 - Tuesday, December 3<sup>rd</sup> | 3.00 - 3.30 pm - Panel discussion

Marseille room

Sponsored by:

Zoetis, the world's leading animal health company, invites you to explore how human and animal health can converge for the mutual benefit of people and companion animals. While technological advancements in human and veterinary nutrition and medicine have helped to extend the lifespans of humans and pets alike, with a larger population of elderly patients we witness a corresponding rise in the incidence of certain chronic and age-related health conditions. Innovative solutions to enhance the care and quality of life for both people and our animal companions are more necessary than ever.

This session will explore how cutting-edge innovations in human medicine can be harnessed to enhance the quality of life of aging pets, and how data generated in animal patients can accelerate the development of human medicines. As we delve into the shared pathways of chronic diseases between pets and people, we will discuss the potential for startups and innovators in the human health sector to contribute to the progression of veterinary medicine while creating additional revenue streams for their businesses. We will discuss the scientific and regulatory parallels that guide the development of medicines across both industries, emphasizing the mutual benefits that arise from this interdisciplinary approach. Join us to discover how the latest breakthroughs in human health can pave the way for transformative therapies in animal care, ultimately leading to a longer, happier and healthier future for our cherished four-legged companions.



**Dieter Vancraeynest**  
External Innovation Lead  
Zoetis



# HOSTED EVENT

## R&D DATING FOR ANIMAL HEALTH AND INNOVATION



BioFIT 2024 hosts the 10<sup>th</sup> edition of the “R&D dating for Animal Health and Innovation” business convention, at the initiative of the French association for the Animal Healthcare industry (SIMV).

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups). By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourages investments and leads to therapeutic innovation.

### Conference session

#### Investors and Animal Health: Expectations and perspectives for 2025

Day 1 - Tuesday, December 3<sup>rd</sup> | 2.00 - 2.45 pm - Panel discussion Marseille room

### Animal Health Presentations

The Animal Health Presentations allow **young companies, TTOs, universities, research institutes and companies** to showcase their innovative project in front of potential partners and investors in the Animal Health sector.

Day 1 - Tuesday, December 3<sup>rd</sup> | 4.15 - 5.00 pm BioFIT Innov'Area

Organised by:  **SIMV**  
SYNDICAT DE L'INDUSTRIE DU  
MÉDICAMENT ET DIAGNOSTIC VÉTÉRINAIRES



# HOSTED EVENT

## AWARDS CEREMONY – PUI LILLE INNOVATION CONTEST

Day 2 - Wednesday, December 4<sup>th</sup>, 2024 | 3.30 - 4.30 pm

Lille room



Designed to encourage and support entrepreneurial spirit, the PUI Lille Innovation Contest is part of a collective approach aimed at raising awareness of the partnership culture among the entrepreneurs selected.

The PUI Lille Innovation Contest is an essential component of the regional and national strategy to promote the development of Deep Tech in France! Its aim is to stimulate the desire for entrepreneurship, to intensify the flow of deeptech projects within the PUI Lille perimeter, and in relation to 5 priority issues in the region:

- Energy solutions,
- Chemistry, materials and production systems for a world in transition,
- Cultural and creative economy,
- Digital, robotics and electronics,
- Technologies and innovations in health and well-being.

The competition is aimed at students, doctoral students, engineers, researchers and healthcare professionals working for one of the PUI's founding members, and invites them to challenge their deeptech project ideas.

### What's in it for the winners?

Prizes worth between €5,000 and €50,000, providing them with technological expertise, contacts, a fast-track route to join the support programmes of the PUI Lille's founding members and partners, training tailored to their needs, and/or visibility at regional and national level

Come and discover the projects taking part in this first edition and the 3 winners who will receive a prize!

Co-founders:



# HOSTED EVENT

## ADVANCING DATA INCORPORATION AND INTEROPERABILITY FOR CANCER IMAGE EUROPE

Day 2 - Wednesday, December 4<sup>th</sup>, 2024 | 9.30 am - 1.00 pm

2.3 room



This workshop offers all attendees an invaluable opportunity to learn about the forefront of data interoperability and incorporation in AI and bioinformatics, especially within the critical field of cancer imaging. Attendees will gain insights into the EUCAIM consortium's efforts to build a scalable, interoperable data framework that aligns with FAIR principles—making data Findable, Accessible, Interoperable, and Reusable. By exploring real-world case studies, hands-on platform demonstrations, and expert panel discussions, participants will understand both the practical challenges and solutions in achieving seamless data integration across complex datasets and models. This knowledge is directly transferable to biotech, medtech, and digital health initiatives, empowering attendees to enhance data standardisation and interoperability in their own projects. Furthermore, this session fosters networking and collaboration, offering direct interaction with EUCAIM's technical leaders and other pioneering organisations focused on advancing data-driven healthcare solutions.

### PROGRAMME

#### 9.30 am Introduction and Overview

9.30 - 9.35 am Welcome and Objectives of the Workshop - Sara Zullino & Nektarios Liaskos, *EATRIS*

9.35 - 9.45 am Introduction to EUCAIM - Patricia Serrano Candelas, *HULAFE*

#### 9.45 - 10.45 am Session 1: Data Incorporation and Interoperability

9.45 - 10.00 am Requirements and Challenges for the Three-tier EUCAIM Data Federation and Interoperability Framework - Valia Kalokyri, *FORTH*

10.00 - 10.15 am Role of Metadata Standards and Ontologies - Christel Daniel & Mirna El Ghosh, *LUMICS*

10.15 - 10.30 am Data Pre-processing Tools and Pipelines - Celia Martín Vicario, *QUIBIM*

10.30 - 10.45 am Tools for Data Interoperability and ETL - Laure Saint-Aubert, *MEDEX* & Víctor Sónora, *BAHIA*

#### 10.45 - 11.15 am Networking Break

#### 11.15 am - 12.05 pm Session 2: Case studies and platform demonstration

11.15 - 11.35 am Case Studies Highlighting Successful Data Integration - Maciej Bobowicz, *GUMED*

11.35 am - 12.05 pm Demonstration of the EUCAIM Platform: Usability, Challenges and Future Outlook - Esther Bron, *ERASMUS MC*

#### 12.05 - 12.55 pm Open Session 3: EUCAIM's Long-term Sustainability

12.05 - 12.25 pm EUCAIM's Long-term Sustainability - Ana Miguel, *MATICAL* & Linda Chaabane, *Euro-Bioimaging*

12.25 - 12.55 pm EUCAIM Panel Discussion: Challenges and Future Directions - Sara Zullino, *EATRIS*, Linda Chaabane, *Euro-Bioimaging* & Patricia Serrano Candelas, *HULAFE*



# EXHIBITORS

## ACTEMIS CONSEIL - STAND D20-F21 /14

[www.actemis.com](http://www.actemis.com)

ACTEMIS is a consulting firm specialising in innovation strategy and financing. We support many start-ups and growing SMEs in the development of their strategic decisions. Our consulting service provides real assistance to entrepreneurs. We tackle the challenges of developing innovative ventures and help you mobilise the financing to achieve your goals. Highly engaged with leaders across various industries, we partner with numerous accelerators, incubators and other competitiveness clusters in France.

## AFSSI - STAND E40-F41 /1

[www.afssi.fr](http://www.afssi.fr)

The AFSSI, the French Association of Service and Innovation Companies for the Life Sciences has the desire to unite French companies of services and technological innovation in the strategic field of Life Sciences.

AFSSI challenges are driven by the vision of life science companies as top players in international competition. AFSSI works toward enriching the life sciences industry with networking, partnering and education opportunities.

## AGATHA INC - STAND F32

[en.agathalife.com](http://en.agathalife.com)

Agatha offers a suite of innovative applications (eTMF - QMS - SOP - Regulatory - Remote Monitoring) dedicated to the life science sector.

With offices in Lyon, Tokyo, Boston, and Shanghai, Agatha enables more than 350 companies and 40,000 users worldwide to streamline their document management, structure clinical study documentation, and secure their quality processes.

Agatha's applications provide highly efficient and easy-to-use solutions and compliant with key regulations.

56

## ANS BIOTECH S.A. - STAND E40-F41 /5

[www.ans-biotech.com](http://www.ans-biotech.com)

ANS Biotech is a French CRO dedicated to the preclinical pharmacology of pain. As a close Pharma and Biotech partner, ANS Biotech helps its Clients to evaluate the efficacy of their candidates using behavioral preclinical models in various pain areas. Since 2006, ANS Biotech has supported over 160 clients worldwide, providing innovative solutions for evaluating the efficacy of drug candidates.

## ANYDIAG - STAND E40-F41 /10

[www.anydiag.fr](http://www.anydiag.fr)

Anydiag is the veterinary pole of the Inovie group, resulting from the merger of 4 veterinary laboratories (including Vebio).

Anydiag offers a wide range of analytical services (including histology) for both GLP-compliant and non-GLP-compliant studies.

Our multi-disciplinary team of qualified veterinarians and technicians benefits from a wide range of training and specializations and constantly improve the quality of our analysis and strengthen communication with our sponsors.

## APOLIKTOS - STAND D20-F21 /12

[www.apoliktos.com](http://www.apoliktos.com)

Apoliktos is a preinception-stage biotech in immunoncology with an international team of experts and founders aiming to develop personalised therapeutics against multiple myeloma.

Apoliktos is establishing a platform, which uses a modular library of neoantigen binders and antibody backbones connected at the patient's bedside for targeted personalised therapeutic antibodies.

## ARTIALIS - STAND E44-F45

[www.artialis.com](http://www.artialis.com)

Artialis is a Contract Research and Development Organisation (CRDO) based in Liege, Belgium offering end-to-end R&D solutions from bench to market for your musculoskeletal product.

## ASEPTIC TECHNOLOGIES - STAND D42

[www.aseptictech.com](http://www.aseptictech.com)

Aseptic Technologies manufactures fill & finish equipment and devices for advanced pharmaceutical manufacturing. Our core expertise lays in the innovation of aseptic filling processes for biopharmaceutical products, including cell and gene therapy products.

As a member of SKAN Group, we leverage technological excellence of SKAN in the isolator design, providing integrated solutions for fill & finish projects, globally. We also share decades of expertise in injection molding and manufacturing.

## ATLANPOLE BIOTHERAPIES - STAND E27

[www.atlanpolebiotherapies.com](http://www.atlanpolebiotherapies.com)

Atlanpole Biotherapies is involved in the medicine of tomorrow, with innovative areas of focus for the development of new therapies and the discovery of unexplored methodologies for human treatments. The projects of network, both academic and industrial, show the excellence of our expertise in personalised medicine.

It is a European Center Of Excellence in 4 domains:

- Biotech/Pharma
- MedTech
- Digital Health
- Disease Prevention

## AUDIT & RISKSOLUTIONS STAND E40-F41 /8

[www.arsolutions.fr](http://www.arsolutions.fr)

Audit & RiskSolutions (A&RS group) is an insurance broker which specialised in Life Sciences with solutions for biotech/pharma/CRO/medical devices/medtechs companies:

- clinical trials
- directors & officers
- liabilities
- supply chain
- properties
- intellectual property
- cyber risks
- ...

## AWEX - AGENCE WALLONNE AUX EXPORTATIONS ET AUX INVESTISSEMENTS ETRANGERS STAND E44-F45

[www.awex.be](http://www.awex.be)

The Walloon Export and Foreign Investment Agency (AWEX) is a public interest organisation in Wallonia created in 1998. It serves as a comprehensive partner for any Walloon company looking to expand internationally and acts as a one-stop shop for any foreign company interested in establishing or expanding its operations in Wallonia.

## BIO ELPIDA - STAND C22

[www.bio-elpida.com](http://www.bio-elpida.com)

Bio Elpida, now part of Sartorius is a CDMO specialising in the cell therapy development process, with GMP production of clinical batches of cell therapies, cell banking and fill and finish.



# EXHIBITORS

## BIOBENCH - STAND C37

[www.bio-bench.com](http://www.bio-bench.com)

BioBench is a biotechnology CRO with a mission to provide high level antibody drug discovery and development service. We focus on delivering best-in-class antibody candidates for clients' therapeutic projects. As of 2024, more than 10 therapeutic antibodies from our platform have entered the clinical trial phase. Would you like to move forward? Talk with us at booth C37 about your challenges. Extended research services: Ab discovery, protein expression, gene synthesis and peptide synthesis.

## BIOLEVATE - STAND E11

[www.biolevate.com](http://www.biolevate.com)

Biolevate leverages artificial intelligence to enhance the speed, accuracy, and compliance of life sciences research. Born from a collaboration between healthcare researchers and AI technologists, we aim to transform complex data into actionable insights, simplifying and accelerating research processes worldwide. We believe that both the user experience and AI models must evolve under the direct influence of domain experts to fulfill the promise of the ongoing technological revolution.

## BIOMNIGENE - STAND E30-F31 /3

[www.biomnigene.com](http://www.biomnigene.com)

BIOMNIGENE, a bio-analysis expert using next-generation sequencing, helps prevent diseases and secure products through genetic analysis. Our services span various sectors (environmental, industrial, medical): microbiome analysis (gut, skin, soil...), biotherapies, species identification, genotyping, and advanced protocol development. Adhering to Good Laboratory and Manufacturing Practices, our tailored solutions include customised sampling kits, combining innovation with precision.

## BIOPARK CHARLEROI - STAND E44-F45

[www.biopark.be](http://www.biopark.be)

Brussels South Charleroi BioPark is a campus that brings together a hundred players and 3,300 people involved in the research, development and production of new therapies, medical devices and diagnostic methods.

We host subsidiaries of large international companies, SMEs from different countries, Belgian companies that are world leaders and three university research institutes from ULB and UMONS. This provides a rich environment in which to collaborate and grow businesses.

## BIOSYMFONIX - STAND A12

[www.biosymfonix.com](http://www.biosymfonix.com)

At Biosymfonix, we're not just another game-design company, we are a company that would like to enhance understanding of complex topics through our visionary game tools that allow personal sense-making and relatability, thereby improved learning. Our games are used by leading institutions around the globe. Apart from making off-the-shelf serious games, our offerings also include tailored serious game and gamification solutions, consultations, workshops, and publishing of serious games.

## BUSINESSOULU - STAND E14-F13

[www.ouluhealth.fi](http://www.ouluhealth.fi)

BusinessOulu strives to promote innovation, growth and competitiveness of companies in many sectors as well as bring new investments to the Oulu region. BusinessOulu's Health & Life Science unit supports companies in developing their health solutions, internationalisation and entrepreneurial success. We are also actively involved in OuluHealth ecosystem's activities.

Bring your knowledge, networks, and passion to our community, and let's make the future healthier.

## CARBOGEN AMCIS - STAND C15

[www.carbogen-amcis.com](http://www.carbogen-amcis.com)

CARBOGEN AMCIS provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. We also offer high quality Cholesterol and Vitamin D analog products produced at our facility in The Netherlands.

## CARLA BIOTHERAPEUTICS STAND E30-F31 /9

[www.carla-biotherapeutics.com](http://www.carla-biotherapeutics.com)

Carla Biotherapeutics is a Biotech company developing first-in-class adoptive cell therapies tailored to treat diseases with high unmet medical need with a first focus on aggressive life-threatening cancer. Carla Biotherapeutics is a company of the Landmark Bioventures nexus spin off of the EFS and Franche-Comté University in Besançon. Carla is founded by a team of seasoned clinicians, cell therapy scientists and biotech professional with access to a world-class and unique cell-therapy platform.

## CARNOT FRANCE FUTUR ELEVAGE STAND E37

[www.francefuturelevage.com](http://www.francefuturelevage.com)

Carnot France Futur Elevage is a french public research network, certified by the french ministry of research, that provides R&D competences to livestock farming sector businesses, including animal health, genetic selection, animal nutrition, socio-economic changes in the livestock industry, and livestock farming practices.

The main objectif of Carnot France Futur Elevage is to develop public-private partnership in order to support innovations for tomorrow's sustainable breeding.

## CELLURA - STAND C42

[www.cellura.io](http://www.cellura.io)

Based on a disruptive stirring principle, Cellura has developed a new kind of low shear bioreactor with efficient resuspension capacities and scalable. Our mission is to empower the bioproduction of shear-stress sensitive cells (i.e. : stem cells) that are of major interest for healthcare and agri-food markets. With our first version of our bioreactors, the SoftXS, you can unlock your process of production and going further into your development.

## CER GROUPE - STAND D26

[www.cergroupe.be](http://www.cergroupe.be)

CER Groupe is a Belgian Research Center supporting human and veterinary health through non-clinical development, bioproduction and analytical CRO services offered to life sciences industry. Our 200+ people are committed to offer flexible and integrated solutions, from innovative research to GLP/ISO services, at the highest quality standards (ISO9001, ISO17025 and GLP).

## CHARLES RIVER LABORATORIES STAND E40-F41 /3

[www.criver.com](http://www.criver.com)

At Charles River, our goal is to accelerate the development and safety of discoveries, drugs, and products. We actively collaborate with academia, biotech, pharma, and governments to provide research solutions. Our extensive portfolio includes in vitro and in vivo studies, drug discovery support, safety assessment, manufacturing, and more. Through collaborations, we contribute to patient safety and drug efficacy by advancing vital treatments and therapies.

# EXHIBITORS

## CILCARE - STAND E40-F41 /9

[www.cilcare.com](http://www.cilcare.com)

Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.

## CILOA - STAND E40-F41 /7

[www.ciloa.fr](http://www.ciloa.fr)

Ciloa, a pioneer in the field of exosomes bioengineered in vivo with membrane and/or cytosolic proteins to develop innovative preventive and therapeutic solutions, will present its GLP-1RA-disrupting co-agonist, Adiponectin stabilised on exosomes. This co-agonist boosts all the therapeutic effects of GLP-1RA on obesity/diabetes/MASH, in particular adiponectin triggers full recovery of insulin sensitivity while protecting against any loss of muscle mass.

## CLINGLOBAL - STAND E12

[www.clinglobal.com](http://www.clinglobal.com)

Clinglobal is a CRO group dedicated to providing solutions to the bioscience R&D sector. From our facilities in Europe, North America, and Africa, we offer preclinical and lab clinical studies in research, companion and production animals, animal clinical and comparative medicine field studies, data management and statistical analysis, histopathology, molecular biology, microbiology, clinical pathology and immunology, product development, regulatory affairs, and quality assurance consultancy.

## CLUBSTER NHL - STAND D20-F21 /3

[www.clubster-nhl.com](http://www.clubster-nhl.com)

Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 360 members in the Nutrition, biotechnology and health sectors. We foster collaboration between academia, private companies (start-up, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes. The activity encompasses the ONE HEALTH concept, close relation between human, animal and plant health.

## COLLABORATIVE DRUG DISCOVERY (CDD) STAND A18

[www.collaborativedrug.com](http://www.collaborativedrug.com)

Collaborative Drug Discovery (CDD) offers a software suite used by biologists and chemists in academia, biotech, and pharma. Our flagship product, CDD Vault, allows researchers to organize and analyse biological and chemical data, collaborate via a web interface, register entities, track inventory, manage bioassay data, capture experiments, capture and share results, and mine data for drug candidates. CDD Vault excels in intuitive design, performance, and secure data sharing.

## DAMOCLES DX - STAND B11

[www.damoclesdx.com](http://www.damoclesdx.com)

Founded in 2023 in Limoges, DAMOCLES Diagnostics develops a point-of-care diagnostic technology for veterinary clinics. It measures a microorganism's biophysical properties within minutes from samples like milk or urine, enabling pathogen identification and antibiotic sensitivity testing. The DAMAST system has been validated on 500 bacteria/antibiotic combinations. The 8-person team is supported by INSERM labs RESINFIT and CAPTUR.

## DELPHARM - STAND B16

[www.delpharm.com](http://www.delpharm.com)

Delpharm is a French CDMO within the top 5 Worldwide. We have more than 30 years' experience manufacturing drug products for our clients (solid, semi solid, liquid, injectable).

We offer:

- Early formulation,
- Process development,
- Analytical methods,
- Stability studies (ICH, accelerated),
- Clinical batches manufacturing
- Commercial manufacturing.

## DEV4ALL - STAND D20-F21 /9

[www.dev4all.bio](http://www.dev4all.bio)

Created by 4P-Pharma, Dev4All is backed by a decade-long track record of a key player in fostering academic scientific innovations. Passionate about science and accelerating R&D, we translate ideas into clinically effective therapeutics. Dev4All provides optimal preclinical development options and insightful decision-making support. Our expertise lies in crafting the optimal experimental in vitro and in vivo model that links the drug's mechanism of action to the disease's pathophysiology.

## DIATHEVA - STAND E39

[www.diatheva.com](http://www.diatheva.com)

DIATHEVA is an Italian biotech CDMO founded in 2002 with the aim to bring research into industrial production by cooperating with firms, public and private institutions. The strong internal know-how makes DIATHEVA the best partner for: Research, development and GMP production of biologics (antibodies, recombinant proteins, enzymes) Research, development and manufacturing of human, veterinary and environmental assays based on both immuno-enzymatic and molecular techniques (ELISA and PCR).

## DRUGABILIS - STAND E40-F41 /2

[www.drugabilis.com](http://www.drugabilis.com)

DRUGABILIS is an established preclinical CRO specialised in assessing the pharmaceutical drugability of early R&D compounds, including cytotoxic drugs. Our expertise includes Early Formulation, from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, topical) and API Solid Form Characterisation and Optimisation (salts, polymorphs). With more than 270 clients supported over 20 years, our experience often makes the difference!

## DYNAPPS - STAND F15

[www.dynapps.eu](http://www.dynapps.eu)

Dynapps, the leading Odoo Gold Partner, empowers businesses with Odoo, the robust ERP and CRM trusted by 12 million+ users globally. Founded in Belgium with offices worldwide, our team of 150 experts optimises operations, reduces costs, and drives revenue growth. With 14+ years of experience, ISO-certified processes, and a 97% client retention rate, we deliver fast, cost-effective implementations and industry-specific solutions like our fully integrated LIMS for lab operations.

## EFOR GROUP - STAND D12

[www.efor-group.com](http://www.efor-group.com)

Founded in 2013, the Efor Group has established itself as one of the leaders in Life Sciences consulting, today bringing together a team of 2,500 employees in 4 countries (France, Belgium, Switzerland, USA). We mobilise all our expertise and methods to ensure that our customers' healthcare products (pharmaceutical, medtech or biotech) are brought to market and kept there, in a constantly evolving technical and standards environment.

# EXHIBITORS

## ENALEES - STAND C40

[www.enalees.com](http://www.enalees.com)

Enalees develops and produces isothermal PCR rapid tests that enable veterinarians to diagnose suspected infectious diseases.

Enalees offers over 50 tests in 2 ranges: Epona® (horses) and Astéria® (dogs/cats). They can detect over 20 infectious diseases, including borreliosis (the agent of Lyme disease), strangles, influenza and leptospirosis, in just 30 minutes.

250 veterinary clinics and hospitals (including 80% of French equine clinics) use Enalees tests.

## ERBC - STAND C11

[www.erbc-group.com](http://www.erbc-group.com)

Stemming from the merger of two reference CROs in pharmacology and toxicology (CERB and RTC), European Research Biology Center (ERBC) is a European leader in non-clinical studies.

It offers to healthcare and chemical professionals a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.

## EURASANTÉ - STAND D20-F21 /3

[lille.eurasante.com](http://lille.eurasante.com)

Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurasante provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 12 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

## EUROFINS - STAND C36

[www.eurofins.com/biopharma-services/cdmo/services/adme-cdmo-optimized](http://www.eurofins.com/biopharma-services/cdmo/services/adme-cdmo-optimized)

Eurofins ADME BIOANALYSES services: Small & Large Molecule Bioanalyses, Biomarkers & Metabolites, Method Development & Validation, ADME, PK/PD, Discovery, Pre-Clinical & Clinical, Topical Product Development.

Eurofins CDMO services: Preformulation, Formulation Development, DP Manufacturing, Clinical Trial Supply and Logistics, CMC/RA.

Eurofins OPTIMED services: Protocol Development & Study Design, Regulatory Analysis / Submission, Site and Trial Monitoring & Management, Bioanalysis, Biometry.

## EUROFINS BIOPHARMA PRODUCT TESTING FRANCE - STAND D24

[www.eurofins.fr/biopharma-product-testing](http://www.eurofins.fr/biopharma-product-testing)

The Eurofins BioPharma Product Testing France laboratory network is a CRO that provides the pharmaceutical, biotechnology and medical device industries with analytical services, in accordance with regulations (EMA, FDA, ISO, etc.) and current GMP, GLP and Cofrac standards, for the development and marketing of human and veterinary (bio)medicines and medical devices.

## EUROGENTEC - STAND E44-F45

[www.eurogentec.com](http://www.eurogentec.com)

Eurogentec is an international company founded in 1985 and part of Kaneka Corp.

Eurogentec is recognised as one of the major suppliers in the field of genomics and proteomics as well as a trusted CDMO for the production process development and manufacturing of vaccines and medicines.

Eurogentec provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic development.

## EUROSCREENFAST - STAND E44-F45

[www.euroscreenfast.com](http://www.euroscreenfast.com)

EuroscreenFast is a pioneer in GPCR science for more than 30 years, offering over 1,000 functional assays (more than 530 GPCR and other targets) and an impressive deorphanisation track record with the identification of 17 natural receptor-ligand pairs. Custom assay development and specialised tools to bridge the gap between in vitro and in vivo data are even more reasons why therapeutic developers worldwide know that EuroscreenFast is the unrivalled GPCR development partner.

## FC'INNOV - STAND E30-F31 /5

[www.fcinnov.fr](http://www.fcinnov.fr)

FRANCHE-COMTE' INNOV is a partnership foundation created in 2013 by the University of Franche-Comté to ensure the interface between academic research and the socio-economic world.

It is an organisation promoting activities of general interest, in line with the missions of the public service of higher education.

In 2022, the EFS Bourgogne Franche-Comté and SUPMICROTECH have joined the UFC to be a founding members of FC'INNOV.

## FETCH - STAND D32-E31 /5

[www.fetch-research.com](http://www.fetch-research.com)

Despite a growing number of available targeted treatments, their usage in metastatic cancer is limited due to a lack of target expression information.

FETCH provides this patient specific, up-to-date treatment target information in metastatic cancer. For this, FETCH utilises the existing technology of leukapheresis, allowing analysis of circulating tumour cells from the full blood volume.

FETCH offers investment and collaboration opportunities to improve and expand its innovative workflow.

## FIRALIS MOLECULAR PRECISION STAND D46

[www.firalismolecularprecision.com](http://www.firalismolecularprecision.com)

Firalis Molecular Precision (FMP) is a fast-growing provider of advanced BioAnalytical Testing services to the Life Sciences sector, based in Huingue, France and in Cambridge, USA. FMP's team has extensive expertise in multi-omics and leverages cutting-edge platforms to provide a range of services - sample storage and management, multi-omics analysis, data analysis, assay development and production - to provide support in the drug development process.

## FLANDERS INVESTMENT AND TRADE STAND E34

[www.flandersinvestmentandtrade.com](http://www.flandersinvestmentandtrade.com)

Flanders Investment & Trade (FIT) is your premier partner for growth in the medtech and biotech sectors. Positioned in one of the world's most open economies, Flanders fosters a dynamic life sciences ecosystem, spanning biotech, medtech, pharma, and healthcare. From start-ups to multinationals, Flanders offers robust support, funding, and a collaborative network that drives innovation. Join us in expanding your business in this strategic hub where opportunity and expertise meet.

## FLOWBEAMS - STAND D32-E31 /4

[www.flowbeams.com](http://www.flowbeams.com)

FlowBeams is developing a groundbreaking needle-free injection technology that aims to revolutionise industries like pharmaceuticals and cosmetics. Our innovative approach tackles issues linked to traditional needle methods, such as needle-phobia, environmental pollution, and safety concerns. We strive to offer personalised, safe, and comfortable treatment options for millions while promoting sustainability by reducing the hazardous waste produced by conventional injections.



# EXHIBITORS

## **FUJIREBIO - STAND E16**

[www.fujirebio.com](http://www.fujirebio.com)

Fujirebio is a global leader in the field of in vitro diagnostic (IVD) testing, development and production of IVD products, from specialised to fully automated clinical laboratory testing covering a range of pathologies. Pioneer in the diagnosis of Alzheimer, Fujirebio has developed this expertise by developing new biomarkers for the screening, diagnosis and treatment monitoring of neurodegenerative diseases for better patient care in a very dynamic environment in terms of new treatments.

## **GENOPOLE - STAND B14-C13/2**

[www.genopole.com](http://www.genopole.com)

The Genopole biocluster is based on an innovative concept: bringing together biotechnology companies, academic laboratories, and institutions of higher education in a single location. Its aim is to support research, promote innovation with a therapeutic focus, and facilitate the transfer of technologies to industry. Although health remains the main area of development for Genopole, other sectors are also experiencing significant growth.

## **GOODBOT GMBH - STAND A16**

[www.goodbot.de](http://www.goodbot.de)

We are a life-science robotics startup transforming biomedical research with an agile pipetting assistant. As a small and affordable automation solution, goodBot streamlines pipetting tasks, while fitting into confined spaces. It enhances result reproducibility, saves time, and empowers scientists to focus on groundbreaking work. With its user-friendly software, experimental set-ups only take few minutes accelerating discoveries to shape a healthier future for all.

## **GRECO - STAND D20-F21/5**

[www.u-picardie.fr/entreprises-et-partenaires/innover-ensemble/groupement-recherche-detudes-en-chirurgie-robotisee-greco](http://www.u-picardie.fr/entreprises-et-partenaires/innover-ensemble/groupement-recherche-detudes-en-chirurgie-robotisee-greco)

Amiens-Picardie University Hospital is one of 2 universities hospitals and health research institution in the Hauts-de-France region, in partnership with UPJV. SimUSanté®-Epione is a center of excellence in innovative training funded by the National Research Agency. It's the largest European interprofessional healthcare simulation center. The GRECO is a federative institute of research of UPJV dedicated to surgery using robotic assistance and IA focused on surgical innovation via simulation.

## **GROUPE ICARE - STAND D10**

[www.groupeicare.com](http://www.groupeicare.com)

With 30 years experience, the Groupe ICARE stands out as a European CRO leader in international standardisation and regulation. We guide healthcare industry through the complex regulatory landscape, ensuring that every device and products is marketed in full compliance and safety.

Our expertise covers a wide range of services critical to deliver the excellence and compliance of your products: Biocompatibility & Toxicology, Validation & Qualification, Microbiology & Contamination Control...

## **HONG KONG TRADE DEVELOPMENT COUNCIL - STAND E15**

[www.hktdc.com](http://www.hktdc.com)

The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.

## **INCUBALLIANCE PARIS-SACLAY STAND B14-C13/1**

[www.incuballiance.fr](http://www.incuballiance.fr)

An incubator for public research and an expert in deeptech entrepreneurship, IncubAlliance Paris-Saclay supports start-ups from the early stages through to the growth phase, and promotes the results of public research through the creation of new companies. IncubAlliance Paris-Saclay receives financial support from the French Ministry of Higher Education and Research, the Île-de-France Region, the Paris-Saclay Agglomeration Community and the European Union.

## **INNOBIOCHIPS - STAND D20-F21/1**

[www.innobiochips.fr](http://www.innobiochips.fr)

Because improved diagnostic solutions contribute to a more precise and personalised medicine and improve the quality of life for patients worldwide, Innobiochips provides disruptive technologies to improve the accuracy, quality and sustainability of in vitro diagnostic approaches.

## **INNOBIOVIR - STAND B15**

[innobiovir.univ-lyon1.fr](http://innobiovir.univ-lyon1.fr)

InnoBioVir is an academic platform resulting from a synergistic alliance between research laboratories and educational platforms. IBV is aimed at supporting innovation in the field of production of innovative therapies. Thanks to a high-quality service, ensured by our solid expertise covering the entire production chain of a biomedicine, access to state-of-the-art equipment and partnerships of excellence, InnoBioVir offers custom services, R&D collaborations and industry-oriented trainings.

## **INNOKAS - STAND E14-F13**

[www.innokasmedical.fi](http://www.innokasmedical.fi)

As a Nordicly reliable full-service CDMO for smart medical devices and SW, our job is to help you create, manufacture and bring safe, effective, compliant and more sustainable products into the market. Innokas is a growing and agile technology service company with 30 years of experience in the Medtech field. We offer flexible product development, SW development, contract manufacturing, and quality & regulatory services to meet our customers' outsourcing needs throughout the product's life cycle.

## **IPEPS THE HEALTHTECH HUB - INSTITUT DU CERVEAU - STAND B12**

[ipeps.institutducerveau-icm.org](http://ipeps.institutducerveau-icm.org)

We support researchers, healthcare professionals, and innovators in launching start-ups in neuroscience. Since 2012, iPEPS has provided a unique accelerator, helping startups in biotech, medtech, and digital solutions. NeurAL, created in 2022, offers philanthropic support to early-stage neuroscience projects with high potential. Together, iPEPS and NeurAL provide resources, funding, and mentorship, enabling over 100 start-ups to thrive, raise capital, and bring innovative products to market.

## **IRCCS CENTRO NEUROLESI BONINO PULEJO - STAND E26-F25**

[www.irccsme.it](http://www.irccsme.it)

IRCCS Centro Neurolesi Bonino Pulejo, located in Messina (Italy), established in 1992 and recognised by Italy's Ministry of Health as an Institute of Hospitality and Care, is a leading neuro-rehabilitation institute. It became a public institute in 1997, excelling in healthcare delivery and scientific research. The Center is noted also for its advanced technological capabilities in robotics and virtual reality, essential for treating severe acquired brain injuries and neurodegenerative diseases.

# EXHIBITORS

## **IRCCS OSPEDALE GALEAZZI - SANT'AMBROGIO - STAND E26-F25**

[www.grupposandonato.it/strutture/ospedale-galeazzi-sant-ambrogio](http://www.grupposandonato.it/strutture/ospedale-galeazzi-sant-ambrogio)

IRCCS Ospedale Galeazzi Sant'Ambrogio is a teaching and research hospital in Milan, Italy. It is a center of excellence in clinical and pre-clinical biomedical research, mainly in the orthopaedics and musculoskeletal fields, with 4 focus areas:

- 1) Tissue engineering and advanced cell therapy;
- 2) Surgical, pharmacological, and technological innovations;
- 3) Bioengineering applied to surgical and rehabilitative therapies;
- 4) Biochemistry, genetics, physiology, and related systemic diseases.

## **IRCCS SAN RAFFAELE - STAND E26-F25**

[sanraffaele.it](http://sanraffaele.it)

The IRCCS San Raffaele in Rome is a leader in the field of rehabilitation, a point of reference in research and in the national healthcare scene. Patient care, supported by the best specialist knowledge and the most advanced technologies for a more effective diagnosis, is complemented by a multidisciplinary approach and supported by a Research activity articulated in 13 clinical and 14 preclinical research areas divided into 45 laboratories.

## **KADANS SCIENCE PARTNER STAND B14-C13/4**

[www.kadans.com](http://www.kadans.com)

Kadans Science Partner is the European leader in investment, development and operating specialised assets in knowledge-intensive environments across Europe, for innovative companies in life sciences and high technologies. Founded over twenty years ago in the Netherlands, Kadans is present in 27 academic campuses and research centers in the Netherlands and then in Europe. Kadans develops world-class technical real-estate at the cutting-edge of new collaborative uses and technology and contributes to support the innovation and knowledge ecosystems (universities, research institutes, incubators, industries) offering them the best workspace environment.

## **LABORATOIRE BACCINEX SA - STAND E47**

[www.baccinex.com](http://www.baccinex.com)

Baccinex SA is a leading Swiss contract development and manufacturing organisation (CDMO) specialising in sterile liquid and lyophilised products. Renowned for its expertise, Baccinex provides end-to-end services, from pharmaceutical formulation development to clinical and small-scale commercial manufacturing. Committed to quality and innovation, it partners with global clients, ensuring efficient, reliable, and compliant solutions tailored to their unique needs.

## **LATERAL DX - STAND C46**

[www.lateraldx.com](http://www.lateraldx.com)

Lateral Dx delivers lateral flow test services to a wide range of industries. Our aim is to provide high quality and cost-effective lateral flow development, manufacture, consultancy and rapid antibody screening services to our business partners. With over 25 years' experience in the lateral flow assay industry we can assist you with every step of your lateral flow test development journey, from short Proof of Principle studies all the way through to full test development and reagent screening.

## **LCSB - STAND D44-E45**

[www.uni.lu/lcsb](http://www.uni.lu/lcsb)

The Luxembourg Centre for Systems Biomedicine (LCSB) is one of the four interdisciplinary research centres of the University of Luxembourg, focusing on a broad spectrum of disciplines – from computational biology to clinical and experimental neuroscience – to study the brain and its diseases.

## **LIST - STAND D44-E45**

[www.list.lu](http://www.list.lu)

The Luxembourg Institute of Science and Technology (LIST) is a mission-driven Research and Technology Organisation that develops competitive and market-oriented product / service prototypes for public and private stakeholders.

## **LUO AUTOMATION - STAND D32-E31 / 1**

[www.luoautomation.com](http://www.luoautomation.com)

Luo improves the visual inspection of liquids for pharmaceutical applications. We develop and produce automated visual inspection machines that relieve the manual tasks.

We believe that this technology should be accessible to both larger and smaller companies. Therefore, Luo delivers machines with speeds ranging from 50-1500 containers per hour. Showing proof and sharing knowledge guarantees a successful implementation of our machine in your facility.

## **MEDITOX S.R.O. - STAND D40**

[www.meditox.eu](http://www.meditox.eu)

MediTox is a GLP-certified CRO with experience in variety of compounds and therapeutic areas, capable to conduct experiments and studies in full compliance with GLP standards and another international guidelines (EMA/ICH, VICH, OECD, FDA, ISO10993), providing core range of nonclinical studies supporting phases I - III of clinical trials and/or registration of human drugs, medical device and food additives and safety/BEQ/efficacy studies for registration of veterinary drugs and feed additives.

## **MENARINI BIOTECH - STAND B38**

[www.menarini-biotech.com](http://www.menarini-biotech.com)

Menarini Biotech is a fast-growing, fully integrated, CDMO for biologics located in the greater Rome area, Italy. Established in 2003, Menarini Biotech's mission is to provide world-class, high-quality, services for biotech companies from preclinical dev. to GMP manufacturing up to BSL-2. These include CHO cell line dev. and analytical dev. for standard and non-standard mAbs, and new molecular formats, e.g. bispecifics, ADCs, fusion proteins. Our QS complies with AIFA/EU/FDA cGMP requirements.

## **MICROSYNTH FRANCE - STAND E41**

[www.microsynth.com](http://www.microsynth.com)

Microsynth (founded in 1989) is a leading European company in the synthesis and analysis of nucleic acids. Its main activities are divided into the following three areas:

- DNA/RNA synthesis
- DNA/RNA analysis and sequencing
- Contract research/project outsourcing

## **NEW ENGLAND BIOLABS FRANCE STAND C21**

[www.neb-online.fr](http://www.neb-online.fr)

NEB is a key supplier of reagents for the life science industry since 1974. NEB offers a wide range of innovative enzymes, reagents and kits for molecular biology.

The quality of our solutions (ISO 9001 / 13485, RUO or GMP-grade) and our capabilities make NEB the partner of choice to support needs associated with the development of MDx, vaccines or therapies.

Come and discuss with our team about your customisation, bulk/OEM, kitting or lyophilisation needs.

# EXHIBITORS

## **NEXOMIS - STAND B22**

[www.nexomis.io](http://www.nexomis.io)

Based in Lyon, France, Nexomis is a spin-off from the University of Lyon 1 (UCBL1), emerging from the Virnext platform. With years of expertise in bioinformatics across various biological fields, our mission is to provide cutting-edge technological support to the scientific and socioeconomic communities leveraging Omics data, including academic researchers, private sector R&D teams, diagnostic lab in health, environment or agronomy.

## **NEXTPHARMA - STAND B42**

[www.nextpharma.com](http://www.nextpharma.com)

NextPharma is a leading European Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with sites located in Germany, France, Finland, Norway and the UK, and with healthcare logistics services in the DACH region. With expertise in solids, semi solids and non-sterile and ophthalmic liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms.

## **NOVALIX - STAND C19**

[www.novalix.com](http://www.novalix.com)

Novalix is a premier drug discovery partner for biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platform to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes.

## **OLINK, PART OF THERMO FISHER SCIENTIFIC - STAND D46**

[www.olink.com](http://www.olink.com)

Olink Proteomics, part of Thermo Fischer Scientific, offers leading solutions for advanced proteomics discovery and development, enabling biopharmaceutical companies and leading academic researchers to gain an understanding of disease at the protein level rapidly and efficiently. Olink's proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis, with a library of more than 5,400 validated protein biomarker targets.

## **OMNISCIENCE - STAND D20-F21 / 10**

[www.linkedin.com/company/omnisciencecloud](http://www.linkedin.com/company/omnisciencecloud)

Omniscience is a French start-up offering the first European platform to simplify clinical trial management by providing a unique workspace for each investigation site. Our intuitive solution centralises data, automates tasks, and concentrates eClinical tools to enhance collaboration between sites, sponsors, CROs, and patients. Sites streamline their operational management, ensuring their engagement and optimising site management.

## **ONCOLOGY REFERENCE CENTRE (CRO) - STAND E26-F25**

[www.cro.sanita.fvg.it](http://www.cro.sanita.fvg.it)

Oncology Reference Centre (CRO) of Aviano is a Scientific Hospitalisation and Cure Institute (IRCCS) classified as a highly specialised center of National importance for Oncology. It is dedicated to the development of excellence in the prevention, diagnosis, treatment and rehabilitation of oncological diseases through multidisciplinary training and patient awareness intervention. It also promotes clinical, preclinical and translational research.

## **PANADEA DIAGNOSTICS GMBH STAND B13**

[www.panadea-diagnostics.com](http://www.panadea-diagnostics.com)

Panadea Diagnostics is a science-driven biotech company in a strong partnership with the Bernhard Nocht Institute for Tropical Medicine. We focus on developing and manufacturing top-quality serological tests for tropical and emerging infectious diseases. Leveraging our patented technology platform, our immunoassay tests have superior specificity and sensitivity, especially targeting the priority diseases in the WHO blueprint list.

## **PARIS-SACLAY DEVELOPMENT AUTHORITY STAND B14-C13 / 5**

[welcometoparissaclay.com](http://welcometoparissaclay.com)

Specialised in understanding the brain and the genome, as well as the treatment of cancer and diabetes, the health sector in the Paris-Saclay responds to current and future health challenges. With world-class higher education establishments and 300 research laboratories and some of the best hospitals in Europe, Paris-Saclay benefits from a complete ecosystem driving health research forward via the crossover of different technologies. More than 100 companies and 15,000 employees work in health R&D.

## **PCV-GROUP - STAND D32-E31 / 3**

[www.pcvgroup.com](http://www.pcvgroup.com)

Handling challenges in the medical market Our dispensing & dosing competences combined with our heating & cooling knowledge have made PCV Group a trusted partner in the medical devices and life science equipment market. In many developments we have been able to crossover experience from areas like food & beverage into this high demanding market. Especially knowledge on high-tech low cost disposables have given us a jump start in various developments.

## **PERFETTO - ITALIAN TECHNOLOGY TRANSFER OFFICE NETWORK IN LIFE SCIENCES - STAND E26-F25**

[www.networkperpetto.com](http://www.networkperpetto.com)

PerfeTTO is the first Italian network of Technology Transfer Offices (TTO) in Life Sciences, funded by the Italian Ministry of Health. Comprising 54 entities, including research hospitals, universities, and research institutions, PerfeTTO aims to bridge the gap between research and innovation. It focuses on developing services, tools, and resources to promote technological development, enhance the global value of Italian scientific research, and foster a national culture of technology transfer.

## **PHARMATORY - STAND E14-F13**

[www.pharmatory.com](http://www.pharmatory.com)

Pharmatory is a private customer-oriented company providing small molecule synthesis, process R&D and cGMP contract manufacturing of active pharmaceutical ingredients (APIs) and critical excipients. The key components in all projects are high dedication to the customer's success and commitment to quality and exceptional customer service. Our worldwide customer base includes both companies running NCE development projects and companies with commercial products.

## **PHINC DEVELOPMENT - STAND C18**

[www.phinc-development.com](http://www.phinc-development.com)

PhinC Development is the expert partner for small to medium sized pharmaceutical or biotech companies, who need to move forward in early drug research. Thanks to a multidisciplinary team with thorough field experience, PhinC Development helps to take the best decisions concerning drug development using all existing pharmacology and pharmacometrics modeling & simulation (M&S) tools.



# EXHIBITORS

## **PORSOLT - PRECLINICAL SERVICES** **STAND E40-F41 /6**

[www.porsolt.com](http://www.porsolt.com)

Porsolt is a long-established preclinical CRO fully GLP compliant. With our Scientist-to-Scientist approach we support you at every step of the preclinical development, providing the best scientific advice and offering tailored solutions for small Molecules, biologics, gene and cells therapies. We have a recognised international reputation for in vitro, ex vivo, and in vivo expertise in physiopathological models, customised procedures, histology, biomarkers, and solutions for discovering treatments in over 10 different therapeutic areas.

## **PRIMO MEDDA - STAND D32-E31 /2**

[www.primomedda.com](http://www.primomedda.com)

As a significant number of patients do not respond well to the existing one-size-fits-all approach for drug development and medicine prescription, there is a clear need for a more personalised approach. Primo Medda focusses on bringing Personalised Medicine as a Service, an end-to-end solution where pharmacists are being supported in personalising medication. We provide this solution through a mobile container, so the impact can be made in even the most remote locations.

## **PROWELLNESS - STAND E14-F13**

[www.prowellness.com](http://www.prowellness.com)

ProWellness provides innovative digital health IT solutions for managing chronic diseases, including diabetes, cardiovascular conditions, and chronic respiratory diseases.

BALANSIO ([www.balansio.com](http://www.balansio.com)) is an intelligent mobile self-management solution featuring digital assistants that offer patients personalised, automated guidance on their smartphones 24/7.

ProWellness Chronic Disease Management System (CDMS) is a specialised clinical system utilised in hospitals and community clinics.

## **QITY - STAND A14**

[www.qity.be](http://www.qity.be)

Qity's experts provide a range of services in Quality Assurance, Regulatory Affairs, Safety Testing, Architecture & Design, Cybersecurity & Data Privacy, Usability Engineering and Clinical to organisations in Life Science industry.

Qity also provide a unified platform that brings all essential activities—product development, HR, cybersecurity, manufacturing, clinical trials, and more—under one roof to streamline operations, simplify compliance, and enhance efficiency across departments.

## **QUALIBLOOD - STAND B17**

[www.qualiblood.eu](http://www.qualiblood.eu)

QUALIBlood aims to provide the industries, hospitals, and universities with all analytical services for blood investigations and hemocompatibility testing.

We offer tailor-made solutions, from the design of analytical protocols up to the development and validation of specific analytical methods in the field of preclinical and clinical studies.

## **QUALITY ASSISTANCE - STAND E44-F45**

[www.quality-assistance.com](http://www.quality-assistance.com)

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products, under one roof, in Belgium. Using our state-of-the-art, product-dedicated expertise in analytical sciences, we assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation.

## **RD-BIOTECH, CRO/CDMO** **BIOMANUFACTURING SERVICES** **STAND C35**

[www.rd-biotech.com](http://www.rd-biotech.com)

RD-Biotech is a French CRO / CDMO providing tailor-made development and production services: plasmid DNA, monoclonal antibodies, recombinant proteins and antibodies, cell lines (R&D, High Quality grades - and GMP grade for pDNA exclusively). Our technological platforms, our capabilities and our expertise allow us to meet your needs to support you in your research, preclinical and clinical projects, up to large-scale batches (up to several grams).

## **RESEARCH LUXEMBOURG** **STAND D44-E45**

[www.researchluxembourg.org](http://www.researchluxembourg.org)

Research Luxembourg aims to become a leader in research & innovation focusing on 3 research priority areas: Industrial and Service Transformation; Personalised Healthcare; Sustainable & Responsible Development. Research Luxembourg is a joint initiative of the main actors in Luxembourg public research, including Luxembourg Institute of Health (LIH), Luxembourg Institute of Science and Technology (LIST), Luxembourg Centre for Systems Biomedicine (LCSB) and Luxembourg National Research Fund (FNR).

## **RESEARCH PIECES - STAND E40-F41 /4**

[www.researchpieces.com](http://www.researchpieces.com)

Deeptech Start-up of Biotechnology based in Poitiers, Southwest of France, our goals are to understand the physiology & the physiopathology of the Central Nervous System through Research, Development & Treatments.

Our preclinical biological & innovative models, an alternative to animal models, to dissect molecular, cellular & tissular mechanisms in a physiological 3D-living tissue environment & find the therapeutic molecules against neurological diseases (neurodegenerative, cancer, etc.).

## **RÉSEAU SATT - STAND C12-D11**

[www.satt.fr](http://www.satt.fr)

The SATT Network brings together 13 Technology Transfer Offices (TTOs) in France. SATTs are committed to foster economic development by providing companies with high-potential technological solutions stemming from French public research to improve their competitiveness. Local, trusted players, we are connected on a daily basis to over 150,000 researchers, and offer privileged access to innovations from public laboratories. We detect, evaluate, protect inventions and bring innovation to the market by entrusting them to an existing company or a future startup. We finance their technological development through an exclusive investment fund. With over 750 start-ups created, SATTs are the first-class local players in the French Government's Deeptech Plan, operated by Bpifrance. With our nationwide network, we are strategic partners for companies seeking growth through innovation.

## **ROOWIN - STAND C17**

[www.roowin.com](http://www.roowin.com)

Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.

We support our customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).

## **SCREENTEC OY - STAND E14-F13**

[www.screentec.com](http://www.screentec.com)

Founded in 1989, Screentec is a Finnish Contract Development and Manufacturing company specialising in printed electronics. Screentec develops and manufactures medical electrodes, diagnostic devices and durable user interfaces. We cater to various industries including medical, automotive, and consumer electronics, delivering custom solutions that meet specific client needs. The company also offers extensive consultation and product development services. We are ISO 9001 and ISO 13485 certified.

# EXHIBITORS

## **SECOYA TECHNOLOGIES SRL** **STAND E44-F45**

[www.secoya-tech.com](http://www.secoya-tech.com)

Secoya, a ULB spin-off in Louvain-La-Neuve (Belgium), provides innovative particle engineering solutions (microfluidics, microparticles, nanoparticles) for the biopharmaceutical industry. Our advanced technologies streamline lab-to-industrial scale processes in crystallization, emulsification/encapsulation, pervaporation, and process intensification, ensuring faster, precise, and secure development and production.

## **SEDIVENTION - STAND E10**

[www.sedivention.com](http://www.sedivention.com)

Sedivention develops a cryo-catheter for a new therapy of obesity. Comparable to gastroscopy, the catheter freezes the gastric trunks of the so-called "hunger nerve" from inside the stomach. An interventional, one-time treatment, avoiding lifelong drug intake, hospitalisation, morbidity, and costs. Sedivention addresses a huge and growing market, owns three international patents, and has developed a prototype, which was successfully tested in first preclinical trials. We help people lose weight.

## **SGS VITROLOGY - STAND C16**

[www.sgs.com](http://www.sgs.com)

SGS Vitrology (Glasgow): As a world leader in biopharmaceutical testing services, we offer you a comprehensive range of biologics safety testing, including virology, cell and molecular biology, as well as microbiology and electron microscopy. As a result, we can help you to ensure product safety and meet your regulatory requirements.

## **SIMV - STAND D36-D38**

[www.simv.org](http://www.simv.org)

The French association for animal health industry (SIMV) represents manufacturers and marketers (on the French market) of medicines and reagents for pets and for farm animals. In order to contribute to the competitiveness of its member companies, the SIMV defines its value creation through its trades:

Federating ;  
Anticipating;  
Advising/training/informing;  
Being watchful;  
Representing the positions of its members.

## **SIRON CLINICAL - STAND D16**

[www.sironclinical.com](http://www.sironclinical.com)

Siron Clinical is a trusted expert in complex clinical trials across orphan diseases, pediatrics, and medical devices. With almost 25 years of regional CRO expertise, our team provides flexible support through a range of services, from Customizable FSP to full-service solutions, designed to grow with your research needs.

## **SPARTNERS - STAND B14-C13/3**

[www.servier.com/en/newsroom/spartners-biotech-start-up-welcome-to-apply](http://www.servier.com/en/newsroom/spartners-biotech-start-up-welcome-to-apply)

Spartners by Servier & BioLabs is on a mission to empower life science innovation in Paris-Saclay by creating a unique place for life science startups to test, develop and grow game changing ideas. Spartners offers state-of-the-art facilities with fully equipped laboratory and office spaces that are supported by an experienced, dedicated, technical team. Designed to build community, Spartners enables high-potential life science companies to work, collaborate and innovate in a setting perfectly suited to meet their needs. Our exclusive approach combines BioLabs' expertise with Servier's know-how, making it stand out in France.

## **SPECTRALYS BIOTECH - STAND E44-F45**

[www.spectralysbiotech.com](http://www.spectralysbiotech.com)

Spectralys Biotech offers analytical services for structural characterisation dedicated to biopharmaceutical products (peptides, proteins, DNA/RNA) leveraging our sharp expertise in infrared spectroscopy (FTIR), atomic-force microscopy coupled with infrared (AFM-IR), circular dichroism (CD) and hydrogen-deuterium exchange monitored by mass spectrometry (HDX-MS). FTIR is exploited for batch-to-batch consistency check and stability studies. HDX-MS is mainly used for epitope mapping.

## **STERLING PHARMA SOLUTIONS** **STAND F40**

[www.sterlingpharmasolutions.com](http://www.sterlingpharmasolutions.com)

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with 50+ years' experience providing small molecule API development/manufacturing services; specialising in challenging chemistries. It also provides Antibody Drug Conjugate (ADC) and peptide development and manufacturing services, and has six facilities across the UK, USA and Europe, employing 1,350+ people.

## **SYNERLAB DEVELOPMENT - STAND B18**

[www.synerlab.com](http://www.synerlab.com)

Synerlab is an European CDMO offering a complete range of services, from pre-clinical to commercial production. Synerlab Development, our R&D Center of Excellence located in Orléans (France), is specialised in development of liquid, solid and sterile forms especially injectable from scratch to industrialisation including clinical supply from Ph1 to Ph3. We are used to develop drug products with small quantity of drug substances (NCEs or NBEs) and are flexible and agile in our development.

## **SYNGENE INTERNATIONAL LTD.** **STAND B36**

[www.syngeneintl.com](http://www.syngeneintl.com)

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA.

## **SYNTHELIS BIOTECH - STAND B20**

[www.synthelis.com](http://www.synthelis.com)

Synthelis Biotech is a French company specialising in the production, purification, and characterisation of proteins using its cell-free technology. Thanks to its proprietary technology, it can synthesize all types of proteins in just a few hours: membrane proteins, toxic proteins, modified proteins, etc., for applications such as drug screening, vaccine and antibody development, and in vitro diagnostics. You can access our expertise either through our service offering or by using our protein expression kits to produce your own proteins.

## **TEMIS - STAND E30-F31**

[www.temis.org](http://www.temis.org)

TEMIS offers a unique approach to translational research in the fields of ATMP and biomanufacturing thanks to Intersection of engineering sciences, microtechnologies and life sciences. The industrial integrator of the French Blood Establishment, suppliers of plasmid RNA, stem cells, monoclonal antibodies, service providers and batch production capacities for early-phase clinical trials make up a dedicated ecosystem. BIO Innovation our Health Tech Center welcomes your projects. Born or settled in TEMIS : Advesya, Carla Biotherapeutics, Cellquest, Diaclone, MIP, RD Biotech.

# EXHIBITORS

## THE LUXEMBOURG INSTITUTE OF HEALTH (LIH) - STAND D44-E45

[www.lih.lu](http://www.lih.lu)

The Luxembourg Institute of Health (LIH) is a public biomedical research institute focused on advancing precision health and translating scientific excellence into impactful healthcare solutions. By prioritising patients and focusing on cancer and immune diseases, LIH fosters industry partnerships to bring marketable health solutions to fruition. Collaborating with industrial partners, LIH accelerates the development of new biomedical tools, ensuring societal and economic benefits.

## TRANSPHARMATION - STAND C38

[www.transpharmation.com](http://www.transpharmation.com)

Transpharmation is an accredited preclinical contract research organisation specialising in translational pharmacology across various therapeutic areas. We offer neuroscience and animal health expertise, using behavioral, electrophysiological and protein-based biomarker assays to help clients benchmark compounds. Committed to on-time data delivery and flexible, customised solutions we support clients in optimising preclinical assets for the development of life-changing medicines.

## TRINITY COLLEGE DUBLIN - STAND C20

[www.tcd.ie](http://www.tcd.ie)

Trinity College Dublin, the University of Dublin has a proud tradition of performing world class research and translating this research excellence into solutions with global economic and social impact. Trinity is the top ranked university in Ireland. Using the QS methodology we are ranked 87<sup>th</sup> in the world and using the Times Higher Education World University Rankings methodology we are 139<sup>th</sup> in the world.

## TRONICO - STAND E25

[www.tronico-agon.com](http://www.tronico-agon.com)

TRONICO is an ISO 13485-certified French company specialising in active medical device engineering and industrial subcontracting.

Founded in 1973, TRONICO has become your privileged partner in all stages of your project, from the design of your medical device to its mass production, including industrialisation and regulatory procedures.

## TWENTE - STAND D32-E31

[www.medtechtwente.nl](http://www.medtechtwente.nl)

The smart manufacturing industry (High Tech Systems and Materials) is characteristic for the Twente region in East-Netherlands. The World Trade Center Twente is building a MedTech cluster together with the Techmed Center at the University and companies in the medical technology sector.

## UNITHER PHARMACEUTICALS - STAND D15

[www.unither-pharma.com](http://www.unither-pharma.com)

Unither Pharmaceuticals is a pharmaceutical subcontractor specializing in the development and manufacturing of single-dose and multidose liquid formulations (including eye drops, saline solutions, asthma medications in BFS single doses, and oral liquid stick-packs) for originator pharmaceutical companies and generic manufacturers. With 2,200 employees and eight manufacturing plants across France, the United States, Brazil and China, Unither Pharmaceuticals reported sales of €475 million in 2023.

## UNITRON GROUP - STAND D14

[www.unitron.nl](http://www.unitron.nl)

Utilising cutting-edge technology, we develop and produce essential medical products with a focus on quality, speed, and flexibility. We serve a diverse range of global customers, from OEMs and SMEs to tech start-ups, often acting as the general contractor coordinating between knowledge centers, technology partners, and regulatory authorities. As a dedicated partner, we are committed to delivering valuable innovations.

## UNIVERSITY HOSPITAL OF LILLE (CHU DE LILLE) - STAND D20-F21 / 15

[www.chu-lille.fr](http://www.chu-lille.fr)

The University hospital of Lille (CHU Lille) is a bench-mark university hospital for primary care, teaching, innovation and research, serving the six million inhabitants of the North of France region. The CHU Lille is structured around 16 departments of excellence and has strong national and international collaborations. Around 400 peoples are fully dedicated to research, managing about 250 research projects and supporting the entire innovation process from idea to valorisation.

## VECTORBUILDER - STAND D39

[vectorbuilder.com](http://vectorbuilder.com)

VectorBuilder is a global gene delivery company providing tailored CRO and CDMO services. We can design and produce custom viral and non viral vectors, mRNA, cell lines and libraries in addition to accompany our researchers from R&D to GMP.

## VETBIOLIX - STAND D20-F21 / 16

[www.vetbiolix.com](http://www.vetbiolix.com)

Vetbiolix is Veterinary Biotech company dedicated to the clinical development of First-in-class drug candidates for Dogs and Cats suffering from Osteoarthritis, Periodontitis and Gut Motility Disorders.

## VUB - OPEN ACCESS CORE FACILITIES STAND E13

[www.vub.be](http://www.vub.be)

Vrije Universiteit Brussel (VUB) presents two open access core facilities. Molecular Imaging and Therapy (MITH) development, preclinical validation, and clinical translation of targeted drugs for diagnostic and therapeutic applications, based on Single-Domain Antibody (SdAb) technology. MICROLAB is a new 300 m<sup>2</sup> class 1,000 cleanroom equipped with state-of-the-art equipment for advanced microfabrication of microfluidic devices in glass and silicon for medical, pharma, and biotech applications.

## VVC - STAND F42

[www.vvc.eu](http://www.vvc.eu)

Medical, automotive, food, or various industries VVC is your partner for the purchase, installation and maintenance of laboratory test equipment. We offer a wide range of equipment, including precision scales, tensile tester, xenon arc chambers, spectrophotometers, ovens and climatic chambers. Our calibration department is also at your disposal for COFRAC-accredited calibration of your testing equipment. Feel free to visit us for more information.



# EXHIBITORS

## WALLONIE-BRUXELLES INTERNATIONAL STAND E44-F45 [www.wbi.be](http://www.wbi.be)

WBI's Research and Innovation Department supports Belgian French-Speaking universities, research centres, clusters and companies to establish and reinforce R&D collaborations with international partners. Please reach out and connect with us! We are delighted to welcome:

- The WEL Research Institute, which supports strategic basic research through programmes - Laurence Borgs
- The LiEU Network, which brings together the Knowledge Transfer Offices (KTO) of our 5 universities
- Yasmina Zeroul

## WHITE RAVEN - STAND E44-F45

[whiteraven.bio](http://whiteraven.bio)

White Raven is a Belgian CDMO, specialising in GMP Formulation and Aseptic Filling for small-batch injectables. We offer flexibility for biotech firms, ensuring high-quality, Annex 1-compliant services. Our state-of-the-art gloveless robotic isolator handles vials, syringes, and cartridges, from 100 to 20,000 units, minimising losses and eliminating cross-contamination risks.

## WUXI APPTec - STAND E43

[www.wuxiapptec.com](http://www.wuxiapptec.com)

WuXi AppTec is a full-service provider of open-access capabilities and technology that enables customers worldwide to advance discoveries in the health sciences and deliver treatment to those in need.

## X'PROCHEM - STAND D19

[www.xprochem.com](http://www.xprochem.com)

Founded in 2012, X'PROCHEM is a CRO (Contract Research Organization) specialised in chemical protein synthesis.

We design and produce therapeutic proteins for our pharmaceutical and biotech partners. We manufacture complex and highly customised proteins up to 400 amino acids (40 kDa) by using an automated process.

## ZOETIS - STAND D35

[www.zoetis.com](http://www.zoetis.com)

Zoetis is the world's leading animal health company. Our purpose is to nurture our world and humankind by advancing care for animals. After more than 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of \$8.5 billion in 2023 with ~14,100 employees.





# SPONSORS AND PARTNERS

## SPONSORS

Platinum sponsor



Silver sponsors



Bronze sponsors



Contributing sponsors



## MAIN SUPPORTERS



# PARTNERS

## SUPPORTERS



## MEDIA PARTNERS





SAVE THE DATE



The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field



14<sup>TH</sup> EDITION

NOVEMBER

& 25<sup>TH</sup> & 26<sup>TH</sup> 2025



STRASBOURG France



MEDFIT & MEDIGIT

Organisers:



Institutional partners:



## MEDFIT AT A GLANCE

MedFIT is your opportunity to connect with international key innovators in the **MedTech, Diagnostic and Digital Health sectors**. As a **unique European partnering event**, MedFIT provides the ideal environment for academic and industrial stakeholders to:

- **Build** partnerships
- **Source** innovative and competitive early-stage R&D projects
- **Foster** the emergence of collaborative projects
- **Increase** licensing opportunities
- **Obtain** funding and **facilitate** market access

This year, MedFIT's focus on Digital Health innovation will be strengthened by launching **medigIT**, the Digital Health dimension of the event.



**650**  
delegates



**+30**  
countries  
represented



**55**  
high-level  
speakers



**3,000**  
meeting  
opportunities



**100**  
exhibitors



**37**  
innovative projects  
presented

## ORGANISERS



### [lille.eurasanté.com](http://lille.eurasanté.com)

Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,100 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within a European-wide scientific and medical site. Eurasanté organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic), MEDigIT (Digital Health) and NutrEvent (Food, Nutrition).



### [www.clubster-nhl.com](http://www.clubster-nhl.com)

Clubster NHL is a competitiveness cluster and a network gathering 360 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.



### [www.biovalley-france.com](http://www.biovalley-france.com)

Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation. BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory's structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow's health technologies.



### [www.medicalps.eu](http://www.medicalps.eu)














MEDICALPS is the health technology cluster for the Alpine arc. Based in Grenoble Alpes, it brings together and represents a community of more than 130 start-ups, SMEs, big companies, research centres, universities and local authorities in the fields of medtech, biotechnologies and digital health. Its aim is to animate, support and structure the sector in order to support and accelerate the deployment of healthcare innovations.





# STEERING COMMITTEE

## MedTech, Diagnostic and Digital Health companies

- |   |  |  |
|---|--|--|
| <br><b>Stig Visti Andersen</b><br>CEO<br>VentriJect 🇩🇪                           | <br><b>Ulf Hengstmann</b><br>Digital Lead Medical Affairs & Pharmacovigilance<br>Bayer 🇩🇪 | <br><b>Hervé Monchoix</b><br>Strategic Innovation Leader<br>Becton Dickinson 🇫🇷             |
| <br><b>Yves Bayon</b><br>Distinguished Scientist<br>Medtronic France 🇫🇷          | <br><b>Fatine El Jebbari</b><br>Innovation & Partnership Manager<br>GE Healthcare 🇫🇷      | <br><b>Hema Purohit</b><br>Strategic Advisor & CTO Healthcare<br>Microsoft 🇮🇳               |
| <br><b>Ravi Chana</b><br>Head of Business Development<br>Roche Diagnostics 🇫🇷    | <br><b>Mike Karim</b><br>CEO<br>Oxford Endovascular 🇫🇷                                    | <br><b>Cécile Réal</b><br>CEO<br>Endodiag 🇫🇷  |
| <br><b>Joël Courville</b><br>VP Strategy & Corporate Affairs<br>MicroPort CRM 🇫🇷 | <br><b>Pierluca Messina</b><br>Chief Innovation Officer<br>Senseme 🇫🇷                     | <br><b>Axel Strombergsson</b><br>Director of Strategy, Emerging MedTech<br>Veeva Systems 🇸🇪 |
| <br><b>James Greene</b><br>CEO<br>MedLumics 🇪🇺                                   |  |  |

## Academia, TTOs

- |  |  |
|--|--|
| <br><b>Vassilis Georgiadis</b><br>Director of Industry Partnerships<br>King's College London 🇬🇧 | <br><b>Michel de Mathelin</b><br>Director<br>i-cube lab 🇫🇷            |
| <br><b>Abhay Pandit</b><br>Scientific Director<br>CURAM 🇮🇳                                      | <br><b>Esther Rodijk</b><br>Impact Director TTT MedTech<br>Novel-T 🇧🇪 |

## Associations, clusters and law firms

- |   |   |  |
|---|---|--|
| <br><b>Caroline Dreyer</b><br>General Manager<br>BioValley France 🇫🇷   | <br><b>Nicolas Lamoureux</b><br>Head of MedTech – Industrial Partnerships Department<br>Réseau SATT 🇫🇷 | <br><b>Sébastien Weisbuch</b><br>Executive Director<br>Medicalps 🇫🇷 |
| <br><b>Anne-Laure Gavory</b><br>Regional Animation and Economic Development Officer<br>SNITEM 🇫🇷                       | <br><b>Cécile Théard-Jallu</b><br>Partner Attorney<br>De Gaulle Fleurance & Associés 🇫🇷                |  |
| <br><b>Camille Gladieux</b><br>Assistant Director of Research and Innovation<br>University Hospital Center of Lille 🇫🇷 | <br><b>Etienne Vervaecke</b><br>General Manager<br>Eurasanté & Clubster-NHL 🇫🇷                         |  |

## Investors

- |  |   |  |
|--|---|--|
| <br><b>Frank Bulens</b><br>Partner<br>Imec.xpand 🇪🇺               | <br><b>Baudouin Hue</b><br>Partner<br>Karista 🇫🇷                 | <br><b>Beatriz Volckaert</b><br>Senior Associate<br>Philips Ventures 🇧🇪 |
| <br><b>Anke Cassing</b><br>Principal<br>High-Tech Gründerfonds 🇩🇪 | <br><b>Daniel O'Mahony</b><br>Partner<br>Seroba Life Sciences 🇮🇪 |  |



## OUR SPONSORS



Launched in 2021, Captech Santé, is an early-stage fund, investing in projects in Biotech, Medtech, Digital Health and Nutrition. With a capital of €35 to €40 million, the fund invests in Seed or Series A. Thanks to its expertise and integration in the healthcare ecosystem, Captech supports its investments over the long term, and co-invests with international funds.

[www.finorpa.fr/gestion/fonds-captech-sante](http://www.finorpa.fr/gestion/fonds-captech-sante)



International leader in implants for visceral and spinal surgery, Cousin Surgery is a group with expertise in implantable textiles: a very rare skill, inherited from a history entirely devoted to textiles and innovation.

Cousin Surgery is a firm specialised in implantable medical devices. It inherits its expertise from a long industrial history that began in 1848. Today, the company is a recognised specialist in implantable textiles and their application to spine surgery and visceral.

[cousin-surgery.com](http://cousin-surgery.com)



Because improved diagnostic solutions contribute to a more precise and personalised medicine and improve the quality of life for patients worldwide, Innobiochips provides disruptive technologies to improve the accuracy, quality and sustainability of in vitro diagnostic approaches.

[www.innobiochips.fr](http://www.innobiochips.fr)  
**STAND D20-F21/1**

## MEDTECH TWENTE

The smart manufacturing industry (High Tech Systems and Materials) is characteristic for the Twente region in East-Netherlands. The World Trade Center Twente is building a MedTech cluster together with the Techmed Center at the University and companies in the medical technology sector.

[medtechtwente.nl](http://medtechtwente.nl)  
**STAND D32-E31**



# PROGRAMME AT A GLANCE

## Tuesday, December 3<sup>rd</sup>

	Conference sessions	Pitch sessions	Partnering	
8.00 am - 9.00 am	Welcome coffee			
9.00 am - 9.30 am	<b>Strasbourg room</b> <b>Keynote session</b> Global investment trends in health industries: 2025 outlook			
9.45 am - 10.45 am	<b>Grenoble room</b> <b>Plenary session</b> Diving into the future of hospital care: Creating value for patients, with patients	<b>MedFIT InnovArea</b> <b>Start-up Slams</b> AI med:it	One-on-one meetings	
10.45 am - 11.15 am	Networking break			
11.15 am - 12.30 pm	<b>Grenoble room</b> Using IVDR and MDR to your advantage to efficiently develop the right products: Innovative thinking or hopeless daydreaming?	<b>Lille room</b> Periodontitis treatments of the future, discover the Healthy Teeth project		<b>MedFIT InnovArea</b> <b>Collaborative and Licensing Opportunity Presentations</b>
12.30 pm - 2.00 pm	Lunch			
2.00 pm - 2.45 pm	<b>Grenoble room</b> Exploring how big-size and mid-size MedTech companies approach collaborations and partnerships with early-stage start-ups	<b>MedFIT InnovArea</b> <b>Start-up Slams</b> Assistive Technology med:it		
3.00 pm - 3.45 pm	<b>Grenoble room</b> Discussing challenges and opportunities of developing business models for prevention in digital health	<b>MedFIT InnovArea</b> <b>Start-up Slams</b> Precision Medicine/ Personalised treatment		
3.45 pm - 4.15 pm	Networking break			
4.15 pm - 5.00 pm	<b>Grenoble room</b> Beyond the seed round: Challenges and opportunities in scaling financing for MedTech market access	<b>MedFIT InnovArea</b> <b>Start-up Slams</b> Oncology		
5.15 pm - 6.00 pm	<b>Grenoble room</b> MedTech ecosystems to boost innovation and care: What are they and how do they work?	<b>MedFIT InnovArea</b> <b>Start-up Slams</b> Monitoring		
From 6.45 pm	BioMed Party			

## Wednesday, December 4<sup>th</sup>

	Conference sessions	Pitch sessions	Partnering		
8.00 am - 9.00 am	Welcome coffee				
9.00 am - 9.30 am	<b>Strasbourg room</b> <b>Keynote Session</b> The Future of Medicine: Unlocking the potential of data				
9.45 am - 10.45 am	<b>Grenoble room</b> Closing 2024, diving into 2025: Discussing the state of the early-stage MedTech investment landscape	<b>Lille room</b> Microplaite: A microfluidic platform to accelerate the development of medical devices for tissue reconstruction	<b>2.3 room</b> Advancing Data Incorporation and Interoperability for Cancer Image Europe	<b>MedFIT InnovArea</b> <b>Start-up Slams</b> Surgery Sustainability	
10.45 am - 11.15 am	Networking break	<b>Marseille room</b> The augmented human: technological advances and research partners	Networking break	One-on-one meetings	
11.15 am - 12.30 pm	<b>Grenoble room</b> How to accelerate the adoption and development of innovative digital health therapies in Europe?	<b>2.3 room</b> Advancing Data Incorporation and Interoperability for Cancer Image Europe	<b>MedFIT InnovArea</b> <b>Collaborative and Licensing Opportunity Presentations</b>		
12.30 pm - 2.00 pm	Lunch		VIP lunch room Investor lunch		
2.00 pm - 3.00 pm	<b>Grenoble room</b> Augmented intelligence: Balancing human expertise with AI in diagnostic decision-making	<b>Marseille room</b> The path to becoming a successful CEO: Tips to wannabe founders	<b>Lille room</b> Getting smarter in the dressing industry: Towards a connected dressing with the DIAMOND project		<b>MedFIT InnovArea</b> <b>Start-up Slams</b> Implantable Medical devices
3.15 pm - 4.15 pm	<b>Grenoble room</b> Planning and mapping a successful reimbursement strategy for European start-ups	<b>Lille room</b> Awards Ceremony PUI Lille Innovation Contest			
4.30 pm	BioFIT InnovArea Pitch sessions - Award ceremony				
6.00 pm					

- TRACK 1 GROWING EARLY-STAGE INNOVATION
- TRACK 2 BRINGING INNOVATION TO MARKET
- TRACK 3 DIGITAL HEALTH & MEDICINE INNOVATION **med:it**
- PROJECT - CEO MATCHMAKING
- HOSTED EVENTS

December 11<sup>th</sup> & 12<sup>th</sup>

Online meetings

## ONE-ON-ONE MEETINGS

**4 days** to meet your future project partners, obtain funding and accelerate innovation

The MedFIT partnering platform is your chance to forge meaningful connections that could drive your projects forward. The partnering activity enables participants to meet each other during 30-minute pre-qualified one-on-one meetings organised prior to the event.

### How to organise your meetings onsite?

- Print out your meeting schedule, which includes meeting times and locations, at the partnering desk.
- Attend your one-on-one meetings at the scheduled time and location.
- Continue to monitor your partnering account on [biofit-medfit-medigit.vimeet.events](https://biofit-medfit-medigit.vimeet.events) on your phone, computer or at the partnering desk.


Access the partnering platform



You didn't get the chance to schedule all of your meetings?  
MedFIT continues online on December 11<sup>th</sup> & 12<sup>th</sup>



## WHO WILL YOU MEET?



## INVESTOR LUNCH

MedFIT has the pleasure to organise an **Investor Lunch** on:

**Wednesday, December 4<sup>th</sup> at 12.30 pm (VIP lunch room)**

This dedicated lunch will provide an opportunity for investors to discuss early-stage investment trends and exchange views on the 2024 highlights. Most importantly, this networking time will be the perfect moment to strengthen co-investment networks.

Investors can sign-up on-site at the partnering desk until December 4<sup>th</sup>.



# PROJECT-CEO MATCHMAKING

## If you are a MedTech entrepreneur seeking a project or you have a project in need of a CEO the Project - CEO matchmaking is for you!

As talented CEOs are frequently sought-after by many players in the MedTech industry, the Project – CEO matchmaking activity aims to connect representatives of emerging start-ups, technology transfer offices, incubators and investing networks with CEOs and aspiring CEOs.

### Find the perfect match:

- Any incubator, technology transfer entity or scientific founder looking for an entrepreneur to lead their start-up project is welcome at the matchmaking activity and to find their ideal candidates! You will be visible on the partnering platform, to be contacted by potential CEOs.
- If you are a MedTech entrepreneur looking for a new project to undertake: projects looking for a CEO will be visible on the platform and easily identifiable.

### Get inspired:

Having the right team is essential for the development of a MedTech project or start-up. The Project – CEO matchmaking activity also offers a conference session to get inspired and explore the best ways to find the right talents for a successful project

Day 2 - Wednesday, December 4<sup>th</sup> | 2.00 - 3.00 pm

## The path to becoming a successful CEO: Tips to wannabe founders

Marseille room

For emerging start-ups in the healthcare industry, the journey to success begins with effective leadership. This session will feature MedTech and Biotech CEOs, sharing their journey and insights for aspiring founders seeking to navigate the challenges of start-up leadership.

What are the essential qualities and skills for effective start-up leadership? How to ensure founders are "business ready", especially when coming from academia? How to build the right team that will convince investors? How to work with your board and engage them as proper advisors? What are the strategies for attracting and retaining top talents?



**Lynn Coorevits**  
Digital Health  
Innovation Manager  
imec



**Alain Barbal**  
Director, Board Advisor  
Novostia



**Georges Rawadi**  
CEO  
StomaCare



**Véronique Foutel**  
CEO  
InBrain Pharma



**Neel Patel**  
CEO  
Zio Health

## PITCH SESSIONS

The MedFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development opportunities in the MedTech, Diagnostic and Digital Health fields.

The winners will be awarded as the most innovative start-up and the most promising technology in Europe in MedTech/ Diagnostic and Digital Health.



**Award Ceremony**  
**Wednesday, December 4<sup>th</sup> at 4.30 pm**  
BioFIT Innov'Area



### Jury members

**Yves Bayon**, Distinguished Scientist, Bakken Research Center, Medtronic 🇫🇷  
**Frank Bulens**, Partner, Imec.xpand 🇧🇪  
**Lynn Coorevits**, Digital Health Innovation Manager, imec 🇧🇪  
**Tristan Debove**, Business Angel, Angels Santé 🇫🇷  
**Victor Evian**, BioMedTech Analyst, Truffle Capital 🇧🇪  
**Thom Frielink**, Associate, Curie Capital 🇧🇪  
**Peter Haasjes**, Director, NextGen Ventures 🇧🇪  
**Ulf Hengstmann**, Digital Lead Medical Affairs & Pharmacovigilance, Bayer 🇩🇪  
**Elizabeth Jennings**, Managing Partner, Venture Atlas Labs 🇺🇸  
**Tom Kersemakers**, Technology Assessment & Strategy Analyst, NLC Health Ventures 🇧🇪  
**Antoine de Lachaux**, Head of Unit – Life Sciences and Biotech, European Investment Bank 🇫🇷  
**James Mayer**, Partner, CABHI Ventures 🇫🇷  
**Filip Pintelon**, Investment Partner Health, Capricorn Partners 🇧🇪  
**Robin Pumo**, Analyst, Turenne Capital 🇫🇷  
**Hema Purohit**, Strategic Advisor & CTO Healthcare, Microsoft 🇺🇸  
**Esther Rodijk**, Impact Director TTT MedTech, Novel-T 🇧🇪  
**Lena-Sophie Schütter**, Investment Manager, High-Tech Gründerfonds 🇩🇪  
**Georges Syrmalis**, CEO, BioScience Equity 🇧🇪  
**Etienne Vervaecke**, General Manager, Eurasanté 🇫🇷  
**Stig Visti Andersen**, Co-Founder, VentiJect 🇩🇪

### Start-up Slams

The Start-up Slams are a great opportunity for young companies (and particularly for start-ups seeking to raise a financing round) to showcase their innovation in front of potential partners and investors.

Tuesday, December 3<sup>rd</sup> | 9.45 - 10.45 am | MedFIT Innov'Area

#### ARTIFICIAL INTELLIGENCE

**INTA** 🇫🇷 Stand E1

In vitro diagnostics - Traumatic Brain Injuries - Deep tech

**REMOTION** 🇫🇷 Stand D20-F21/11

Virtual Rehabilitation - Tele Rehabilitation - AI Biofeedback

**BIEL GLASSES** 🇪🇸 Stand IA20

Low vision - Artificial intelligence - Assistive-technology

**ACCREA MEDICAL ROBOTICS** 🇧🇪 Stand IA17

Minimally invasive surgery - Medical Robotics - Efficiency

Tuesday, December 3<sup>rd</sup> | 2.00 - 2.45 pm | MedFIT Innov'Area

#### ASSISTIVE TECHNOLOGY

**LIFEBLOOM** 🇫🇷 Stand D20-F21/2

Walk assistance - Gait rehabilitation - Handicap Compensation

**AXOMOVE** 🇫🇷 Stand IA18

Digital clinic - Telerehabilitation - Musculoskeletal disorders

# PITCH SESSIONS

## Start-up Slams

Tuesday, December 3<sup>rd</sup> | 3.00 - 3.45 pm | MedFIT Innov'Area

### PRECISION MEDICINE/PERSONALISED TREATMENT

#### ABBATIALABS Stand IA16

Precision Medicine - Combination Product - Dose Individualization

#### CLEAR.BIO Stand D32-E31/9

Precision Nutrition - Digital Therapeutics - Digital Dietitian

#### OPTIRXLAB Stand IA23

CT radiation dose - Monte carlo calculation - Optimisation

Tuesday, December 3<sup>rd</sup> | 4.15 - 5.00 pm | MedFIT Innov'Area

### ONCOLOGY

#### ACTIPULSE NEUROSCIENCE Stand IA18

Blood-Brain Barrier - Non-Invasive Neuromodulation - CNS Drug Delivery

#### FETCH Stand D32-E31/6

Precision medicine - Circulating tumour cells - Oncology

#### HEMERION THERAPEUTICS Stand IA7

Oncology - Neurosurgery - Combination product

Tuesday, December 3<sup>rd</sup> | 5.15 - 6.00 pm | MedFIT Innov'Area

### MONITORING

#### BRAINDEXTM Stand IA21

Anesthesia - Neuro-complications - Elderly

#### CORTEX MACHINA SRL Stand IA22

Brain to computer (BCI) - EEG - Medical Wearable

#### QUANTILIGHT Stand IA25

IVD - Bloodtesting - TherapeuticDrugMonitoring

Wednesday, December 4<sup>th</sup> | 9.45 - 10.45 am | MedFIT Innov'Area

### SURGERY

#### PFFI Stand IA24

Spine - Flexible Surgical Implant - Innovative Carbon composite

#### SURGERY ROBOTICS Stand D20-F21/6

Med Tech - Surgical Robotics - Bone Surgery

#### SURGERIX Stand IA27

Microsurgery - Image guided surgery - Minimally invasive surgery

### SUSTAINABILITY

#### FLOWBEAMS Stand D32-E31/4

Needlefree - Sustainability - Healthcare innovation

#### VOLTIFY Stand IA28

Deeptech - Energy - Hardware

Wednesday, December 4<sup>th</sup> | 2.00 - 3.00 pm | MedFIT Innov'Area

### IMPLANTABLE

#### OPEN STENT SOLUTION Stand IA26

Transcatheter valve replacement - Ribbon valve technology - Mitral & Tricuspid regurgitation

#### CORQUEST MEDTECH

Cardiology - Mitral - Transcatheter

#### LATTICE MEDICAL Stand F12-G13

Breast Reconstruction - Resorbable implant - 3D-Printed

### MEDICAL DEVICES

#### PLAS-FREE LTD (BLOOD)

Bleeding - Trauma - Hemorrhage

#### BARTHECO BY Stand IA19

Valeb - Cervical precancer - Cone biopsy



# PITCH SESSIONS

## Collaborative and licensing opportunity presentations

The Collaborative and Licensing Opportunity Presentations enables TTOs, universities, research institutes and companies to showcase their technologies in front of potential partners, in order to entail a collaborative project and/or a licensing deal.

Tuesday, December 3<sup>rd</sup> | 11.15 am - 12.30 pm | MedFIT Innov'Area

### BIOASTER

Rapid diagnostic test - Multiplexing - Differential diagnosis

### SATT SAYENS - METHYLSCAN

AI - Lung cancer - Blood test

### SATT SAYENS - ORINOVA

Gold nanoparticles - Bitherapy - Glioblastoma

### IRCCS OSPEDALE GALEAZZI - SANT'AMBROGIO Stand E26-F25

miRNA - In Vitro Diagnostics - Osteoporosis

### IRCCS SAN RAFFAELE ROMA - CONN&SENS

Functional Evaluation - Digital twin of motor process - Personalisation of care

### SATT AQUITAINE

Delivery device - Cementoplasty - Interventional Radiology

Wednesday, December 4<sup>th</sup> | 11.15 am - 12.30 pm | MedFIT Innov'Area

### SATT LUTECH - OS & DENTINE INJECTABLE

Biomaterial - Bone - Dentin

### SATT LUTECH - MIMETUBE

Biomaterial - 3D cell culture - Tissue Engineering

### CAREFUL SYSTEMS LIMITED

Digital health - Clinical Collaboration - Productivity

### SCREENTEC OY Stand E14-F13

Medical Electrodes - Sustainable Materials - Disposables

### EUROPEAN INSTITUTE OF ONCOLOGY (EIO) - PETSIGN

Breast cancer - Multigene signature - Cancer Prognosis

### EUROPEAN INSTITUTE OF ONCOLOGY (EIO) - PROSIBLAD

Prognostic signature - Bladder cancer - Disease progression and recurrence



Steered by a prestigious committee, the MedFIT conference programme brings together bright minds to discuss the latest trends in MedTech, Diagnostic and Digital Health, to debate innovation-driven topics, to foster learning and to spark conversations that matter.

International experts will address current industry issues related to growing early-stage innovation, bringing innovation to market, and Digital Health and medicine innovation.

## Sessions' format

**Keynote:** A keynote is designed to convey a central message, set the tone, and captivate the audience by featuring notable and high-level speakers.

**Plenary session:** Panel of high-level speakers discussing a main topic/trend for the industry.

**Toolbox session:** A toolbox session is designed to provide practical skills, easy-to-follow guidelines and take-home tools which delegates can put into practice to deal with their current issues.

**Panel discussion:** Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.

**Case studies:** Session that comprise a series of illustrative presentations followed by Q&As from the moderator and the audience.

**Fireside chat:** Personal and interactive discussion involving a moderator and a guest, in which the audience can gain insights through the guest's personal stories and thoughts on various topics.

Day 1 - Tuesday, December 3<sup>rd</sup> | 9.00 - 9.30 am - *Keynote session*

## Global investment trends in health industries: 2025 outlook

Strasbourg room

Let's explore the landscape of global investments in health industries, emerging opportunities and challenges for 2025. What are the key drivers in the sectors of biotech and MedTech? What can we anticipate for the increasingly popular digital health sector, as well as for the One Health approach? How are regulatory changes, technological advancements, and market dynamics impacting these fields? Gain insight into the evolving priorities of investors and the strategic approaches shaping the future of growth and innovation in the health sector.



**Antoine de Lachaux**

Head of Unit –  
Life Sciences and Biotech  
European Investment Bank

Day 2 - Wednesday, December 4<sup>th</sup> | 9.00 - 9.30 am - *Keynote session*

## The Future of Medicine: Unlocking the potential of data

Strasbourg room

Data is the new gold. And what better way to invest it than in health? From precision diagnostics to predictive care models, how is data already transforming medicine and what future breakthroughs lie ahead? How are advancements in data analytics, AI, and secure data sharing impacting patient outcomes and healthcare efficiency, and what challenges need to be addressed? Gain a forward-looking perspective on how data-driven insights are paving the way for more personalised healthcare —making better outcomes and accessibility a reality for all.



**Hema Purohit**

Strategic Advisor &  
CTO Healthcare  
Microsoft





Day 1 - Tuesday, December 3<sup>rd</sup> | 9.45 - 10.45 am - Plenary session

## Dividing into the future of hospital care: Creating value for patients, with patients

Grenoble room

Imagine, decades from now: Patients would have their own health data at hand, personalised health monitoring deeply linked to their individual needs, educational content easily accessible, and tailored treatment. Utopia? Not so much, as hospitals have already acknowledged the necessity of a more patient-centric culture. Learning on inspirational examples, experts will discuss what the future of hospital care would look like and the steps towards a patient-centric culture.

What is implied in a patient-centric culture and how this shift for hospitals functioning impacts MedTech ecosystems and stakeholders? How are the technological advancements apprehended for better health outcomes and how are they reshaping the traditional hospital models? What kind of collaborative approaches between hospitals and MedTech companies optimise value creation for healthcare delivery and patient outcomes and which impact can we foresee for innovation development? How is the digitisation of hospitals and treatment processes inherent to a patient-centric approach? What opportunities does is present for MedTech solutions and how are hospitals walking through their digital transformation? What economic challenges do hospitals face in adopting new MedTech, and how can companies contribute to cost-effective healthcare? What are the obstacles in creating a patient-centric culture, as well as in implementing new devices and procedures, for hospitals and how can they be lifted?



Moderator

**Susie A. Ruff**  
Founder & CEO  
RUFF & CO.



**DJ Hamblin-Brown**  
Emergency doctor  
NHS  
CEO  
Careful



**So Yung Straga**  
President  
Shared Patient  
eXperience - SPX



**Coralie Dorard**  
Head of Research  
Actipulse Neuroscience



**Ahmed Hussein**  
Surgery Research and Innovation  
director - ER4Surgery  
University of Eastern Finland  
Clinical Instructor  
, Kuopio University Hospital



## Growing early-stage innovation

#R&Dcollaboration #TechTransfer #EarlyStageFinancing

Day 1 - Tuesday, December 3<sup>rd</sup> | 2.00 - 2.45 pm - Panel discussion

### Exploring how big-size and mid-size MedTech companies approach collaborations and partnerships with early-stage start-ups

Grenoble room

Large companies and mid-size companies increasingly depend on external innovation to find new sources of growth of competitiveness. How do big and mid-size MedTech companies handle early-stage partnerships and investment opportunities with start-ups and academic assets? How do these companies balance between the different types of collaborations that exist? What criteria do they take account when evaluating potential partnerships? Are there differences in their approach when dealing with early-stage assets? As a result, what makes a start-up an attractive target for partnerships?



**Suzanne Elvidge**  
Freelance writer  
Biopharma, Healthcare,  
Business



**Julien Payen**  
CEO  
Lattice Medical



**Hanaa Safya**  
Partnerships Manager  
& Strategic Alliances for  
Diagnostics  
BIOASTER



**René Pompl**  
Senior director Venture  
Technology  
Siemens Healthineers

Day 1 - Tuesday, December 3<sup>rd</sup> | 5.15 - 6.00 pm - Case studies

### MedTech ecosystems to boost innovation and care: What are they and how do they work?

Grenoble room

MedTech ecosystems serve as hubs for collaboration, enabling stakeholders to address complex healthcare challenges and drive innovation. As they are constantly evolving, this session will look at different ecosystems and provide.

What are the main ingredients of a MedTech ecosystem? What defines a successful ecosystem and how do different stakeholders contribute to it? What to look for when trying and joining the right ecosystem? What are the key benefits of participating in a MedTech ecosystem and when are they really successful from a start-up/scale-up point of view? What is their role in accessing new financing sources? How do stakeholders build on regional strengths towards more internationalisation?



**Yves Bayon**  
Chief Scientist  
Medtronic



**Bodil Christine Reumert**  
Head of Strategic Innovation  
AUH Innovation &  
International Affairs,  
Aarhus University Hospital



**Filip Pintelon**  
Investment Partner Health  
Capricorn Partners



**Garth Smith**  
VP, Business Development  
and Partnerships  
Ontario Brain Institute

Day 2 - Wednesday, December 4<sup>th</sup> | 9.45 - 10.45 am - Panel discussion

### Closing 2024, diving into 2025: Discussing the state of the early-stage MedTech investment landscape

Grenoble room

2023 was a slowdown year for seed and series A rounds in MedTech, what about 2024? This panel of investors will provide insights into the current state of early-stage MedTech investment, emerging trends, and future outlook. What has been the landscape for venture capital investment in early-stage MedTech in 2024 and what to expect in the coming months? Has the perceived shift towards mid to later-stage investments been confirmed? Who are the current most active investors in Seed and Series A MedTech: pure players, newcomers? How does the geographic distribution of investment opportunities impact early-stage MedTech financing? What about grant financing availability? What types of technologies and digital health solutions are attracting investment, and what criteria do investors prioritise? What tools, networks, and strategies are currently available to start-ups seeking early-stage funding, and how can they optimise their fundraising efforts?



**Arezki Yaïche**  
Head of Coverage France  
& Benelux  
Mergermarket  
(ION Group)



**Albert-Jan de Croes**  
Investment Specialist  
Novel



**James Mayer**  
Partner  
CABHI Ventures



**Jan Engels**  
Investment Manager  
High Tech Gründerfonds



**Frank Bulens**  
Partner  
imec.xpand

## Bringing innovation to market

#MarketAccess #Reimbursement #Pricing #Design

Day 1 - Tuesday, December 3<sup>rd</sup> | 11.15 am - 12.30 pm - Panel discussion

### Using IVDR and MDR to your advantage to efficiently develop the right products: innovative thinking or hopeless daydreaming?

Grenoble room

While regulatory compliance is essential for bringing MedTech products to market, it is often perceived as a burden. Let's explore how companies developing in Europe can leverage regulatory frameworks to enhance their market competitiveness.

Where are we on the impact of MDR on the development and commercialisation of MedTech products in Europe? Can companies still work their way through regulations or are we reaching a critical point of overly stringent measures? What challenges and requirements can start-ups anticipate to adapt their development strategies accordingly? What strategies can companies employ to manage the growing waiting list of notified bodies and navigate regulatory uncertainties effectively? When is it a good idea to consider the US market for EU companies?



**Kyun Thibaut**  
Founder & Managing Director  
COVARTIM



**Nabil Riahi**  
Sales Director  
GMED



**Päivi Leppänen**  
Business Development Director  
Innokas Medical



**Susana de Azevedo Wäsch**  
Vice President Quality Management & Regulatory Affairs & Medical Affairs  
Ypsomed



**Peter Haasjes**  
Director  
NextGen Ventures

Day 1 - Tuesday, December 3<sup>rd</sup> | 4.15 - 5.00 pm - Panel discussion

### Beyond the seed round: Challenges and opportunities in scaling financing for MedTech market access

Grenoble room

Securing seed financing is just the first for MedTech startups on the journey to market access. This panel discussion gathering expert investors and successful entrepreneurs aims to provide a better understanding of the timelines, operations, and budgets required to best measure the available funding options at the onset of new start-ups. How do startups and investors navigate the transition from seed funding to scaling financing for market access? How do they collaborate to optimise financing strategies? What role do regulatory considerations and reimbursement pathways play in shaping financing decisions? What lessons can be learned from successful start-up scaling pathways?



**Arezki Yaïche**  
Head of Coverage France & Benelux  
Mergermarket (ION Group)



**Elizabeth Jennings**  
Managing Partner  
Venture Atlas Labs



**Thom Frielink**  
Associate  
Curie Capital



**Laia Pascual**  
Investment Manager  
Ship2B Ventures

Day 2 - Wednesday, December 4<sup>th</sup> | 3.15 - 4.15 pm - Toolbox session

### Planning and mapping a successful reimbursement strategy for European Start-ups

Grenoble room

One of the key pieces of advice for MedTech start-ups is to start developing a reimbursement strategy from day one. The 'problem to solution' approach is crucial when it comes to attracting VC attention but is nothing without a solid revenue model and pricing strategy. Yet, navigating European funding systems can be a challenge for start-ups, as each national healthcare system has its own characteristics: different levels of reimbursement decisions, fees paid per service, etc. This session aims to map current payment systems for innovative medical technologies and procedures, including concrete initiatives to transform reimbursement and funding systems. Where can MedTech innovators go for reimbursement support in the EU? How can companies familiarise themselves with the decision-making process and engage with key stakeholders? What are the most important reimbursement considerations when targeting France, Germany, Belgium or the UK? What about new pathways emerging for digital health solutions such as DiGA or PECAN?



**Carole Absil**  
HealthTech Strategist



**Clément Morel**  
CEO  
Axomove



**Christof Debèfve**  
Strategic Business Partner  
Xper Research



**Serap Konak**  
Senior consultant  
Flying Health

## Digital Health & medicine innovation

#DTx #AI #DrugDiscovery #Training&Adoption



Day 1 - Tuesday, December 3<sup>rd</sup> | 3.00 - 3.45 pm - Panel discussion

### Discussing challenges and opportunities of developing business models for prevention in digital health

Grenoble room

Preventive healthcare has the potential to generate economic benefits and improve long-term health outcomes, but developing effective business models presents real challenges. What are the economic benefits of investing in preventive healthcare and how can they be quantified? What challenges do stakeholders face in designing reimbursement strategies for preventive digital health solutions? What examples of successful business models for prevention in digital health exist, and what lessons can be learned from their implementation? How to scale preventive digital health interventions effectively?



**Hadleigh Stollar**  
Chief Executive  
Healthcare Innovation  
Consortium



**Tristan Debove**  
Country Manager France  
Orion Health



**Gudmundur Ebenezer**  
CEO  
Lifekeys



**Alexandre Morel**  
Chief Innovation Officer  
and Co-founder  
Vipali

Day 2 - Wednesday, December 4<sup>th</sup> | 11.15 am - 12.30 pm - Panel discussion

### How to accelerate the adoption and development of innovative digital health therapies in Europe?

Grenoble room

Despite the potential of digital health therapies to revolutionize healthcare, adoption and development remain complex challenges. How do we define and characterise digital health therapies? What is the current state of the regulatory and reimbursement pathways for digital health and how does it impact the development of the sector? What initiatives are underway to promote interoperability and data sharing? What are the key components of successful value proposition and revenue model for digital health innovations? How do investment strategies of VCs and big players influence the development and adoption of the innovative technologies in the sector? How can further collaboration between healthcare providers, regulators, industry, and patients accelerate their adoption?



**Susie A. Ruff**  
Founder & CEO  
RUFF & CO.



**Cristian Toader**  
Digital Health Lead EMEA  
Boston Scientific



**Francesco Infarinato**  
Biomedical Engineer –  
Neurophysiologist  
San Raffaele Roma



**Cécile van der Heijden**  
Attorney at law  
Axon Lawyers



**Rick Overkleef**  
CEO  
4MedBox

Day 2 - Wednesday, December 4<sup>th</sup> | 2.00 – 3.00 pm - Panel discussion

### Augmented intelligence: Balancing human expertise with AI in diagnostic decision-making

Grenoble room

Augmented intelligence has the potential to enhance diagnostic decision-making in healthcare, but striking the right balance between human expertise and AI is crucial. How do clinicians work with AI systems in diagnostic decision-making, and what are the implications for patient care? What are the current training and education programmes available to equip clinicians with the skills and knowledge needed? What measures can be taken to ensure transparency and explainability of AI algorithms for both clinicians and patients? What ethical considerations arise when integrating AI into clinical practice? What lessons can be learned from successful implementations of AI in diagnostic decision-making?



**Paul Borm**  
Co-Founder & CTO  
Nano4Imaging



**Simon Lajboschitz**  
CEO  
Khora



**Josua Ziegler**  
CEO  
Punktum



**Garnette Sutherland**  
Professor of Neurosurgery  
University of Calgary  
CEO  
OrbSurgical Ltd.



**Chris Xu Yurong**  
Senior Business  
Development  
Manager  
Huawei



Day 1 - Tuesday, December 3<sup>rd</sup> | 11.15 am - 12.30 pm

Lille room

## Periodontitis treatments of the future, discover the Healthy Teeth project

This event will be held in English with live translations available in French and Dutch.



Come and discover future advances in the treatment of periodontitis at the **Healthy Teeth** project launch conference. This event will plunge you into the heart of a major medical innovation: the development of new, more effective treatments for this disease that causes adult tooth loss. The current standard treatment for periodontitis is to mechanically eliminate the bacteria. Healthy Teeth will offer more effective alternatives to this treatment by developing innovative materials, easy-to-inject liquids, new 3D implants and new restorative products, capable of treating inflammation at source.

Take part in this unique opportunity to meet the researchers behind this innovative project, coordinated by the University of Lille. Discover how Healthy Teeth could change the future of dental care!

### PROGRAMME

- 11.15 - 11.20 am Presentation of the Interreg France-Wallonie-Vlaanderen programme  
> *Eve-Marie Virey (Région Hauts-de-France)*
- 11.20 - 11.35 am Periodontitis, What is it? And what are the current treatments?  
> *Pr Juergen Siepmann (ULille)*
- 11.35 am - 12.20 pm Healthy Teeth innovations, find out about the technologies we will be developing.  
> *Dr Jérôme Follet (Junia), Dr Jasper Van Hoorick (BIOINX)*
- 12.20 - 12.30 pm Question and Answer session

Partners:



Day 2 - Wednesday, December 4<sup>th</sup>, 2024 | 9.30 am - 1.00 pm

2.3 room

## Advancing Data Incorporation and Interoperability for Cancer Image Europe



This workshop offers all attendees an invaluable opportunity to learn about the forefront of data interoperability and incorporation in AI and bioinformatics, especially within the critical field of cancer imaging. Attendees will gain insights into the EUCAIM consortium's efforts to build a scalable, interoperable data framework that aligns with FAIR principles—making data Findable, Accessible, Interoperable, and Reusable. By exploring real-world case studies, hands-on platform demonstrations, and expert panel discussions, participants will understand both the practical challenges and solutions in achieving seamless data integration across complex datasets and models. This knowledge is directly transferable to biotech, medtech, and digital health initiatives, empowering attendees to enhance data standardisation and interoperability in their own projects. Furthermore, this session fosters networking and collaboration, offering direct interaction with EUCAIM's technical leaders and other pioneering organisations focused on advancing data-driven healthcare solutions.

### PROGRAMME

#### 9.30 am Introduction and Overview

- 9.30 - 9.35 am Welcome and Objectives of the Workshop - *Sara Zullino & Nektarios Liaskos, EATRIS*
- 9.35 - 9.45 am Introduction to EUCAIM - *Patricia Serrano Candelas, HULAFE*

#### 9.45 - 10.45 am Session 1: Data Incorporation and Interoperability

- 9.45 - 10.00 am Requirements and Challenges for the Three-tier EUCAIM Data Federation and Interoperability Framework - *Valia Kalokyri, FORTH*
- 10.00 - 10.15 am Role of Metadata Standards and Ontologies - *Christel Daniel & Mirna El Ghosh, LIMICS*
- 10.15 - 10.30 am Data Pre-processing Tools and Pipelines - *Celia Martín Vicario, QUIBIM*
- 10.30 - 10.45 am Tools for Data Interoperability and ETL - *Laure Saint-Aubert, MEDEX & Víctor Sónora, BAHIA*

#### 10.45 - 11.15 am Networking Break

#### 11.15 am - 12.05 pm Session 2: Case studies and platform demonstration

- 11.15 - 11.35 am Case Studies Highlighting Successful Data Integration - *Maciej Bobowicz, GUMED*
- 11.35 am - 12.05 pm Demonstration of the EUCAIM Platform: Usability, Challenges and Future Outlook - *Esther Bron, ERASMUS MC*

#### 12.05 - 12.55 pm Open Session 3: EUCAIM's Long-term Sustainability

- 12.05 - 12.25 pm EUCAIM's Long-term Sustainability - *Ana Miguel, MATICAL & Linda Chaabane, Euro-Bioimaging*
- 12.25 - 12.55 pm EUCAIM Panel Discussion: Challenges and Future Directions - *Sara Zullino, EATRIS, Linda Chaabane, Euro-Bioimaging & Patricia Serrano Candelas, HULAFE*

Day 2 - Wednesday, December 4<sup>th</sup> | 9.40 am - 12.15 pm

Marseille room

## The augmented human: Technological advances and research partnerships

*This event will be held in French*

This interactive session will highlight successful collaborations, cutting-edge technologies, and essential ethical debates. Discover how current innovations are transforming the future of healthcare! You'll also find valuable partnership opportunities.

### PROGRAMME

9.40 - 9.50 am - **Welcome** Introduction to the event and overview of the programme.

9.50 - 10.05 am - **Technology Transfer & Valorisation**

Learn how SATTs (French TTOs), technology platforms, and collaborative programs (Labcom, CIFRE theses) bridge the gap between academic research and industry, and how these mechanisms can help you accelerate innovation.

10.05 - 10.20 am - **MedTech industry: Key figures, regulatory and technical challenges**

10.20 - 11.20 am - **Review of Innovative Projects**

Discover disruptive projects pushing the boundaries of medical technology. These start-ups and initiatives are at the forefront of innovation, with solutions designed to radically improve patient care and revolutionise medical devices. You'll have the opportunity to understand their approaches and contributions to the healthcare sector.

11.35 - 11.55 am - **Roundtable 1: Valorisation & Collaborative Research**

*Theme: How can we strengthen links between academic research and industry to reduce "time to market" and maximize patient impact?*

This roundtable will shed light on the advantages (and current challenges) of collaboration between academia and the business world. Participants will share their experiences and best practices for building stronger partnerships.

11.55 am - 12.15 pm - **Roundtable 2: Technology, Health, and Ethics**

*Theme: What are the ethical and technological challenges associated with medical innovations?*

This roundtable will address the promises of health technologies, as well as the ethical challenges they pose.

### Why Participate?

This session is the ideal opportunity for healthcare professionals, startups, researchers, and investors to discover unique opportunities, connect with experts, and reflect on the future challenges of health and technological innovation.

Join us to explore trends, collaborate, and shape the future of healthcare for generations to come!

Day 2 - Wednesday, December 4<sup>th</sup> | 9.45 - 11.00 am

Lille room

## Microplaite: A microfluidic platform to accelerate the development of medical devices for tissue reconstruction

*This event will be held in English with live translations available in French and Dutch.*



Take part in the launch conference of the **MICROPLAITE** project, a revolutionary initiative in the field of tissue reconstruction! This unique microfluidic platform will recreate the microenvironment of natural tissues, reducing the use of animals for in vivo tests. Find out how this project, which brings together experts from France, Wallonia and Flanders, could transform the development of medical devices with faster, more accurate and ethical solutions. Join us as we explore this technological breakthrough, powered by innovations in microfluidics, biomaterials and cell growth, and contribute to the future of regenerative therapies.

### PROGRAMME

9.45 - 10.10 am Why the MICROPLAITE project?

- Context – Rémi Tilkin (Centexbel)
- From cell growth to organ-on-chip – Lieven Thorrez (KU Leuven)
- Microfluidic approaches in health and biology: the game changer – Denis Vandermael (SIRRIS)

10.10 - 10.40 am The Microplaite Project in a nutshell

- Presentation of the Interreg FWWL Program – Pierre Delavalle (Eurasanté)
- Microplaite Project Presentation: development of a microfluidic platform dedicated to medical device and tissular reconstruction evaluation – Denis Vandormael (SIRRIS)

10.40 - 11.00 am What is in it for you ? A roundtable with all the speakers

Partners:



Day 2 - Wednesday, December 4<sup>th</sup> | 2.00 - 3.15 pm

Lille room

## Getting smarter in the dressing industry: Towards a connected dressing with the DIAMOND project

*This event will be held in English with live translations available in French and Dutch.*



Come and discover an innovation that could change the lives of thousands of diabetic patients at the DIAMOND launch conference. The **DIAMOND** project is developing an intelligent dressing capable of monitoring wounds in real time and intervening automatically if necessary. Thanks to integrated sensors, this dressing detects signs of infection and releases medicines directly into the wound at the right time. This technology means that foot ulcers can be treated more effectively, avoiding serious complications such as amputation, which is still a frequent outcome. Join us to find out how this revolutionary innovation can improve the care of diabetic patients, avoiding many amputations and making their daily lives easier.

### PROGRAMME

2.00 - 2.10 pm Presentation of the Interreg FWWL Programme

> Joel David, Interreg France

2.10 - 2.30 pm DIAMOND PROJECT PRESENTATION: Development of an Innovative Smart Connected Dressing for Diabetic Wound Healing.

> Pr. Marc Debliquy (U Mons, BE), Pr. Bernard Martel (UMET, U Lille, France), Pr. Nicolas Blanchemain (U1008, U Lille, F), Willem Uyttendaele (Centexbel, BE)

2.30 - 2.50 pm Landscape of Diabetic wounds treatments

> Pr. Anne Vambergue, Diabetologist, Lille University Hospital Center

2.50 - 3.10 pm Towards a smarter generation of textiles-based MedTech

> Cyril Chaigneau, Head of global innovations, Sigvaris Group France

3.10 - 3.15 pm Question and Answer session

Partners:



Day 2 - Wednesday, December 4<sup>th</sup> | 3.30 - 4.30 pm

Lille room

## Awards Ceremony – PUI Lille Innovation Contest



Designed to encourage and support entrepreneurial spirit, the PUI Lille Innovation Contest is part of a collective approach aimed at raising awareness of the partnership culture among the entrepreneurs selected.

The PUI Lille Innovation Contest is an essential component of the regional and national strategy to promote the development of Deep Tech in France! Its aim is to stimulate the desire for entrepreneurship, to intensify the flow of deeptech projects within the PUI Lille perimeter, and in relation to 5 priority issues in the region:

- Energy solutions,
- Chemistry, materials and production systems for a world in transition,
- Cultural and creative economy,
- Digital, robotics and electronics,
- Technologies and innovations in health and well-being.

The competition is aimed at students, doctoral students, engineers, researchers and healthcare professionals working for one of the PUI's founding members, and invites them to challenge their deeptech project ideas.

### What's in it for the winners?

Prizes worth between €5,000 and €50,000, providing them with technological expertise, contacts, a fast-track route to join the support programmes of the PUI Lille's founding members and partners, training tailored to their needs, and/or visibility at regional and national level

Come and discover the projects taking part in this first edition and the 3 winners who will receive a prize!

Co-founders:





## EXHIBITORS

### ACTEMIS CONSEIL - STAND D20-F21 / 14

[www.actemis.com](http://www.actemis.com)

ACTEMIS is a consulting firm specialising in innovation strategy and financing. We support many start-ups and growing SMEs in the development of their strategic decisions. Our consulting service provides real assistance to entrepreneurs. We tackle the challenges of developing innovative ventures and help you mobilise the financing to achieve your goals. Highly engaged with leaders across various industries, we partner with numerous accelerators, incubators and other competitiveness clusters in France.

### AFSSI - STAND E40-F41 / 1

[www.afssi.fr](http://www.afssi.fr)

The AFSSI, the French Association of Service and Innovation Companies for the Life Sciences has the desire to unite French companies of services and technological innovation in the strategic field of Life Sciences.

AFSSI challenges are driven by the vision of life science companies as top players in international competition. AFSSI works toward enriching the Life sciences industry with networking, partnering and education opportunities.

### AGATHA INC - STAND F32

[en.agathalife.com](http://en.agathalife.com)

Agatha offers a suite of innovative applications (eTMF - QMS - SOP - Regulatory - Remote Monitoring) dedicated to the lifescience sector.

With offices in Lyon, Tokyo, Boston, and Shanghai, Agatha enables more than 350 companies and 40,000 users worldwide to streamline their document management, structure clinical study documentation, and secure their quality processes.

Agatha's applications provide highly efficient and easy-to-use solutions and compliant with key regulations.

### AGUILA - EXPERTISE DM - STAND D1

[www.expertise-dm.fr](http://www.expertise-dm.fr)

AGUILA - Expertise DM specializes in innovative medical devices: electromedical devices, connected technologies, and software as medical devices. We provide specialized engineering and regulatory expertise, assisting with CE marking for sales in Europe and ensuring compliance with ISO 13485 standards. Our expert team supports projects from initial idea to market, as well as research projects to develop technologies, ensuring products meet all safety, efficacy, and regulatory requirements.

### AIKA - ARCTIC DATA INTELLIGENCE AND SUPERCOMPUTING ECOSYSTEM IN KAINUU - STAND D3

[www.aikaecosystem.com](http://www.aikaecosystem.com)

AIKA - Arctic Data Intelligence and Supercomputing Ecosystem in Kainuu is a digital innovation hub that supports companies in their digital business transition and the development of new innovative solutions. AIKA offers access to the latest digital technologies, such as artificial intelligence, supercomputing, and data analytics, to enhance business and product development. The ecosystem aims to establish an internationally significant digital technology competence center in Kainuu, providing companies with strong conditions for ecological and sustainable growth. AIKA's services include digitalisation support, data-analytics, and AI, supercomputing resources, and high-technology professional training, all designed to foster collaboration and innovation.

### ALIGNED AG - STAND F33

[www.aligned.ch](http://www.aligned.ch)

Aligned AG provides Aligned Elements, an Application Lifecycle Management (ALM) software tailored for medical device development. The platform simplifies compliance by managing design control, risk, traceability, and testing, enabling teams to create regulatory-compliant products efficiently. Aligned Elements is designed to reduce time-to-market, lower costs, and empower teams to focus on innovation, meeting FDA, ISO, and European MDR/IVDR standards.

### AMAROB TECHNOLOGIES STAND E30-F31 / 7

[www.amarob.com](http://www.amarob.com)

AMAROB Technologies is an emerging surgical products company with a core competency in microrobotics. Leveraging our advanced machine park, we develop a wide range of medical devices, from simple prototypes to complex serial productions. Our capabilities include CNC machining, EDM, microwelding laser, and laser marking, ensuring high precision and quality in every product we create.

### ANTELEC - STAND F16

[www.antelec.fr](http://www.antelec.fr)

ANTELEC: Your Expert in Complete Connectivity and Electrical Interface Solutions

With extensive expertise, our team dedicates its know-how daily to meet your specific needs for connectors, cables, and harnesses. Through advanced engineering services, innovative design tools, and a rigorous approach to industrialisation and quality assurance, we optimise the performance of your projects. We provide tailored solutions, precisely adapted to your requirements.

### ANYDIAG - STAND E40-F41 / 10

[www.anydiag.fr](http://www.anydiag.fr)

Anydiag is the veterinary pole of the Inovie group, resulting from the merger of 4 veterinary laboratories (including Vebio).

Anydiag offers a wide range of analytical services (including histology) for both GLP-compliant and non-GLP-compliant studies.

Our multi-disciplinary team of qualified veterinarians and technicians benefits from a wide range of training and specialisations and constantly improve the quality of our analysis and strengthen communication with our sponsors.

### ASSEMBLICS - STAND B7

[www.assemblics.com](http://www.assemblics.com)

Assemblics is an EMS specialised in assembling complex printed circuit boards and finished products for niche industries, one of the main target markets is the medical devices. Since our foundation in 1985, we have proven to be a professional and credible partner for many respectable customers, in Belgium and international.

### ATLANPOLE BIOTHERAPIES - STAND E27

[www.atlanpolebiotherapies.com](http://www.atlanpolebiotherapies.com)

Atlanpole Biotherapies is involved in the medicine of tomorrow, with innovative areas of focus for the development of new therapies and the discovery of unexplored methodologies for human treatments. The projects of network, both academic and industrial, show the excellence of our expertise in personalised medicine.

It is a European Center Of Excellence in 4 domains :

- Biotech/Pharma
- MedTech
- Digital Health
- Disease Prevention

### AUDIT & RISKSOLUTIONS STAND E40-F41 / 8

[www.arsolutions.fr](http://www.arsolutions.fr)

Audit & RiskSolutions (A&RS group) is an insurance broker which specialised in Life Sciences with solutions for biotech/pharma/CRO/medical devices/medtechs companies:

- clinical trials
- directors & officers
- liabilities
- supply chain
- properties
- intellectual property
- cyber risks

- ...

## B CONSULTANT - STAND D5

[noe-app.fr](http://noe-app.fr)

B Consultant, historically a consulting company in the medical device (MD) sector, has developed N.O.E, the New Clinical Evaluation Tool, with the aim of becoming a major player in the digital transformation of the medical device sector, thanks to the NOÉ web application. NOÉ, a web application using artificial intelligence to speed up the marketing of medical devices by optimising the scientific literature review and the drafting of reports necessary for CE mark.

## BENCHMARK ELECTRONICS - STAND F36

[www.bench.com](http://www.bench.com)

Global CDMO combining 21 electronics manufacturing sites and 2 large medical design departments to help develop your product from rough idea to series or volume manufacturing according to the MDR and FDA. Our design departments are located on two continents: Almelo (The Netherlands) Design Center with ~210 engineers with multidisciplinary background with core capabilities around IVD, Microfluidic Instruments and development of accurate body-sensing devices. And Minnesota (US) Design Center with ~220 engineers with core capabilities and track record on medical optical devices.

## BIOASTER - STAND C6

[www.bioaster.org](http://www.bioaster.org)

Our purpose is to design and implement tailored technological solutions that open new areas of opportunity or overcome technological barriers that you have identified during the development process.

We aim to provide unmatched scientific and technological expertise throughout the discovery and development pathways in microbiology and infectious diseases.

## BIOLEVATE - STAND E11

[www.biolevate.com](http://www.biolevate.com)

Biolevate leverages artificial intelligence to enhance the speed, accuracy, and compliance of life sciences research. Born from a collaboration between healthcare researchers and AI technologists, we aim to transform complex data into actionable insights, simplifying and accelerating research processes worldwide. We believe that both the user experience and AI models must evolve under the direct influence of domain experts to fulfill the promise of the ongoing technological revolution.

## BIOSYMFONIX - STAND A12

[www.biosymfonix.com](http://www.biosymfonix.com)

At Biosymfonix, we're not just another game-design company, we are a company that would like to enhance understanding of complex topics through our visionary game tools that allow personal sense-making and relatability, thereby improved learning. Our games are used by leading institutions around the globe. Apart from making off-the-shelf serious games, our offerings also include tailored serious game and gamification solutions, consultations, workshops, and publishing of serious games.

## BUSINESS TURKU - STAND D3

[www.investinturku.com](http://www.investinturku.com)

Business Turku Ltd is a non-profit development company that provides cost-free services to companies operating in the Turku Region. We help local companies grow and develop their business and internationalise their operations.

In the Turku region, you can become part of Finland's strongest life science cluster with the top drug development and diagnostics companies. Our region is also a pioneer in digital and data-driven health technologies.

## BUSINESSOULU - STAND E14-F13

[www.ouluhealth.fi](http://www.ouluhealth.fi)

BusinessOulu strives to promote innovation, growth and competitiveness of companies in many sectors as well as bring new investments to the Oulu region. BusinessOulu's Health & Life Science unit supports companies in developing their health solutions, internationalisation and entrepreneurial success. We are also actively involved in OuluHealth ecosystem's activities.

Bring your knowledge, networks, and passion to our community, and let's make the future healthier.

## CER GROUPE - STAND D26

[www.cergroupe.be](http://www.cergroupe.be)

CER Groupe is a Belgian Research Center supporting human and veterinary health through non-clinical development, bioproduction and analytical CRO services offered to life sciences industry. Our 200+ people are committed to offer flexible and integrated solutions, from innovative research to GLP/ISO services, at the highest quality standards (ISO9001, ISO17025 and GLP).

## CHU AMIENS-PICARDIE STAND D20-F21 / 5

[www.chu-amiens.fr](http://www.chu-amiens.fr)

Amiens-Picardie University Hospital is one of 2 universities hospitals and health research institution in the Hauts-de-France region, in partnership with UPJV. SimUSanté@-Epione is a center of excellence in innovative training funded by the National Research Agency. It's the largest European interprofessional healthcare simulation center. The GRECO is a federative institute of research of UPJV dedicated to surgery using robotic assistance and IA focused on surgical innovation via simulation.

## CLEAR.BIO - STAND D32-E31 / 9

[www.clear.bio](http://www.clear.bio)

We're Clear.bio from Amsterdam, we reverse diabetes type 2 by digital precision nutrition, we just got reimbursed in NL and are expanding abroad. Best in class digital therapeutic (DTx) based on real-time glucometry, designed as a consumer product (instead of a medical intervention). Think of a realtime sensor (IoT), a smart app (AI) and a real dietician (behavioral change). Spotify tells you what to listen to, Netflix tells you what to watch, nobody tells you what to eat. We do.

## CLINGLOBAL - STAND E12

[www.clinglobal.com](http://www.clinglobal.com)

Clinglobal is a CRO group dedicated to providing solutions to the bioscience R&D sector. From our facilities in Europe, North America, and Africa, we offer preclinical and lab clinical studies in research, companion and production animals, animal clinical and comparative medicine field studies, data management and statistical analysis, histopathology, molecular biology, microbiology, clinical pathology and immunology, product development, regulatory affairs, and quality assurance consultancy.

## CLUBSTER NHL - STAND D20-F21 / 3

[www.clubster-nhl.com](http://www.clubster-nhl.com)

Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 360 members in the Nutrition, biotechnology and health sectors. We foster collaboration between academia, private companies (start-up, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes. The activity encompasses the ONE HEALTH concept, close relation between human, animal and plant health.

## COMUNICARE SOLUTIONS - STAND D2

[www.comunicare.be](http://www.comunicare.be)

Comunicare Solutions develops and commercialises a digital multipathology solution to support patients in chronic care and post-hospitalisation contexts. The Comunicare telemedicine platform provides, through patient empowerment, remote monitoring and disease-specific predictive models, a non-pharmacological strategy to improve disease management at home. It also provides support for patient data collection in clinical trials, is already reimbursed in France for four diseases and is used in more than 15 care pathways.

## COVARTIM - STAND A10

[www.covartim.com](http://www.covartim.com)

COVARTIM is an engineering company that helps medtech manufacturers develop and certify their Medical Devices, In Vitro Diagnostic Medical Devices and Medical software. Located in Belgium (Brussels, Liège) and France (La Rochelle), COVARTIM supports its clients from all around the world at every step of the development of their solutions: R&D, prototyping, manufacturing, V&V, QA, RA. COVARTIM implements its own QMS called APEX QMS © at its clients and provides a wide range of trainings.

## CREATEMPS - STAND E30-F31 /4

[www.createmps.com](http://www.createmps.com)

Createmps is one of the European leaders in precision marking, packaging and assembling for medical devices - to be implanted or not - on all types of materials, including silicones, polymers, metals and textiles. Our workshop masters all marking techniques, i.e. pad and screen printing, laser marking and micro-dosing. Our entire production can be manufactured in a ISO 5 clean room environment.

## D'ANDREA & EVERS DESIGN STAND D32-E31 /5

[www.de-design.nl](http://www.de-design.nl)

D'Andrea & Evers Design is a product development agency specialised in innovative and user-centered design solutions for medical technology. Our expertise encompasses the entire design process, from initial concept to final product. Emotional product experience is essential to create successful products in the market. This also applies to medical devices. Based on this vision, we have built up extensive knowledge and experience and realised successful medical devices in the past 20 years.

## DAMOCLES DX - STAND B11

[www.damoclesdx.com](http://www.damoclesdx.com)

Founded in 2023 in Limoges, DAMOCLES Diagnostics develops a point-of-care diagnostic technology for veterinary clinics. It measures a microorganism's biophysical properties within minutes from samples like milk or urine, enabling pathogen identification and antibiotic sensitivity testing. The DAMAST system has been validated on 500 bacteria/antibiotic combinations. The 8-person team is supported by INSERM labs RESINFIT and CAPTUR.

## DYNAPPS - STAND F15

[www.dynapps.eu](http://www.dynapps.eu)

Dynapps, the leading Odoo Gold Partner, empowers businesses with Odoo, the robust ERP and CRM trusted by 12 million+ users globally. Founded in Belgium with offices worldwide, our team of 150 experts optimises operations, reduces costs, and drives revenue growth. With 14+ years of experience, ISO-certified processes, and a 97% client retention rate, we deliver fast, cost-effective implementations and industry-specific solutions like our fully integrated LIMS for lab operations.

## DYSCOVERI - STAND D20-F21 /7

[www.dyscoveri.fr](http://www.dyscoveri.fr)

Dyscoveri creates digital solutions to support people with disabilities and their caregivers. We believe technology is key to inclusion. Our first tool, Dyscours, is a multi-support AAC (Alternative and Augmented Communication) app. It allows people with language disorders to communicate using images, form syntactically correct sentences, and have them vocalised. A complementary tool provides professionals with insights to better tailor their work to patients' needs.

## EFOR GROUP - STAND D12

[www.efor-group.com](http://www.efor-group.com)

Founded in 2013, the Efor Group has established itself as one of the leaders in Life Sciences consulting, today bringing together a team of 2,500 employees in 4 countries (France, Belgium, Switzerland, USA). We mobilise all our expertise and methods to ensure that our customers' healthcare products (pharmaceutical, medtech or biotech) are brought to market and kept there, in a constantly evolving technical and standards environment.

## ENNOÏA - STAND E30-F31 /8

[www.ennoia-med.fr](http://www.ennoia-med.fr)

ennoia is a French company, based in Besançon, specialising in surgical simulation and the development of standard or specific single-use medical devices. Thanks to our digital tools and our renowned experience in medical image processing, we are able to develop innovative and ingenious solutions with professionals in the world of health, and particularly in the field of surgery.

## ÉOLANE - STAND C9

[www.eolane.com](http://www.eolane.com)

French leader EMS (Electronic Manufacturer Services), éolane designs manufacturing cutting-edge PCBA in small, medium and large series for 8 markets, including medical health care. éolane's teams combine expertise and certifications to support its customers throughout their products life cycle, from design to obsolescence management. With 2,400 employees worldwide, éolane is an international Made-In-France group. In 2023, the group achieved a turnover of 326 Million euros.

## ERBC - STAND C11

[www.erbc-group.com](http://www.erbc-group.com)

Stemming from the merger of two reference CROs in pharmacology and toxicology (CERB and RTC), European Research Biology Center (ERBC) is a European leader in non-clinical studies. It offers to healthcare and chemical professionals a comprehensive range of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.

## EURASANTÉ - STAND D20-F21 /3

[lille.eurasante.com](http://lille.eurasante.com)

Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, startups and companies with their development projects. To do so, Eurasante provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 12 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.



## EUROFINS BIOPHARMA PRODUCT TESTING FRANCE - STAND D24

[www.eurofins.fr/biopharma-product-testing](http://www.eurofins.fr/biopharma-product-testing)

The Eurofins BioPharma Product Testing France laboratory network is a CRO that provides the pharmaceutical, biotechnology and medical device industries with analytical services, in accordance with regulations (EMA, FDA, ISO, etc.) and current GMP, GLP and Cofrac standards, for the development and marketing of human and veterinary (bio)medicines and medical devices.

## FC'INNOV - STAND E30-F31 / 5

[www.fcinnov.fr](http://www.fcinnov.fr)

FRANCHE-COMTE' INNOV is a partnership foundation created in 2013 by the University of Franche-Comté to ensure the interface between academic research and the socio-economic world.

It is an organisation promoting activities of general interest, in line with the missions of the public service of higher education.

In 2022, the EFS Bourgogne Franche-Comté and SUPMICROTECH have joined the UFC to be a founding members of FC'INNOV.

## FETCH - STAND D32-E31 / 6

[www.fetch-research.com](http://www.fetch-research.com)

Despite a growing number of available targeted treatments, their usage in metastatic cancer is limited due to a lack of target expression information.

FETCH provides this patient specific, up-to-date treatment target information in metastatic cancer. For this, FETCH utilises the existing technology of leukapheresis, allowing analysis of circulating tumour cells from the full blood volume.

FETCH offers investment and collaboration opportunities to improve and expand its innovative workflow.

## FIT MUSCULAR - STAND D32-E31 / 8

[www.fitmusclecare.com](http://www.fitmusclecare.com)

FIT International BV specialises in effective products marketed under the FIT Muscle Care brand. Designed for professional use and also available for OTC. Our leading product FIT Sports Balm provides fast relief from muscle discomfort and supports fast recovery from muscle and joint complaints. Endorsed by professionals in fields such as sports therapy and elderly care, and driven by loyal repeat buyers, we are seeking distributor partnerships to expand our reach - Keep your muscles FIT.

## FLANDERS INVESTMENT AND TRADE STAND E34

[www.flandersinvestmentandtrade.com](http://www.flandersinvestmentandtrade.com)

Flanders Investment & Trade (FIT) is your premier partner for growth in the medtech and biotech sectors. Positioned in one of the world's most open economies, Flanders fosters a dynamic life sciences ecosystem, spanning biotech, medtech, pharma, and healthcare. From startups to multinationals, Flanders offers robust support, funding, and a collaborative network that drives innovation. Join us in expanding your business in this strategic hub where opportunity and expertise meet.

## FLOWBEAMS - STAND D32-E31 / 4

[www.flowbeams.com](http://www.flowbeams.com)

FlowBeams is developing a groundbreaking needle-free injection technology that aims to revolutionise industries like pharmaceuticals and cosmetics. Our innovative approach tackles issues linked to traditional needle methods, such as needle-phobia, environmental pollution, and safety concerns. We strive to offer personalised, safe, and comfortable treatment options for millions while promoting sustainability by reducing the hazardous waste produced by conventional injections.

## FUJIREBIO - STAND E16

[www.fujirebio.com](http://www.fujirebio.com)

Fujirebio is a global leader in the field of in vitro diagnostic (IVD) testing, development and production of IVD products, from specialized to fully automated clinical laboratory testing covering a range of pathologies. Pioneer in the diagnosis of Alzheimer, Fujirebio has developed this expertise by developing new biomarkers for the screening, diagnosis and treatment monitoring of neurodegenerative diseases for better patient care in a very dynamic environment in terms of new treatments.

## GMED - STAND E32

[www.lne-gmed.com](http://www.lne-gmed.com)

Our expertise is to assess the conformity of MDs and quality systems, enabling manufacturers to place their products on the market worldwide. We offer training courses tailored to your needs, the development of high-value technical and regulatory content and the support provided throughout your certification cycle are all available assets for your projects' success.

## GRECO- STAND D20-F210 / 5

[www.u-picardie.fr/entreprises-et-partenaires/innover-ensemble/groupeement-recherche-detudes-en-chirurgie-robotisee-greco](http://www.u-picardie.fr/entreprises-et-partenaires/innover-ensemble/groupeement-recherche-detudes-en-chirurgie-robotisee-greco)

Amiens-Picardie University Hospital is one of 2 universities hospitals and health research institution in the Hauts-de-France region, in partnership with UPJV. SimUSanté@-Epione is a center of excellence in innovative training funded by the National Research Agency. It's the largest European interprofessional healthcare simulation center. The GRECO is a federative institute of research of UPJV dedicated to surgery using robotic assistance and IA focused on surgical innovation via simulation.

## GRENOBLE ALPES METROPOLE STAND F10-G11

[www.grenoblealpesmetropole.fr](http://www.grenoblealpesmetropole.fr)

We are Grenoble-Alpes Metropole, a vibrant and dynamic urban community in the heart of the French Alps. Our organisation is dedicated to fostering sustainable development, innovation, and collaboration among businesses, local governments, and residents. Together, we work to enhance our region's economic vitality while promoting environmental stewardship and high quality of life. Join us as we leverage our strengths to create a prosperous future for all stakeholders in our metropole.

## GROUPE EMITECH - STAND B10

[www.emitech.fr](http://www.emitech.fr)

The Emitech Group, an independent French company with more than 700 employees, specialises in testing and engineering for the marketing of equipment, particularly Medical Devices (MD). We help you from the development phase to approval, including characterisation, regulatory strategy, testing, and CE marking. We also offer training, expertise and technical assistance, and have testing laboratories capable of varying qualifications.

## GROUPE ICARE - STAND D10

[www.groupeicare.com](http://www.groupeicare.com)

With 30 years expérience, the Groupe ICARE stands out as a European CRO leader in international standardisation and regulation. We guide healthcare industry through the complex regulatory landscape, ensuring that every device and products is marketed in full compliance and safety.

Our expertise covers a wide range of services critical to deliver the excellence and compliance of your products: Biocompatibility & Toxicology, Validation & Qualification, Microbiology & Contamination Control...

## HAMAMATSU PHOTONICS FRANCE STAND F35

[www.hamamatsu.com](http://www.hamamatsu.com)

Hamamatsu Photonics is a global leader in optoelectronic components, modules, and systems. Our sensors, detectors, and imaging systems cover the full optical spectrum for demanding applications. Present in industries such as medical, automotive, research, and environmental, we enhance efficiency in markets like food, semiconductors, and manufacturing. Our expert sales team provides tailored advice and support for any technical inquiries.

## HEALTHHUB FINLAND EDIH STAND D3

[www.healthhubfinland.eu](http://www.healthhubfinland.eu)

HealthHub Finland EDIH is a one-stop-shop for the development of digital solutions for health and wellbeing, and a gateway to Finnish health and wellbeing data. To SMEs and public sector organisations, we offer free or discounted test-before-invest and innovation services, financing advice, training and skills development. We are part of the EDIH Network, a pan-European partnership of over 150 European Digital Innovation Hubs: service points boosting the digitalisation of SMEs.

## HONG KONG TRADE DEVELOPMENT COUNCIL - STAND E15

[www.hktdc.com](http://www.hktdc.com)

The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels.

## I2S - STAND B8

[www.i2s.fr](http://www.i2s.fr)

i2S supports its industrial customers in their imaging projects, throughout the entire life cycle of their products, thanks to its technical and industrial expertise in the design and manufacture of specialised cameras. i2S also offers world-renowned solutions through two activities: DigiBook in heritage digitisation, and Orphie in underwater imaging.

## IDCP MEDTECH - STAND F34

[www.idcp.eu](http://www.idcp.eu)

As master distributor for Europe IDCP Medtech from The Netherlands is responsible for several medtech brands. Dino-Lite (Taiwan) is a range of handheld digital microscopes for applications such as dermoscopy, capillarscopy, otoscopy and trichoscope. Also represented are the Dermengine and MoleScope products from Meta Optima (Canada) for skin cancer screening and the RetinaScope (Netherlands) solutions for screening for eye diseases at primary care. RetinaScope is a startup company established in the Netherlands and Scotland developing hard and software for retinal imaging.

## INNOKAS - STAND E14-F13

[www.innokasmedical.fi](http://www.innokasmedical.fi)

As a Nordicly reliable full-service CDMO for smart medical devices and SW, our job is to help you create, manufacture and bring safe, effective, compliant and more sustainable products into the market. Innokas is a growing and agile technology service company with 30 years of experience in the Medtech field. We offer flexible product development, SW development, contract manufacturing, and quality & regulatory services to meet our customers' outsourcing needs throughout the product's life cycle.

## INNOV'A - STAND D20-F21 /4

[www.innov-a.com](http://www.innov-a.com)

Innov'a has been your go-to partner for supporting innovative projects from inception to maturity. We unite a dynamic ecosystem, providing tailored assistance in project structuring, partner matchmaking, the transition from the lab to the market, and research of funding. With our own incubator and accelerator, we also support young innovators. Our mission is to empower innovators at every stage—transforming ideas into impactful, large-scale, multi-partner initiatives that drive progress.

## INTA - STAND E1

[www.intasystems.net](http://www.intasystems.net)

Diagnostics for everyone, everywhere. INTA develops portable diagnostic solutions to revolutionise the detection of traumatic brain injuries (TBI) and more. Our NanoAnalyzer uses surface acoustic wave (SAW) technology and AI to deliver rapid, non-invasive results, improving patient care, especially in emergencies and remote areas. Founded in 2020 as a joint spinoff of the Scuola Normale Superiore and CNR-NANO, INTA is a venture capital backed company that drives accessible healthcare innovation.

## INVEST IN GRENOBLE ALPES STAND F10-G11

[www.investingrenoblealpes.com](http://www.investingrenoblealpes.com)

Invest in Grenoble Alpes is the inward investment team for Greater Grenoble. We promote the Greater Grenoble area's assets internationally and support French and foreign companies to successfully develop their business. Grenoble Alpes has top expertise in healthcare (medical technologies, biotechnologies), digital technologies (IT, micro and nanoelectronics), energy (hydrogen, smart grids), cleantechs, sport & outdoor, and mechanical industry.

## IPEPS THE HEALTHTECH HUB - INSTITUT DU CERVEAU - STAND B12

[ipeps.institutducerveau-icm.org](http://ipeps.institutducerveau-icm.org)

We support researchers, healthcare professionals, and innovators in launching startups in neuroscience. Since 2012, iPEPS has provided a unique accelerator, helping start-ups in biotech, medtech, and digital solutions. NeurAL, created in 2022, offers philanthropic support to early-stage neuroscience projects with high potential. Together, iPEPS and NeurAL provide resources, funding, and mentorship, enabling over 100 start-ups to thrive, raise capital, and bring innovative products to market.

## IRCCS CENTRO NEUROLESI BONINO PULEJO - STAND E26-F25

[www.irccsme.it](http://www.irccsme.it)

IRCCS Centro Neurolesi Bonino Pulejo, located in Messina (Italy), established in 1992 and recognised by Italy's Ministry of Health as an Institute of Hospitality and Care, is a leading neuro-rehabilitation institute. It became a public institute in 1997, excelling in healthcare delivery and scientific research. The Center is noted also for its advanced technological capabilities in robotics and virtual reality, essential for treating severe acquired brain injuries and neurodegenerative diseases.

## IRCCS OSPEDALE GALEAZZI - SANT'AMBROGIO - STAND E26-F25

[www.grupposandonato.it/struttura/ospedale-galeazzi-sant-ambrogio](http://www.grupposandonato.it/struttura/ospedale-galeazzi-sant-ambrogio)

IRCCS Ospedale Galeazzi Sant'Ambrogio is a teaching and research hospital in Milan, Italy. It is a center of excellence in clinical and pre-clinical biomedical research, mainly in the orthopaedics and musculoskeletal fields, with 4 focus areas:

- 1) Tissue engineering and advanced cell therapy;
- 2) Surgical, pharmacological, and technological innovations;
- 3) Bioengineering applied to surgical and rehabilitative therapies;
- 4) Biochemistry, genetics, physiology, and related systemic diseases.

## JOOL - STAND D32-E31 / 7

[www.jool.health](http://www.jool.health)

Jool is at the forefront of digital health solutions, revolutionising caregiving with advanced, user-friendly technology designed to support caregivers globally. Our platform enhances daily caregiving routines by providing essential tools and real-time insights, making it easier for caregivers to manage and improve quality of life for those they care for. Join us in transforming caregiving into a more effective and compassionate experience.

## KAJAANI UNIVERSITY OF APPLIED SCIENCES (KAMK) - STAND D3

[www.kamk.fi](http://www.kamk.fi)

Kajaani University of Applied Sciences (KAMK) is a proactive and international institution located in central Finland. Established in 1992, KAMK has built a strong reputation for innovation both regionally and nationally. The university offers a range of English-taught Bachelor's degrees, particularly excelling in game development, simulator education, and application development. With approximately 2,200 students and 230 staff members, KAMK is known for its vibrant, genuinely international community and its commitment to developing customers' products, services, and processes through needs-based applied research.

## KUOPIO HEALTH CO-OP. - STAND D3

[kuopiohealth.fi](http://kuopiohealth.fi)

Kuopio Health is an ever-growing, international community of entrepreneurs, seasoned business professionals, educational, medical and governmental experts who are dedicated to working together towards discovering and accelerating relevant ideas based on pressing human needs and ultimately transforming them into viable commercial applications.

Kuopio Health enables agile network between companies, private and public sector as well as academic world to growth for business.

## KYOMED INNOV - STAND C4

[www.kyomedinnov.com](http://www.kyomedinnov.com)

With over 10 years of expertise, we help digital health solutions succeed through our five areas of expertise :

- Clinical CRO
- Customer Success
- User Experience
- Health Data
- Project Management

With an extensive network of qualified partners, we have developed a unique ecosystem to meet all your needs. From business strategy to user acceptability, clinical investigation and reimbursement, we're with you every step of the way as you embark on your digital health journey.

## LATTICE MEDICAL - STAND F12-G13

[www.lattice-medical.com](http://www.lattice-medical.com)

LATTICE MEDICAL is a French company that provides patients and healthcare professionals with innovative solutions for soft tissue reconstruction following tumor removal. Their approach uses faster, less invasive technology, blending tissue engineering, biomaterials, and 3D printing.

In 2020, they launched LATTICE SERVICES, which offers medical-grade filaments for 3D printing and provides co-development services for medical devices.

## LIFEBLOOM - STAND D20-F21 / 2

[www.lifebloom.eu](http://www.lifebloom.eu)

Lifebloom offers patients in wheelchairs the ability to walk on their own and live on their feet thanks to a breakthrough therapy named Lifebloom One. The therapy combines unseen walk assist devices with pioneer autonomous embedded systems, software and methods. A Pitié-Salpêtrière efficacy study demonstrated a 6x increase in daily standing time. All patients recovered their ability to walk in the first week of use. Discover the therapy at our booth and be among the first facilities to offer it.

## LUO AUTOMATION - STAND D32-E31 / 1

[www.luoautomation.com](http://www.luoautomation.com)

Luo improves the visual inspection of liquids for pharmaceutical applications. We develop and produce automated visual inspection machines that relieve the manual tasks.

We believe that this technology should be accessible to both larger and smaller companies. Therefore, Luo delivers machines with speeds ranging from 50-1,500 containers per hour. Showing proof and sharing knowledge guarantees a successful implementation of our machine in your facility.

## MEDICALPS - STAND F10-G11

[www.medicalps.eu](http://www.medicalps.eu)

MEDICALPS is an NPO and the health technology cluster for the Alpine arc. Based in Grenoble Alpes, it brings together and represents a community of more than 130 start-ups, SMEs, big companies, research centres, universities and local authorities in the fields of medtech, biotechnologies and digital health. Its aim is to animate, support and structure the sector in order to support and accelerate the deployment of healthcare innovations.

## MIPIH SIB - STAND D20-F21 / 8

[www.mipih.fr](http://www.mipih.fr)

Mipih SIB is a public software company leading digital health and hospital information systems in France. In addition, it is a specialist in interoperability and a leading health data host. Our goal is to contribute to building an ethical and sovereign IT system for the sector.

Mipih SIB, a public player in digital health, is accelerating the integration of AI across all of its offers with a transversal, trusted and fully integrated approach for the benefit of health players.

## MULTIHEALTH GROUP - STAND C7

[www.multihealthgroup.com](http://www.multihealthgroup.com)

We group together several entities (Clinact, Clinfile, Statitec, Tempopharma, Formatiss) specialised in clinical trials and real-life monitoring of healthcare products. Our main expertises:

- Project management: conception, clinical & regulatory operations, biometrics, medical writing and vigilance...
- Digital solutions: CTMS, eTMF, eCRF with eCRF generator, ePRO, rSDV platform...
- Consulting: provision of resources (one-off services or platforms/FSPs)
- Center of excellence: training academy.

## OMNISCIENCE - STAND D20-F21 / 10

[www.linkedin.com/company/omnisciencecloud](http://www.linkedin.com/company/omnisciencecloud)

Omniscience is a French start-up offering the first European platform to simplify clinical trial management by providing a unique workspace for each investigation site. Our intuitive solution centralises data, automates tasks, and concentrates eClinical tools to enhance collaboration between sites, sponsors, CROs, and patients. Sites streamline their operational management, ensuring their engagement and optimising site management.

## ONCOLOGY REFERENCE CENTRE (CRO) - STAND E26-F25

[www.cro.sanita.fvg.it](http://www.cro.sanita.fvg.it)

Oncology Reference Centre (CRO) of Aviano is a Scientific Hospitalisation and Cure Institute (IRCCS) classified as a highly specialised center of National importance for Oncology.

It is dedicated to the development of excellence in the prevention, diagnosis, treatment and rehabilitation of oncological diseases through multidisciplinary training and patient awareness intervention. It also promotes clinical, preclinical and translational research.



## PANADEA DIAGNOSTICS GMBH STAND B13

[www.panadea-diagnostics.com](http://www.panadea-diagnostics.com)

Panadea Diagnostics is a science-driven biotech company in a strong partnership with the Bernhard Nocht Institute for Tropical Medicine. We focus on developing and manufacturing top-quality serological tests for tropical and emerging infectious diseases. Leveraging our patented technology platform, our immunoassay tests have superior specificity and sensitivity, especially targeting the priority diseases in the WHO blueprint list.

## PCV-GROUP - STAND D32-E31 /3

[www.pcvgroup.com](http://www.pcvgroup.com)

Handling challenges in the medical market  
Our dispensing & dosing competences combined with our heating & cooling knowledge have made PCV Group a trusted partner in the medical devices and life science equipment market.  
In many developments we have been able to crossover experience from areas like food & beverage into this high demanding market.  
Especially knowledge on high-tech low cost disposables have given us a jump start in various developments.

## PELICAN HEALTH - STAND F10-G11

[www.pelican-health.com](http://www.pelican-health.com)

Pelican Health is pioneering a targeted intestinal sampling device in the form of an ingestible capsule. This innovative device enables precise sampling from 3 distinct regions of the small intestine, ensuring high-quality preservation of each sample for advanced analysis. Alongside the device, Pelican Health is developing digital solutions that leverage these samples to uncover diagnostic signatures, offering a powerful tool for personalised medicine and improved health insights.

## PERFETTO - ITALIAN TECHNOLOGY TRANSFER OFFICE NETWORK IN LIFE SCIENCES - STAND E26-F25

[www.networkperpetto.com](http://www.networkperpetto.com)

PerfeTTO is the first Italian network of Technology Transfer Offices (TTO) in Life Sciences, funded by the Italian Ministry of Health. Comprising 54 entities, including research hospitals, universities, and research institutions, PerfeTTO aims to bridge the gap between research and innovation. It focuses on developing services, tools, and resources to promote technological development, enhance the global value of Italian scientific research, and foster a national culture of technology transfer.

## PHARMATORY - STAND E14-F13

[www.pharmatory.com](http://www.pharmatory.com)

Pharmatory is a private customer-oriented company providing small molecule synthesis, process R&D and cGMP contract manufacturing of active pharmaceutical ingredients (APIs) and critical excipients. The key components in all projects are high dedication to the customer's success and commitment to quality and exceptional customer service. Our worldwide customer base includes both companies running NCE development projects and companies with commercial products.

## PRIMO MEDDA - STAND D32-E31 /2

[www.primomedda.com](http://www.primomedda.com)

As a significant number of patients do not respond well to the existing one-size-fits-all approach for drug development and medicine prescription, there is a clear need for a more personalised approach. Primo Medda focusses on bringing Personalised Medicine as a Service, an end-to-end solution where pharmacists are being supported in personalising medication. We provide this solution through a mobile container, so the impact can be made in even the most remote locations.

## PROWELLNESS - STAND E14-F13

[www.prowellness.com](http://www.prowellness.com)

ProWellness provides innovative digital health IT solutions for managing chronic diseases, including diabetes, cardiovascular conditions, and chronic respiratory diseases.

BALANSIO ([www.balansio.com](http://www.balansio.com)) is an intelligent mobile self-management solution featuring digital assistants that offer patients personalised, automated guidance on their smartphones 24/7.  
ProWellness Chronic Disease Management System (CDMS) is a specialised clinical system utilized in hospitals and community clinics.

## QITY - STAND A14

[www.qity.be](http://www.qity.be)

Qity's experts provide a range of services in Quality Assurance, Regulatory Affairs, Safety Testing, Architecture & Design, Cybersecurity & Data Privacy, Usability Engineering and Clinical to organizations in Life Science industry.

Qity also provide a unified platform that brings all essential activities—product development, HR, cybersecurity, manufacturing, clinical trials, and more—under one roof to streamline operations, simplify compliance, and enhance efficiency across departments.

## QSERVE CONSEIL SA - STAND A8

[www.qservegroup.com](http://www.qservegroup.com)

Our mission is to help manufacturers of medical devices and in vitro diagnostics with a practical approach, translating global regulations into accessible requirements. Our team has over 900 years' experience in the healthcare sector, at industrial and regulatory, or clinical and quality level. We are passionate about tackling complex regulatory issues in a fast-changing environment (artificial intelligence, globalisation, rapidly evolving healthcare controls and regulations...).

## QUAD INDUSTRIES - STAND F14

[www.quad-ind.com](http://www.quad-ind.com)

Quad Industries specialises in the design and production of innovative printed electronics, with a strong focus on healthcare applications. We are a leading provider of advanced skin patches that enable non-invasive monitoring and diagnostics. Our skin patches are equipped with cutting-edge sensors, designed for precise, real-time data collection, improving patient outcomes. At Quad Industries, we combine our expertise in printed electronics with a commitment to enhancing healthcare through tech.

## REMOTION - STAND D20-F21 /11

[www.remotion.rehab](http://www.remotion.rehab)

**\*\*ReMotion\*\*** is an innovative digital health platform revolutionising rehabilitation with immersive VR and motion-tracking technology. Designed for clinical and remote use, it provides therapists with real-time data and customisable exercises, enhancing patient engagement and outcomes in physical and cognitive therapy.

## RÉSEAU SATT - STAND C12-D11

[www.satt.fr](http://www.satt.fr)

The SATT Network brings together 13 Technology Transfer Offices (TTOs) in France. SATTs are committed to foster economic development by providing companies with high-potential technological solutions stemming from French public research to improve their competitiveness. Local, trusted players, we are connected on a daily basis to over 150,000 researchers, and offer privileged access to innovations from public laboratories. We detect, evaluate, protect inventions and bring innovation to the market by entrusting them to an existing company or a future startup. We finance their technological development through an exclusive investment fund. With over 750 startups created, SATTs are the first-class local players in the French Government's DeepTech Plan, operated by Bpifrance. With our nationwide network, we are strategic partners for companies seeking growth through innovation.

## SCREENTEC OY - STAND E14-F13

[www.screentec.com](http://www.screentec.com)

Founded in 1989, Screenshot is a Finnish Contract Development and Manufacturing company specialising in printed electronics. Screenshot develops and manufactures medical electrodes, diagnostic devices and durable user interfaces. We cater to various industries including medical, automotive, and consumer electronics, delivering custom solutions that meet specific client needs. The company also offers extensive consultation and product development services. We are ISO 9001 and ISO 13485 certified.

## SEDIVENTION - STAND E10

[www.sedivention.com](http://www.sedivention.com)

Sedivention develops a cryo-catheter for a new therapy of obesity. Comparable to gastroscopy, the catheter freezes the gastric trunks of the so-called "hunger nerve" from inside the stomach. An interventional, one-time treatment, avoiding lifelong drug intake, hospitalisation, morbidity, and costs. Sedivention addresses a huge and growing market, owns three international patents, and has developed a prototype, which was successfully tested in first preclinical trials. We help people lose weight.

## SELENIUM MEDICAL - STAND B9

[www.selenium-medical.com](http://www.selenium-medical.com)

Selenium Medical is an innovative contract manufacturing company, 100% dedicated to medical devices and pharmaceutical applications. Its know-how is offered to all manufacturers and subcontractors in the healthcare sector (orthopaedic implants, soft tissues, dental, IVD, robotics, etc.) and covers today 4 areas of expertise:

- Surface treatment,
- Plastic injection in ISO7 environment,
- Clean room assembling / kitting / sterile packaging,
- R&D, consulting, and validation management services.

## SIMUSANTÉ EPIONE - STAND D20-F21 /5

[www.simusante.com](http://www.simusante.com)

Amiens-Picardie University Hospital is one of 2 universities hospitals and health research institution in the Hauts-de-France region, in partnership with UPJV. SimUSanté®-Epione is a center of excellence in innovative training funded by the National Research Agency. It's the largest European interprofessional healthcare simulation center. The GRECO is a federative institute of research of UPJV dedicated to surgery using robotic assistance and IA focused on surgical innovation via simulation.

## SIRON CLINICAL - STAND D16

[www.sironclinical.com](http://www.sironclinical.com)

Siron Clinical is a trusted expert in complex clinical trials across orphan diseases, pediatrics, and medical devices. With almost 25 years of regional CRO expertise, our team provides flexible support through a range of services, from Customizable FSP to full-service solutions, designed to grow with your research needs.

## SPARTA CARE - STAND C4

[www.sparta.care](http://www.sparta.care)

Sparta Care supports CE marking for Software as Medical Devices (SaMD), leveraging expertise as ex-manufacturers to simplify regulatory pathways. As the first in France to achieve CE marking for a Class IIa software device under the MDR, Sparta Care brings a pragmatic and business-oriented approach.

## STATICE - STAND E30-F31 /6

[www.statice.com](http://www.statice.com)

STATICE is a medical device Contract Design and Manufacturing Organisation. Created in 1978, we are certified ISO 13485.

We provide 360° services to our customers: design, regulatory affairs, production through to labelling and packaging.

Our technical strengths include all types of silicone transformation, welding, gluing and assembly of catheter based devices as well as mechatronics system assembly.

Among other areas, we have references in cardiology, neurology, urology and orthopaedic.

## SURGITEC ROBOTICS

### STAND D20-F21 /6

[www.surgitec.com](http://www.surgitec.com)

At Surgitec robotics, we are aiming to pioneer the future of surgery with our advanced, user-friendly robotic systems.

Our mission is to accelerate the adoption of surgical robotics, bringing precision, efficiency, and excellence to operating rooms worldwide.

By leveraging state-of-the-art technology, we aim to make high-quality surgical care accessible to a larger demographic, reducing disparities in healthcare and improving patient outcomes on a global scale.

## SYNGENE INTERNATIONAL LTD.

### STAND B36

[www.syngeneintl.com](http://www.syngeneintl.com)

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA.

## TEMIS - STAND E30-F31

[www.temis.org](http://www.temis.org)

Our science park offers an efficient environment for innovation in the fields of medical devices and biomedicine.

CROs, Engineering and Clinical investigation centers associated with cleanrooms are available for your R&D projects from proof of concept to your CE label thanks to technologic platforms and scientific and legal expertises.

They have chosen TEMIS: Affuent Medical, Alcis, Carl Zeiss Meditec, Maincare solutions, Sophysa, EOS Imaging, MicroMega, Statice...

## TRACEX - STAND E2

[www.tracex.co](http://www.tracex.co)

TraceX is the first free of charge and open-source eQMS designed to improve the efficiency of your medical device lifecycle.

## TRONICO - STAND E25

[www.tronico-agon.com](http://www.tronico-agon.com)

TRONICO is an ISO 13485-certified French company specialising in active medical device engineering and industrial subcontracting.

Founded in 1973, TRONICO has become your privileged partner in all stages of your project, from the design of your medical device to its mass production, including industrialisation and regulatory procedures.

**TWENTE - STAND D32-E31**[www.medtechtwente.nl](http://www.medtechtwente.nl)

The smart manufacturing industry (High Tech Systems and Materials) is characteristic for the Twente region in East-Netherlands. The World Trade Center Twente is building a MedTech cluster together with the Techmed Center at the University and companies in the medical technology sector.

**UNITRON GROUP - STAND D14**[www.unitron.nl](http://www.unitron.nl)

Utilising cutting-edge technology, we develop and produce essential medical products with a focus on quality, speed, and flexibility. We serve a diverse range of global customers, from OEMs and SMEs to tech start-ups, often acting as the general contractor coordinating between knowledge centers, technology partners, and regulatory authorities. As a dedicated partner, we are committed to delivering valuable innovations.

**UNIVERSITY HOSPITAL OF LILLE (CHU DE LILLE) - STAND D20-F21 / 15**[www.chu-lille.fr](http://www.chu-lille.fr)

The University hospital of Lille (CHU Lille) is a bench-mark university hospital for primary care, teaching, innovation and research, serving the six million inhabitants of the North of France region. The CHU Lille is structured around 16 departments of excellence and has strong national and international collaborations. Around 400 people are fully dedicated to research, managing about 250 research projects and supporting the entire innovation process from idea to valorisation.

**USAREA - STAND E3**[www.usarea.fr](http://www.usarea.fr)

Usarea: Your partner for the usability of your medical device

We support you in the development and market launch of a safe, user-friendly device that complies with regulatory requirements for CE marking and FDA approval. Our services include:

- Usability Engineering (EN 62366 and ISO 60601-1-6)
- User Research
- Market Authorisation for drugs
- Design

Together, we ensure that your devices are not only compliant but also safe and intuitive to use.

**USECONCEPT - STAND D20-F21 / 13**[www.useconcept.com](http://www.useconcept.com)

UseConcept is the only French compagny specialised in usability of medical device and health products. We support you in taking human factors and user experience into account in the design and improvement phases of your products and services.

- UX/UI design and user experience support
- CE marking of a Medical Device (EN 62366-1:2015)
- Usability for FDA approval
- Marketing authorization (MA)
- Participants recruitment with HealthSquad (all-comers, patients and healthcare professionals)


**VUB - OPEN ACCESS CORE FACILITIES STAND E13**[www.vub.be](http://www.vub.be)

Vrije Universiteit Brussel (VUB) presents two open access core facilities. Molecular Imaging and Therapy (MITH) development, preclinical validation, and clinical translation of targeted drugs for diagnostic and therapeutic applications, based on Single-Domain Antibody (SdAb) technology. MICROLAB is a new 300 m<sup>2</sup> class 1,000 cleanroom equipped with state-of-the-art equipment for advanced microfabrication of microfluidic devices in glass and silicon for medical, pharma, and biotech applications.



Understanding life.  
**innobiochips**

**MEDTECH  
TWENTE**





# PARTNERS

## Main supporters



## Supporters



## Media partners



9<sup>th</sup> edition

A unique event in Europe for innovation partnerships and investment rounds in the **MedTech, Diagnostic and Digital Health** sectors

**October  
8<sup>th</sup> & 9<sup>th</sup>  
2025**  
**Grenoble,  
France**

2<sup>nd</sup>  
edition



**medigit**  
Inspiring Digital Health Innovation

The European partnering event fostering **innovation** in **Digital Health**


## CONNECTING TO THE WIFI



1. Select the **Lille Grand Palais** network
2. Accept the general conditions of use
3. You are connected!


Automatic disconnect every 30 minutes

## TURN YOUR PHONE INTO A BADGE SCANNER



1. Log in to the partnering platform:  
<https://biofit-medfit-medigit.vimeet.events>



2. Click on the scanner icon  Scanner
3. Scan the badges of the participants you're interacting with

4. Find all the contacts you have scanned in the «Contacts» tab and download the file

*We look forward to seeing you  
again next year!*



**MEANWHILE, FOLLOW THE EVENTS ON  
LINKEDIN TO STAY UPDATED!**



**Biofit**

FOSTERING  
INNOVATION  
& TRANSFER



**MedFIT**

Fostering Innovation in MedTech

**medigIT**

Inspiring Digital Health Innovation